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Chapter 1
General introduction

Chapter 1
INTRODUCTION
Processing of intracellular molecules, which serve as second messengers, is a key feature of 
many signaling pathways. These second messengers help to establish the physiological 
response of a cell intended by the extracellular ligand. Phospholipid breakdown has gained a 
lot of attention as it results in the formation of important signaling molecules and is 
manifested by a broad range of stimuli. The conversion of phospholipids into second 
messengers is predominantly catalyzed by phospholipase C (PLC), phospholipase A2 (PLA2) 
and phospholipase D (PLD) (Fig. 1).
Activation of PLC occurs through many cell surface receptors and has been 
characterized in great detail. PLC hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to 
yield inositol 1,4,5-trisphosphate (Ins(1,4,5)P3), releasing calcium from intracellular stores, 
and diacylglycerol (DAG), which activates protein kinase C (PKC) (Nishizuka, 1992; 
Berridge, 1993). At present, three PLC families are characterized, referred to as PLCP, PLCy 
and PLC8, each of which containing several members (Lee and Rhee, 1995). These PLC 
families are used in different signal transduction routes. Activation of PLC^ occurs through 
receptors coupled to heterotrimeric G-proteins, whereas activation of PLCy is mediated via 
tyrosine kinase receptors. How the activity of PLC8 is regulated is currently not known. 
However, crystal structure analysis suggests that PLC8 hydrolyses PIP2 in a calcium- 
dependent manner (Essen et al., 1996). It is currently hypothesized that PLCy activity 
generates increases in cytosolic calcium levels that activate PLC8.
PLA2 is specific for the sn-2 position of phosphatidylcholine (PtdCho) and 
phosphatidylethanolamine (PtdEtn) to yield lysophosphatidylcholine respectively 
lysophosphatidylethanolamine and fatty acids. Interestingly, especially arachidonic acid, a 
precursor for eicosanoids, is formed (Exton, 1994). PLA2 exists both in an extracellular and 
an intracellular form, of which only the latter is believed to be involved in cell signaling. 
Although its main mode of activation appears to be phosphorylation at serine 505 by MAP 
kinase, it is not clear how extracellular stimuli regulate PLA2 activity (Lin et al., 1993).
O
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Figure 1. Mechanism o f action o f PLC, PLA2 and PLD on phospholipids. The abbreviation R indicates choline, 
ethanolamine, inositol, serine or OH. For details see text.
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PLD (phosphatidylcholine phosphatidohydrolase, EC 3.1.4.4) has recently gained a lot 
of interest because its activity seems to be controlled by proteins which are involved in 
important processes like mitogenesis, cytoskeletal organization and vesicle trafficking 
(Liscovitch et al., 2000). How PLD activity is regulated and which role it serves in 
physiological responses is still not completely resolved. PLD hydrolyses predominantly 
PtdCho and PtdEtn resulting in phosphatidic acid (PtdOH) and the related base (Exton, 1994). 
PLD activity was initially discovered in plants but is also present in bacteria, yeast and 
mammalian cells (Gomez-Cambronero and Keire, 1998). Cloning studies identified several 
PLD genes (summarized in Liscovitch et al., 2000). Among these genes are two mammalian 
PLDs that have been termed PLD1 and PLD2. PLD1, and not PLD2, is believed to be under 
regulatory control by many extracellular-signal molecules. A major topic of this thesis is the 
signaltransduction route via which hormones activate PLD. Therefore, this introduction 
focuses on PLD1. A summary is presented concerning the mechanisms of PLD activation, its 
enzymology and its putative biological significance.
MECHANISMS OF PHOSPHOLIPASE D ACTIVATION
In the presence of small primary alcohols, PLD catalyses a unique reaction called 
transphosphatidylation, which results in the formation of phosphatidylalcohol (Dawson, 
1967). This property is used in many studies to measure PLD activity. The first direct 
evidence for receptor-linked activation of PLD in intact cells was provided with the 
chemotactic peptide A/-formyl-Met-Leu-Phe in HL60 granulocytes (Pai et al., 1988). Since 
then, the list of mammalian cells in which receptor-induced PLD activity was observed, 
expanded rapidly. To date, it contains different types of fibroblasts, endothelial and epithelial 
cells, but also ovarian granulosa cells and sea urchin spermatozoa (Shukla and Halenda, 1991; 
Cockcroft, 1996a; Exton, 1999). Activation of PLD can be established either via receptors 
which couple to heterotrimeric G-proteins or receptors possessing intrinsic tyrosine kinase 
activity (Exton, 1997a,b). There are four re-occurring themes in which these routes can be 
categorized. Firstly, receptor-mediated PLD activity is often dependent on the presence of 
PKC. Secondly, perturbation of an increase in cytosolic free calcium can disturb hormone- 
induced PLD activation in some systems. Thirdly, recent data imply a role for monomeric or 
small GTPases, especially RhoA and ARF. Finally, PLD activation can occur in a protein 
tyrosine kinase-dependent manner. These four routes are summarized in figure 2 and will be 
discussed hereafter.
Protein kinase C
PKC is recognized to be the most dominant regulator of PLD as in many, if not all, cell types 
PLD activity is stimulated by the addition of phorbol esters. The initial observation made in 
1981-1982 was that phorbol 12-myristate 13-acetate (PMA) stimulated choline release from 
HeLa cells (reviewed in Kiss, 1996). Approximately 5 years later it was proven that PLD was 
responsible for this release of choline. Thereafter, the list of different cells in which a phorbol 
ester sensitive PLD activation was observed expanded rapidly (Billah et al, 1991). In 
addition, many different agonists were found to be capable to stimulate PLD activity (Exton, 
1999). Therefore, the role of PKC in receptor-mediated PLD activation was extensively 
studied. Initially, these experiments were carried out using prolonged phorbol ester treatment, 
which is a powerful tool to downregulate diacylglycerol sensitive PKC-isotypes. In addition, 
PKC inhibitors such as staurosporine, H-7, Ro-31-8220 and chelerythrine were used
12
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Figure 2. The many proposed signal transduction pathways for extracellular ligands to stimulate PLD 
activation. Notice the central role o f PKCa. GPCR= G-protein coupled receptor, ICRAC= Ca2+ release-activated 
Ca2+ channel. For details see text.
(Rodriguez-Pena and Rozengurt, 1984; Ballester and Rosen, 1985). Later on, more elegant 
methods such as overexpression of specific PKC-isoforms or antisense techniques to 
specifically ‘knock out’ a certain PKC-isoform, were used to elucidate which isoform is 
responsible for PLD activation.
PKC downregulation. Martin et al. (1989) reported that long-term phorbol ester treatment 
prevented bradykinin-induced phospholipase D activation but not bradykinin-induced 
phosphoinositide hydrolysis and prostacyclin synthesis in bovine endothelial cells. This was 
one of the first papers demonstrating that receptor-mediated PLD activation occurs 
completely in a PKC-dependent manner. Similarly, bradykinin-induced PLD activation in 
human fibroblasts and human amnion cells was also completely abrogated after 
downregulation of PKC (van Blitterswijk et al., 1991; Mizunuma et al., 1993). The pivotal 
role of PKC, demonstrated with prolonged phorbol ester treatment, was shown in many other 
cell types using a wide variety of agonists like cholecystokinin and platelet-activating factor 
in Chinese hamster ovary (CHO) cells, nucleotides in Madin-Darby canine kidney (MDCK) 
cells, thyroid-stimulating factor in FRTL-5 thyroid cells and endothelin in striatal astrocytes 
and cultured cardiomyocytes (Balboa et al, 1994; Liu et al., 1995; Gupta et al., 1995; 
Eskildsen-Helmond et al., 1997; Desagher et al., 1997; Bosch et al., 1999). Intriquingly,
13
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however, others have found that PLD can also be stimulated in a PKC-independent fashion. 
Prolonged phorbol ester treatment resulted in a complete abrogation of phorbol ester-induced 
PLD activation, but did not attenuate the stimulation of PLD in case of carbachol in HEK 
cells expressing the M3 muscarinic acetylcholine receptor and in neuroblastoma cells 
expressing multiple types of muscarinic acetylcholine receptors (Sandmann and Wurtman, 
1991; Schmidt et al., 1994). Similar observations were reported with parathyroid hormone in 
UMR-106 osteoblastic cells and with activation of the a1-adrenergic receptor by epinephrine 
in MDCK cells (Balboa and Insel, 1998; Singh et al., 1999). How receptors activate PLD in a 
PKC-independent fashion is not resolved yet, although it is believed that members of the Ras 
superfamily are involved. Surprisingly, carbachol-induced PLD activation does not 
necessarily have to occur in a PKC-independent manner as in astrocytoma cells, carbachol- 
induced PLD activation was abrogated following long-term PMA treatment, suggesting that 
these cells lack proteins which are involved in the PKC-independent pathway (Martinson et 
al., 1989). Alternatively, it is possible that astrocytoma cells do not express the similar 
muscarinic acetylcholine receptor subtype as in HEK and neuroblastoma cells. The PKC- 
dependent pathway is not unique for receptors coupling to G-proteins as the tyrosine kinase 
receptors for platelet-derived growth factor (PDGF) and epidermal-derived growth factor 
(EGF) also stimulate PLD in a PKC-dependent manner (Plevin et al., 1991; Yeo et al., 1994; 
Yeo and Exton, 1995).
PKC inhibitors. Many studies used, in addition to chronic phorbol ester treatment, PKC 
inhibitors such as staurosporine, chelerythrine and Ro-31-8220, to investigate the involvement 
of PKC in hormone-induced PLD activation. Each of these drugs has its own specificity, 
efficacy and mode of action to inhibit PKC-isoforms (Hofmann, 1997). While some block 
activation by interfering with the catalytic domain, others interact with the substrate-binding 
domain. Surprisingly, the effect of these drugs was not always as dramatic as observed with 
downregulation of PKC via prolonged phorbol ester treatment. Especially staurosporine, 
known to inhibit ATP binding by PKC, inhibited agonist-induced PLD activation less 
potently than long-term phorbol ester treatment (Ruegg and Burgess, 1989). In PKC-deprived 
NIH-3T3 cells activation of PLD by PDGF, prostaglandin F2a and PMA was completely 
abrogated (Ben Av et al., 1993). Consistently, staurosporine inhibited activation of PLD by 
PDGF and PMA, but, surprisingly, it potentiated the stimulation by prostaglandin F2a. 
Conflicting results were also observed with human stromal cells, in which bradykinin-induced 
PLD activation was absent after chronic PMA treatment but only partially blocked by 
staurosporine (Ahmed et al., 1995). This discrepancy was observed by us and others (Gupta et 
al., 1995; Singh et al., 1998; Cook et al., 1998; Bosch et al., 1999). Similar observations were 
reported with the PKC inhibitors H-7 and Ro-31-8220, but not with chelerythrine, which very 
effectively blocked hormone-induced PLD activition under conditions that staurosporine had 
no effect (Eskildsen-Helmond et al., 1997; Singh et al., 1998). In rabbit peritoneal neutrophils 
and human polymorphonuclear leukocytes staurosporine even stimulated PLD activity by 
itself (Kanaho et al., 1992; Perianin et al., 1993). Since this latter effect was dependent on the 
presence of extracellular calcium, it was suggested that the drug acts by increasing the 
cytosolic calcium concentration, which in many cases increases PLD activity. These observed 
discrepancies suggest a complex action of PKC in the regulation of PLD.
Phosphorylation (in)dependent mechanisms. Conricode et al. (1992) showed that PKC can 
also stimulate PLD via a phosphorylation-independent mechanism. These authors showed that 
PMA-induced [14C]choline production in membranes from Chinese hamster lung fibroblasts 
depends on the presence of either a cytosolic fraction or partially purified PKC. Most
14
Chapter 1
surprisingly, this stimulation did not require the presence of ATP. This led to the conclusion 
that a non-phosphorylation mechanism might be involved and that complex formation 
between PKC and PLD is sufficient for the latter to become activated. This ATP-independent 
but phorbol ester-dependent activation of PLD was also observed with partially purified PLD 
from membranes of porcine brain and recombinant human and rat PLD1 (Hammond et al., 
1995; Singer et al., 1996; Min et al., 1998a). PKC-mediated phosphorylation of rat PLD1 
resulted even in inhibition of its catalytic activity. In contrast, in human neutrophils phorbol 
ester-induced PLD activation proved to be dependent on the presence of ATP (Olson et al., 
1991; Lopez et al., 1995). Taken together, these findings suggest that PKC can stimulate PLD 
both via a phosphorylating and a non-phosphorylating mechanism. However, it remains to be 
resolved whether these two mechanisms exist in vivo, and if so, to what extent they contribute 
in agonist-induced PLD activation. Of note, the presence of these two mechanisms might also 
explain the incomplete inhibitory effect of staurosporine as this drug prevents 
phosphorylation but not interaction of PKC with its substrate. Chelerythrine, which 
completely blocks PLD activity acts as a competitive inhibitor with respect to the substrate 
and thus prevents the association of PLD and PKC (Herbert et al., 1990).
PKC-isotype specificity. The PKC family consists of 12 isoforms and can be divided into 
three 3 classes. The classical or conventional PKC-isotypes (a, Pi, Pn and y) which are 
stimulated by both calcium and diacylglycerol; the novel isozymes (8, e, n, 0 and ^) which 
are stimulated by diacylglycerol but are calcium insensitive; and the atypical isozymes (Z, ^ 
and l) of which the stimulating factors are not identified yet (Nishizuka, 1995; Jaken, 1996; 
Hofmann, 1997). To address the question which PKC-isotype activates PLD, Conricode et al. 
(1994) added different PKC-isoforms to membranes of CCL39 cells and showed that PMA- 
dependent PLD activation occurred only upon addition of PKCa or P but not y, 8, e or Z. 
Identical results were obtained using membranes from HL60 cells (Ohguchi ef al., 1996). In 
agreement with this, PMA increased PLD activity in a PKC-depleted cell-free system derived 
from human neutrophils only after addition of the conventional PKC-isoforms a, PI and y 
(Lopez et al., 1995).
In intact Caco-2, Swiss 3T3 and rat or R6 fibroblasts cells, phorbol ester-induced PLD 
activation was shown to be greatly enhanced after overexpression of either PKCa or P (Pai et al, 
1991; Pachter et al, 1992; Eldar et al., 1993; Mukherjee et al., 1996; Khare et al., 1999a). 
However, in COS-1 cells overexpression of PKCa inhibited the PMA-induced increase in PLD 
activity (McKinnon and Parker, 1994). Negative regulation of PLD was also observed following 
overexpression of PKCe in NIH 3T3 fibroblasts (Kiss et al, 1999). Both PMA- and PDGF- 
induced PLD activity was reduced following overexpression of this PKC isoform. By 
overexpressing different domains of PKCe it was shown that the regulatory domain of the kinase 
was responsible for this inhibitory effect.
In contrast to selective overexpression, transfection of MDCK cells with antisense PKCa 
to “knock out” this isozyme prevented nucleotide- and phorbol ester-induced PLD activation, 
whereas antisense PKCP was without effect (Balboa ef al., 1994). Similar observations were 
made with respect to 1,25-dihydroxivitamin D3-induced PLD activation in Caco-2 cells (Khare et 
al, 1999b).
PKC-PLD Interaction. In 1995, human phosphatidylcholine-specific PLD1 was cloned. This 
enabled to study the interaction between PLD and PKC in more detail. In lysates from COS7 
cells and NIH 3T3 and rat1 fibroblasts, immunoprecipitation of PLD or addition of the fusion 
protein GST-PLD, enabled to co-immunoprecipitate PKCa in a PMA-dependent manner (Lee 
et al, 1997; Min and Exton, 1998). This finding confirmed the direct interaction between
15
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these two proteins. Park et al. (1998) showed that a PLD1 deletion mutant which lacked the 
first N-terminal 115 amino acids of the total 1036 amino acids of rat PLD1 was no longer 
activated upon addition of the phorbol ester, indicating that PKCa likely interacts with this 
part of the enzyme. Similarly, a hPLD1 mutant which lacked the amino-terminal 325 amino 
acids was also no longer activated in a phorbol ester-dependent manner (Sung et al., 1999a). 
However, the latter deletion mutant was still co-immunoprecipitated with PKCa, 
demonstrating that PLD1 contains multiple interaction sites for the kinase. Indeed, Kim et al. 
(1999) showed that PKCa phosphorylates a serine at position 2 and 561 and a threonine at 
position 147. Mutations of these sites into alanines reduced PMA-induced PLD activity, 
indicating that, in addition to the proposed non-phosphorylating mechanism, PLD activity can 
be increased following PKC-mediated phosphorylation.
A different approach to investigate important PKC interacting domains of PLD was 
performed by Zhang et al. (1999). They used transposon mutagenesis to generate a library of 
PLD1 alleles containing random pentapeptide insertions. An insertion at position 87, which is 
within the 115 N-terminal part, generated a PLD unresponsive to PKC. Expression of this 
mutant into HEK cells revealed that a direct interaction between PLD and PKC is critical for 
G protein-coupled receptors to increase PLD activity. Even in systems, in which receptor- 
mediated PLD activation has been proposed to act in a PKC-independent manner (which will 
be discussed later), this maneuver hampered PLD activation. These data strongly suggest that 
PKC not only stimulates PLD but, in addition, makes this enzyme more susceptible for 
additional activators.
In brief, the conventional isoforms of PKC play a dominant role in agonist-induced PLD 
activation. Evidence shows that PKC physically interacts with PLD albeit that this interaction 
does not necessarily lead to phosphorylation of the enzyme. At present, it is a matter of debate 
whether phosphorylation of PLD by PKC, acts as a negative or positive modulator. Taken 
together, the relationship between the interaction of PKC and PLD and the activation of PLD 
by PKC is not well understood.
Calcium
Similarly to PMA, an increase in cytosolic calcium readily increases PLD activity in many 
cell types. Calcium ionophores such as A23187 and ionomycin, and the specific endoplasmic 
reticulum calcium ATPase inhibitor thapsigargin cause a prolonged increase in the cytosolic 
calcium concentration and as a result PLD is activated (Gardner et al., 1980; Lytton et al., 
1991; Cockcroft, 1996a,b). This common finding urged researchers to investigate the role of 
calcium in agonist-induced PLD activation.
Calcium-dependent mechanism. Initially, it was proposed that calcium switches on the 
classical PKC isotypes to activate PLD (Thompson et al, 1991). An additional PKC- 
independent pathway could, however, not be excluded. In fact, there are a number of 
publications arguing in favor of the existence of such a pathway. In human platelets, phorbol 
ester-induced PtdOH formation, reflecting PLD activation, was inhibited by staurosporine 
(Huang et al., 1991). In contrast, A23187-induced PtdOH formation was insensitive for the 
PKC inhibitor, which suggests a PKC-independent route via which calcium stimulates PLD. 
Others showed that in osteoblast-like MC3T3-E1 cells, this drug did not inhibit the 
stimulation of PLD by foetal calf serum, while it was blocked upon chelation of intracellular 
calcium (Tokuda et al., 1996). This suggests a PKC-independent but calcium-dependent 
activation of PLD. More convincing evidence for the presence of such a pathway was
16
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provided by Freeman et al. (1995), who showed that in vascular smooth muscle cells 
angiotensin II-induced PLD activation was not influenced by prolonged phorbol ester 
treatment but attenuated upon simultaneous chelation of extracellular calcium with EGTA and 
intracellular calcium with BAPTA. Similar results were obtained with antigen-stimulated rat 
basophilic leukemia cells and epinephrine-stimulated MDCK cells stably expressing the a1- 
adrenergic receptor (Kumada et al., 1995; Balboa and Insel, 1998). The mechanism via which 
an increase in cytosolic calcium promotes activation of PLD in a PKC-independent manner is 
poorly defined. However, treatment with W-7, an antagonist for calmodulin, seemed to be an 
effective manner to inhibit this pathway (Suzuki et al., 1995; Imamura et al., 1995; Takahashi 
et al., 1996). This suggests the existence of a calcium/calmodulin-mediated pathway leading 
to the activation of PLD. Another putative component of this pathway was elucidated in 
permeabilized rat cortical synaptosomes where the calcium/calmodulin-dependent kinase II 
inhibitor KN-62 was shown to inhibit calcium-induced PLD activation (Sarri et al., 1998).
Calcium is also required in cells in which receptor-mediated PLD activity does depend 
on PKC (Liu et al., 1994; Balboa et al., 1994; Chung and Fleming, 1995; Rivard et al., 1995; 
Garces et al., 1995; Bosch et al., 1999). However, in these systems it is difficult to assess 
whether calcium acts via PKC or another route such as the calcium/calmodulin pathway. Thus 
far, it is not reported whether PKC-dependent systems are sensitive to W-7 treatment.
Calcium-independent mechanism. Although regulated-PLD activity is sensitive for calcium 
in many cell types, some investigators reported that agonist-induced PLD activation was 
insensitive for calcium chelators and PLD activity was not increased by calcium ionophores. 
This occurred both in PKC-dependent and -independent cell systems. The presence of PKC is 
a prerequisite in endothelin-, ATP- or angiotensin II-stimulated PLD activation in rat 
mesangial cells (Pfeilschifter and Huwiler, 1993; Pfeilschifter and Merriweather, 1993; 
Kester, 1993). However, BAPTA treatment was without effect. Moreover, ionomycin, 
A23187 and thapsigargin poorly stimulated PLD in these cells. In contrast, in HEK cells PLD 
was readily activated upon addition of A23187. However, PKC-independent activation of 
PLD via the human M3 muscarinic acetylcholine receptor was not inhibited by BAPTA, 
suggesting the involvement of a PKC- and calcium-independent pathway (Schmidt et al.,
1994).
Calcium in cell-free systems. The advantage of using permeabilized cells or cell free systems 
over intact cells is that this enables to control the intracellular calcium concentration more 
adequately. By varying the calcium content the effect of calcium alone and in combination 
with several stimuli can be investigated. In streptolysin O-permeabilized HL60 cells, both the 
PMA- and guanosine 5’-0-(3-thiotriphosphate) (GTPyS)-induced PLD activity dramatically 
increased upon increasing of the calcium concentration from 10 nM to 10 (Geny and 
Cockcroft, 1992). Similar observations were made in a cell-free system from human 
neutrophils (Olson et al., 1991). In complete contrast, in permeabilized NG108-15 cells and 
U937 promonocytic leucocytes and in liver plasma membranes, GTPyS-stimulated PLD 
activity was maximal in the absence of calcium (Bocckino et al., 1987; Liscovitch and Eli, 
1991; Kusner and Dubyak, 1994).
Omission of extracellular calcium is regularly found to be more effective than 
chelation of intracellular calcium in attenuating agonist-induced PLD activation. This might 
point to a crucial role of calcium influx. This observation was also reported by Gustavsson et 
al. (1994), who performed an extensive study on the role of calcium in rat hepatocytes. These 
authors showed that both ionophore-induced and receptor-mediated PLD activation was 
completely inhibited upon omission of extracellular calcium. Subsequently, by clamping the
17
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cytosolic calcium concentration they were able to show the presence of two distinct routes 
leading to PLD activation. First, millimolar calcium induced a marked increase in PLD 
activity, which was supressed by prolonged PMA treatment and PKC inhibitors. Second, a 
small increase in PLD activity was already detected at a cytosolic calcium concentration of 2 
^M. Remarkably, this latter stimulation was enhanced by staurosporine. These different 
characteristics led to the conclusion of two different routes via which calcium can stimulate 
PLD: a PKC-independent route that is activated at low (micromolar) calcium and a PKC- 
dependent route that is activated at high (millimolar) calcium.
Structure analysis of PLD revealed no binding domain for calcium, suggesting that calcium 
acts through other proteins to influence PLD activity (Frohman et al., 1999; Frohman and 
Morris, 1999). However, all the cloned PLD isoforms do require the presence of calcium in 
order to be stimulated by other factors (Gomez-Cambronero and Keire, 1998). Taken 
together, these findings emphasize that the mechanism of action of calcium during regulated- 
PLD activity is complex and not fully understood.
The Ras superfamily
GTPyS, a non-discriminatory activator of GTP-binding proteins, very potently stimulates 
PLD activity in many different permeabilized cells and cell-free systems (Cockcroft, 1996a). 
Although literature shed some light on the involvement of heterotrimeric GTP-binding 
proteins in the regulation of PLD activity, the amount of papers on the role of proteins from 
the Ras superfamily of monomeric GTP-binding proteins, also referred to as GTPases, is vast 
and in particular focused on ARF and RhoA. These two are the most prominent PLD 
activators of this family, although other small GTPases like Rac1 and RalA were also 
discovered to be involved in signal transduction cascades that activate PLD. Monomeric G- 
proteins are involved in many important processes, such as proliferation, cytoskeletal 
rearrangements, vesicle trafficking and nuclear protein import (Vojtek and Cooper, 1995). 
When bound to GTP, these proteins transduce signals to effector proteins. When bound to 
GDP, these proteins are in an inactive state. The cycling between these two states is 
controlled by guanine exchange factors (GEF), which promote the dissociation of GDP, and 
GTPase activating proteins (GAP), which increase the intrinsic GTPase activity.
ADP-ribosylating factor (ARF). ARF was the first monomeric GTP-binding protein that was 
shown to act as an activator of PLD. Initially, it was found that GTPyS-dependent stimulation 
of membrane-bound PLD in HL60 cells required the presence of a cytosolic factor of 
approximately 18 kDa (Geny et al., 1993). This factor was subsequently identified to be 
ARF1 (Brown et al., 1993; Cockcroft et al., 1994). The family of ARF proteins is implicated 
in the regulation of endocytic and exocytic membrane trafficking in yeast and mammalian 
cells (Kahn et al., 1996). At present, the family consists of 6 members with an amino acid 
sequence identity of 65-95% (Hong et al., 1995). ARF was initially discovered as a factor 
necessary for cholera toxin-catalyzed ADP-ribosylation of heterotrimeric Gs-proteins (Welsh 
et al., 1994). ARF proteins are predominantly localized at the cytosolic side of cis-Golgi 
structures, but are also found at the endoplasmic reticulum, the plasma membrane and in early 
endosomes. A unique feature of this sub-group within the Ras superfamily is that they 
specifically bind phosphatidyl 4,5-bisphosphate (PIP2). Binding of PIP2 increases the rate of 
GDP dissociation at least 100-fold thus making ARF more susceptible to activating signals
18
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(Terui et al., 1994; Randazzo, 1997). Remarkably, PIP2 is also an essential co-factor for PLD 
(discussed in enzymology section).
PLD was shown to be present in ARF containing Golgi-enriched membranes from 
CHO cells and several other cell lines (Ktistakis et al., 1995). Its activity was greatly 
enhanced upon addition of ARF proteins together with different GTP analogs. Moreover, 
brefeldin A, a drug that prevents binding of ARF to the Golgi complex, inhibits this 
activation. This indicates that ARF binding is a prerequisite for PLD activation. ARF- 
dependent activation is not restricted to the Golgi as it was also detected in other organelles. 
In plasma membrane fractions from HL60 cells and human neutrophils, GTPyS-induced PLD 
activation was established by the addition of ARF (Bourgoin et al., 1995; Lambeth et al., 
1995). Similarly, ARF-dependent PLD activity was observed in rat brain membranes 
(Massenburg et al., 1994). In this tissue also an ARF-insensitive PLD activity was observed 
which was stimulated by oleate. Although, it was initially discovered that ARF1 regulates 
PLD activity, addition of other ARF isoforms, such as ARF5 or ARF6, also increased PLD 
activity in rat brain membranes. In parallel, sepharose-purified porcine brain PLD is 
effectively stimulated with the different ARF isoforms (Brown et al., 1995). It seems that the 
stimulatory action of ARF is restricted within this subfamily as ARF-like (Arl) proteins, 
which are 40-55% homologous with ARF, do not activate PLD (Clark et al., 1993; Brown et 
al., 1995; Zhang et al., 1995).
Caumont et al. (1998) showed that direct elevation of calcium triggers the 
translocation of ARF6 from secretory granules to the plasma membrane and the concomitant 
activation of PLD in chromaffin cells. This activation was inhibited upon addition of either 
specific anti-ARF6 antibodies or a synthetic myristoylated peptide corresponding to the N- 
terminal domain of ARF6. In CHO cells, ARF6 is present at the plasma membrane, whereas 
ARF1, 3, 4 and 5 are predominantly cytosolic (Cavenagh et al., 1996). The latter 4 ARF 
subtypes are, when activated, translocated to several organelles but not to the plasma 
membrane. Several studies have shown that agonist-induced PLD activity in these cells is 
dependent on a prolonged increase in the cytosolic calcium (Liu et al., 1994; Garces et al., 
1995; Bosch et al., 1999). In analogy with chromaffin cells, calcium might act by increasing 
the activity of ARF6 to activate plasma-membrane localized PLD.
Cloning of hPLD1 revealed that ARF-dependent PLD activation is established through 
direct interaction (Hammond et al., 1997). Addition of ARF1 to recombinant PLD1 resulted 
in a GTPyS-dependent activation of the enzyme. Moreover, chimeras between ARF1 and the 
poor PLD activator ARF2 showed that for the interaction between ARF1 and PLD amino 
acids 35-94 play an important role (Liang et al., 1997). Further proof for a direct interaction 
between ARF1 and PLD1 was presented by the observation that ARF1 could be co- 
immunoprecipitated with recombinant PLD1 (Kim et al., 1998). In addition to PLD1, cloning 
and characterization of human PLD2 revealed also a direct interaction between this PLD 
isoform and ARF proteins (Lopez et al., 1998). However, the extent of PLD2 activation was 
10-fold lower as compared to PLD1.
Presently, there is limited evidence for a role of ARF in receptor-mediated PLD 
activation. In HEK cells stably expressing the human M3 muscarinic acetylcholine receptor, 
carbachol-induced PLD activation was inhibited upon addition of brefeldin A (Rumenapp et 
al., 1995). In contrast, this drug did not affect PKC-dependent PLD activation. Similar data 
were obtained with HIRcB fibroblasts, rat submandibular acinar and rat basophilic leukemia 
cells (Nakamura et al., 1996; Shome et al., 1998; Li et al., 1998). A major disadvantage of 
brefeldin A is that it severely affects Golgi structure at concentrations that inhibit PLD 
activity (Meacci et al., 1999). As an alternative, dominant negative ARF1 and ARF6 were 
introduced in HIRcB fibroblasts to prevent regulated-ARF activity. With both mutants
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complete inhibition of the PDGF-induced PLD activation was obtained, whereas the 
stimulatory effect of PMA was only partially blocked (Shome et al., 1998).
RhoA. The first indication that, next to ARF, RhoA stimulates PLD activity comes from the 
observation that human neutrophil lysates contained a GTPyS-dependent factor that 
stimulated membrane-bound PLD activity (Bowman et al., 1993). This stimulation was 
prevented by the RhoGDP dissociation inhibitor RhoGDI. The Rho subfamily consists of 11 
members and is divided into Rho-, Rac- and Cdc42-like groups (Ridley, 1996). It is well 
recognized that Rho proteins are involved in organization of the actin cytoskeleton, but they 
have also been implicated in other processes, such as adhesion, endocytosis and cell cycle 
progression (Ridley et al., 1992; Ridley and Hall, 1992; Hall, 1994; Nobes and Hall, 1995). 
Rho proteins are tightly controlled by modulators bringing them either in the active GTP- or 
inactive GDP-conformation. However, how these modulators are activated in signal 
transduction pathways is still poorly defined. Heterotrimeric Ga12 and Ga13-proteins can 
stimulate p115 RhoGEF and therefore may act as an intermediary in hormonal regulation of 
Rho proteins (Hart et al., 1998; Kozasa et al., 1998). Alternatively, recently it has been 
demonstrated that monomeric G-proteins can directly interact with G-protein coupled 
receptors (Mitchell et al., 1998). It was shown that receptors containing the amino acid 
sequence AsnProXXTyr in the seventh transmembrane domain activated PLD in an ARF- and 
Rho-dependent manner, whereas receptors containing an AspProXXTyr stimulated PLD via 
Gq/11 proteins coupling to PLC. Co-immunoprecipitation of receptors with the 
AsnProXXTyr motive and either ARF or RhoA, revealed that these receptors can form 
functional complexes with these two monomeric G-proteins.
Experiments were performed to identify which member(s) of the Rho family can 
stimulate PLD activity. Rat liver plasma membranes and homogenates of human neutrophils, 
treated with RhoGDI to deplete Rho proteins, showed full reconstitution of GTPyS-induced 
PLD activation upon addition of recombinant RhoA but not recombinant Cdc42 (Malcolm et 
al., 1994; Kwak et al., 1995). This stresses the role of RhoA in regulated-PLD activity. 
Orginally, it was observed that impure preparations of ARF stimulated partially purified PLD 
from porcine brain membranes considerably better than recombinant ARF (Singer et al.,
1995). Detailed analysis of this impure ARF preparation revealed at least two other 
stimulatory factors that were identified as RhoA and PKCa. Simultaneous addition of all 
three stimulators resulted in an optimal PLD activity. A similar observations was reached with 
cloned human and rat PLD1 (Hammond et al., 1997; Min et al., 1998a). Taken together, these 
data demonstrate the presence of three different stimulatory domains on PLD.
Many studies have employed Clostridium botulinum C3 exoenzyme (C3 toxin), which 
ADP-ribosylates RhoA thereby rendering it inactive, as a tool to investigate the involvement 
of RhoA in PLD activation. In rat brain homogenates, nuclei from MDCK cells and 
permeabilized HEK cells, GTPyS-induced PLD activity was completely inhibited after C3 
toxin treatment (Balboa and Insel, 1995; Kuribara et al., 1995; Schmidt et al., 1996). 
Moreover, C3 toxin was shown to inhibit agonist-induced PLD activation in intact rat1 
fibroblasts, HL60 cells and human neutrophils (Malcolm et al., 1996a; Guillemain and Exton, 
1998; Fensome et al., 1998). Importantly, however, Rumenapp et al. (1998) reported that C3 
toxin significantly lowered the PIP2-levels in HEK cells. As RhoA-mediated PLD activation 
is highly dependent on PIP2 , inhibition by C3 toxin cannot be interpreted as evidence for a 
role of RhoA (Yokozeki et al, 1996). In this context, Schmidt et al. (1997) showed that re­
addition of PIP2 to C3 toxin-treated HEK cells fully restored GTPyS-induced PLD activity. 
Other C3 toxin related drugs such as lethal toxin from Clostridium sordellii that blocked PLD
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activity, also affected PIP2 levels (El Hadj et al., 1999). This suggests that the primary action 
of these toxins is a reduction of the PIP2 -level rather than an inhibition of RhoA.
Malcolm et al. (1996b) investigated the role of RhoA in receptor-mediated PLD 
stimulation by overexpressing this small GTPase in rat1 fibroblasts. This maneuver resulted 
in an enhanced activation of PLD upon stimulation with lysophosphatidic acid (LPA), PDGF 
and PMA. This is in agreement with a role of RhoA in agonist-stimulated PLD activity.
The molecular mechanism via which RhoA activates PLD is still obscure. However, 
there is good evidence that the two proteins interact directly. Firstly, recombinant RhoA is 
able to stimulate recombinant PLD1 (Bae et al., 1998). Moreover, mutation of conserved 
amino acids in the effector domain (switch I region) of RhoA completely abolished activation 
of purified PLD. Secondly, their interaction was demonstrated by yeast two-hybrid analysis 
(Yamazaki et al, 1999). Thirdly, constitutively active RhoA and the C-terminal part of PLD 
could be co-immunoprecipitated following overexpression in COS-7 cells (Yamazaki et al., 
1999). The latter observation also demonstrates that the RhoA-interaction site is located in 
this part of PLD.
Although a substantial amount of evidence is provided for a physical interaction 
between RhoA and PLD, an alternative mechanism cannot be excluded. PLD activity in a 
plasma membrane fraction of human neutrophils was not restored by the addition of RhoA but 
required the additional presence of a thus far unidentified 50 kD factor (Kwak et al, 1995). 
Furthermore, several Rho-binding proteins are identified, like rhophilin, p160ROCK, p65PAK 
and protein kinase N (Manser et al, 1994; Fujisawa et al., 1996; Watanabe et al, 1996). It is 
possible that these proteins play a role in RhoA-dependent PLD activation. For instance, it has 
been shown that overexpression of p160ROCK and constitutively active p160ROCK increased 
agonist-, but not PMA-, induced PLD activation in HEK cells (Schmidt et al., 1999).
Relative importance o f RhoA and ARF. Several studies demonstrated a synergistic effect of 
PMA and GTPyS on PLD activity in a cell-free system (Whatmore et al., 1994; Balboa and 
Insel, 1995; Houle et al., 1995; Ohguchi et al., 1995; Cockcroft, 1996a; Dubyak and Kertesy,
1997). This is in line with the observation that recombinant PLD1 is maximally stimulated 
upon the combined action of PKCa, RhoA and ARF (Hammond et al., 1997; Min et al., 
1998a). However, in some cell types PLD is stimulated in either an ARF- or a RhoA- 
dependent manner, suggesting that although PLD can be stimulated with ARF and RhoA in 
vitro this does necessarily have to occur in vivo. For instance, PDGF- and PMA-induced PLD 
activity was blocked by brefeldin A, but not C3-toxin, in HIRcB fibroblasts (Shome et al.,
1998). Moreover, re-addition of recombinant ARF, but not recombinant RhoA, restored 
agonist-induced PLD activity in permeabilized cells. This preference for ARF was also 
observed in HL60 cells (Martin et al., 1996).
In other cells, however, it appears that RhoA is favored over ARF. For instance, 
agonists- and PMA-induced PLD activity was blocked after C3-toxin treatment or 
transfection with dominant negative RhoA, while brefeldin A was without effect in human 
adenocarcinoma A549 cells (Meacci et al., 1999). Similarly, in Caco-2 cells receptor- 
mediated PLD activity depends on RhoA and not ARF (Khare et al., 1999b). Rat brain PLD1 
is only activated by constitutively active RhoA and not constitutively active ARF following 
expression in COS-7 cells (Park et al., 1997). Conversely, recombinant RhoA and ARF 
readily activated this recombinant PLD in vitro. This suggests that ARF is not co-localized 
with PLD in vivo or, alternatively, activation of recombinant rat PLD1 by recombinant ARF 
does not reflect the in vivo situation.
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Rac. Although it is generally agreed that ARF and RhoA play a dominant role in PLD 
activation, some reports show effects of Rac. Addition of recombinant Rac to partially 
purified or recombinant PLD results in an enhanced activity (Malcolm et al., 1994; Siddiqi et 
al., 1995; Hammond et al., 1997). Hess et al. (1997) transfected rati fibroblasts with wild 
type Rac1 and interfering mutants and observed that dominant negative Rac1 completely 
abrogated EGF-, but not PDGF- or PMA-, induced PLD activation. Others showed that this 
mutant inhibited EGF-induced calcium release in these cells (Peppelenbosch et al., 1996). At 
present, it is not clear whether these two processes are related, but it demonstrates the 
importance of Rac1 in EGF signaling.
Ral. In addition to Rac1, RalA has been implicated in agonist-induced PLD activation. RalA 
does not stimulate PLD activity by itself but forms a complex with ARF and PLD in the 
presence of GTPyS (Luo et al, 1997; Kim et al, 1998; Luo et al., 1998). PLD activity is 
markedly increased in Ras transformed cells and it has been suggested that Ras acts through 
Ral-GEF to activate Ral thus promoting the formation of this complex (del Peso et al., 1996; 
Feig et al., 1996; Wittinghofer and Nassar, 1996). Pretreatment of HEK cells with toxins that 
inactivate Ras-like proteins impaired PMA-induced PLD activation, whereas carbachol- and 
GTPyS-induced PLD activity remained undisturbed (Schmidt et al, 1998). PMA-induced 
PLD activity was restored upon addition of either RalA or RalB but not with Ras or Rap. This 
suggests an essential role of Ral in PKC-mediated signaling to PLD.
In conclusion, evidence is accumulating that several members of the Ras superfamily 
including ARF, RhoA, Rac1 and Ral can modulate the activation state of PLD. However, 
whether cell surface receptors use one or more of these small GTPases to promote PLD 
activity is not resolved yet.
Tyrosine kinases
In different cell types both receptor and non-receptor tyrosine kinases stimulate PLD activity 
(Natarajan et al., 1996a; Houle and Bourgoin, 1999). Various ligands of tyrosine kinase 
receptors, such as EGF, PDGF and insulin, have been shown to increase PLD activity 
(Dunlop and Clark, 1993; (Yeo et al., 1994; Lee et al., 1994; Karnam et al., 1997; Voss et al.,
1999). Expression of the non-receptor tyrosine kinases v-src upregulated PLD activity in 
BALB/C 3T3 and rat mesangial cells (Song and Foster, 1993; Reiser and Goppelt-Struebe, 
1997). It is proposed that v-src stimulates Ras to promote the formation of the complex 
between Ral, ARF and PLD (Jiang et al., 1995; Feig et al., 1996). Additional evidence that 
tyrosine phosphorylation is involved in PLD regulation comes from the observation that 
oxidants, such as H2O2, vanadate and pervanadate increase PLD activity in Swiss 3T3 
fibroblasts and HL60, rat pheochromocytoma PC 12 and endothelial cells (Bourgoin and 
Grinstein, 1992; Natarajan et al., 1996b; Ito et al., 1997; Min et al., 1998b). The mechanism 
of PLD activation by these oxidants is still unresolved. Sequence analysis of human PLD1 
revealed two putative tyrosine phosphorylation sites. In agreement with this, H2 O2 and 
vanadate were shown to induce tyrosine phosphorylation of PLD1 (Marcil et al., 1997; Min et 
al., 1998b). At present, it is unclear whether this phosphorylation influences the activity of the 
enzyme.
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ENZYMOLOGY
The most widely used assay to determine PLD activity is the transphosphatidylation reaction. 
This unique reaction enabled not only to study the regulation of PLD but also its enzymology 
in great detail. Of importance, the recent cloning of various PLD isoforms opened the door to 
new types of investigation involving the relationship between structure and activity.
Transphosphatidylation
Over the years, the PLD-catalyzed transphosphatidylation reaction has been proven to be a 
powerfull tool to study the properties of this enzyme (Waite, 1999). In the presence of a small 
primary alcohol, this reaction yields phosphatidylalcohol (Fig. 3). Primary alcohols are 
excellent substrates for PLD and are preferred over water, the actual substrate in vivo, by at 
least a factor 400 (Frohman et al., 1999; Frohman and Morris, 1999). This preference is the 
basis for the widely used transphosphatidylation assay (Dawson, 1967). Structure analysis 
revealed a motif, designated HKD motif, which is present in all PLDs and responsible for the 
catalytic activity of the enzyme. This motif will be discussed in more detail below. This motif 
is also present in two related bacterial enzymes namely cardiolipin synthase and 
phosphatidylserine synthase. Both of these enzymes catalyze phospholipid synthesis reactions 
in which an alcohol is conjugated to a phospholipid. It is believed that PLD has evolved from 
this family of alcohol transphosphatidylase enzymes.
It is not well documented whether the PLD-catalyzed transphosphatidylation reaction 
is of any physiological relevance. One report shows that in bradykinin-stimulated human 
fibroblasts DAG can serve as an alcohol to yield PLD-catalyzed bisphosphatidic acid (van 
Blitterswijk and Hilkmann, 1993). It is suggested that via this transphosphatidylation reaction, 
the level of the second messenger DAG is maintained within certain limits.
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Figure 3. Mechanism of PLD action. HX-PLD= Enzyme-active site moiety. R=polar headgroup
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Substrate specificity
PLD preferentially hydrolyses PtdCho as elegantly demonstrated by the finding that the 
molecular species of phosphatidylethanol (PtdEth) in PMA- and bradykinin-stimulated PC12 
cells were identical to those of PtdCho (Holbrook et al., 1992). For this reason, investigators 
use radiolabelled fatty acids that are preferentially incorporated into PtdCho. Interestingly, 
upon prelabelling with different radiolabelled fatty acids different PLD activities were 
revealed. PMA activated a PLD that predominantly catalyzed the degradation of the ether-, 
but not the ester-, linked molecular species of PtdCho (Daniel et al., 1993; Huang et al., 1995; 
Daniel et al., 1999). In contrast, GTPyS stimulated predominantly the hydrolysis of ester- 
linked molecular species. PMA-induced PLD activity could be discriminated from v-src- and 
v-Fps-induced PLD activity by differential radiolabelling of the phospholipids (Song and 
Foster, 1993; Jiang et al., 1994). While PMA-induced PLD activity was detected irrespective 
of the label used, no v-src- and v-Fps-increased PLD activity was observed upon prelabelling 
with either archidonic acid or 1-0-alkyl-s«-glyceryl-3-phosphoryl choline. In contrast, the 
stimulatory effect of both protein-tyrosine kinases became apparent when the phospholipids 
were labeled with either [3H]myristic acid or [3H]palmitate. At present, the physiological 
implication for the different pathways to either ether-linked or ester-linked species 
degradation is unclear.
Biochemical properties
In order to stimulate PLD in a cell-free system the presence of calcium and magnesium and 
different cytosolic factors is required (Qian and Drewes, 1989; Anthes et al., 1989; Van der 
Meulen and Haslam, 1990; Kiss and Anderson, 1990; Olson et al., 1991; Xie and Dubyak, 
1991; Geny and Cockcroft, 1992; Coorssen and Haslam, 1993). This work resulted in the 
identification of PKCa, RhoA and ARF as major regulators of PLD activity. Subcellular 
fractionation showed that PLD activity is present in different cellular compartments such as 
cytosol, plasma membrane, microsomes, Golgi and nuclei (Wang et al., 1991; Whatmore et 
al., 1996; Ktistakis et al., 1996; Banno et al., 1997). Provost et al., (1996) observed that in all 
subcellular fractions considerably more ARF than RhoA was needed for the activation of 
PLD. Plasma membranes exhibited the highest specific activity. Moreover, the efficacy of 
RhoA was higher in the plasma membranes whereas that of ARF was higher in the Golgi and 
nuclei. These observations tempted the authors to propose the existence of different PLD 
isoforms with organelle-specific localization. This idea is further confirmed by the 
observation that membrane-PLD has a high preference for PtdCho whereas cytosolic PLD 
seems to be more permissive in its interaction with phospholipids and, in addition to PtdCho, 
hydrolyses PtdIns and PtdEtn. Indeed, recently three phosphoinositide-specific PLD subtypes, 
designated PI-PLDa, PI-PLDb and PI-PLDc, were isolated from rat brain cytosol (Ching et 
al., 1999). They require sodium deoxycholate for optimal activity and do not hydrolyze 
PtdCho, PtdEtn or phosphatidylserine (PtdSer). Purification of HL60 membrane-bound PLD 
revealed, in addition to an ARF-sensitive PLD, also a sodium deoxycholate-sensitive PLD 
that does hydrolyze PtdCho (Massenburg et al., 1994). Taken together, these observations 
strongly suggest the existence of multiple PLD isozymes.
Activation of partially purified PLD requires, with the exception of the membrane- 
bound sodium deoxycholate-sensitive PLD, the presence of phosphatidylinositol 4,5- 
bisphosphate (PIP2) (Liscovitch et al., 1994; Pertile et al., 1995; Hammond et al., 1997). 
Phosphoinositides are known to play an important role in membrane anchoring of different
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proteins (Lemmon et al., 1996). Therefore, PIP2  was believed to anchor PLD at the cell 
surface placing it in close proximity with its substrate. However, PLD mutants that fail to 
bind PIP2 and therefore are inactive, can associate with membrane structures and are still 
properly localized (Sciorra et al., 1999). This shows that PIP2 binding rather than localization 
is important for PLD activation. At present, the mechanism of action of PIP2 is unclear, but it 
is speculated that it either holds PLD to a substrate-containing phospholipid surface or 
stabilizes the catalytic domain of the enzymes. However, other evidence suggests the 
involvement of an unidentified protein (220 kDa) in PLD anchoring to the membrane (Min 
and Exton, 1998).
Structure
Cloning of mammalian PtdCho-specific PLD provided definite evidence for the existence of 
multiple isozymes. Based on the conserved sequences of cloned bacterial PtdCho-specific 
PLDs from Corynebacterium pseudotuberculosis, yeast (SPO14 gene) and plant (castor bean), 
a mammalian PLD was cloned from a cell line originating from a HeLa library (Hammond et 
al., 1995; Gomez-Cambronero and Keire, 1998; Frohman et al., 1999; Frohman and Morris, 
1999). This mammalian PLD exists in two spliced forms, designated hPLD1a (1074 aa) and 
hPLD1b, which are identical with the exception that hPLD1b lacks a 38 amino acids stretch 
(Hammond et al., 1997). Both forms have identical biochemical properties and can be 
regulated by the same set of proteins. A second mammalian PLD (PLD2) was subsequently 
cloned from mouse, rat and human (Colley et al., 1997; Kodaki and Yamashita, 1997; Steed 
et al., 1998). PLD2 displays 50% homology with PLD1 and shares in part its biochemical 
properties. In contrast to PLD1, PLD2 has a very high constitutive basal activity and cannot 
be activated by PKCa and RhoA and only minimally with ARF. Similarly to PLD1, PLD2 
requires the presence of PIP2 to be active.
Using PLD1 and PLD2 as a template, PCR reactions and Northern hybridization 
techniques showed that both isoforms are expressed in virtually any mammalian tissue and in 
many different cell lines (Park et al., 1997; Katayama et al., 1998; Meier et al., 1999). 
Furthermore, primers designed to discriminate between PLD1a and PLD1b, revealed that the 
latter is more ubiquitously expressed.
Sequence analysis revealed the presence of several conserved regions (Frohman et al., 1999; 
Frohman and Morris, 1999). The most conserved region is the ‘HKD’ domain (Fig. 4). This 
domain contains the motif HxKxxxxD and is present twice in all known PLD enzymes. Point 
mutagenesis revealed that these amino acids are critical for catalysis (Sung et al., 1999a). 
Moreover, it is required that both domains are intact, which suggests that for PLD activity the 
protein is folded in such a way that the domains are brought into close proximity.
PIP2 / membrane 
interaction
HKD HKD
N PX PH-like CRI LOOP CRIII MA C
t t
PKC interaction RhoA interaction
Figure 4. Domain structure of the human PLD1 protein. The relative positioning of the conserved sequences is 
similar in PLD2. However, PLD2 lacks the loop region. CR= conserved region, MA= putative membrane 
association domain. For details see text.
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Another important region for catalytic activity is the IYIENQFF domain in conserved 
region Ill (Frohman et al., 1999; Frohman and Morris, 1999). This region is proposed to 
interact with PtdCho. A PH-like region that is weakly related to the consensus sequence for 
PH domains and therefore is suggested to be involved in the interaction with PIP2 (Steed et 
al., 1998). However, PLD mutants lacking this putative PH domain are still able to bind PIP2, 
suggesting a different role for this region (Sciorra et al., 1999). PLD1, PLD2 and spo14 (yeast 
PLD) contain a conserved 21 amino acid stretch between the loop region and region III, 
which predominantly consists of basic and hydrophobic residues. Mutation of two arginine 
residues in this conserved region into glycine, completely abolished PIP2  binding to PLD, 
demonstrating that this region is the PIP2 interaction site and that the proposed PH domain is 
needed for another function. The phox (PX) consensus sequence is believed to interact with 
factors that promote translocation and/or activation as similar motifs in other proteins are 
documented to mediate protein-protein interactions. However, additional interaction domains 
are present, since PKCa, RhoA and ARF interact at other domains than this phox site (Park et 
al., 1998; Sung et al., 1999b). Lastly, only the PLD1 isotype contains a loop sequence of 100­
150 amino acids long. Mutagenesis of this loop hardly affects enzymatic activity, regulation 
and subcellular localization, which makes it hard to ascribe, at present, a role for this loop.
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BIOLOGICAL SIGNIFICANCE
PLD hydrolyzes PtdCho to yield PtdOH and choline. Therefore, it appears that its main 
mission concerns phospholipid turnover and maintenance of the structural integrity of cellular 
or intracellular membranes. However, there is evidence that PtdOH serves as a second 
messenger involved in processes like mitogenesis, inflammation, tissue damage, respiratory 
burst, cell signaling, vesicle trafficking and cytoskeletal rearrangements. The involvement of 
PLD in some of these processes will be discussed.
Signal-evoked PtdOH formation is observed in many different cells suggesting that 
PtdOH serves as a second messenger. Therefore it was investigated which proteins are 
stimulated by PtdOH. PI 4-phosphatase 5-kinase, the n and Z isoforms of PKC, protein 
tyrosine phosphatase 1c, Rac-GAP and PLCy were all shown to be activated by PtdOH in 
vitro (Singer et al., 1997; Exton, 1997a). However, evidence that they are targets of this lipid 
in vivo is lacking. More convincing evidence shows that PLD is involved in long-term 
hormone-induced DAG formation. In many systems, hormone-induced production of DAG is 
biphasic by nature (Nishizuka, 1992; Hodgkin et al., 1998). A small transient increase is 
followed by a larger sustained increase. Polyunsaturated DAGs predominate during the initial 
phase of stimulation and are thought to be derived from PIP2 by the action of PLC (Pettitt et 
al, 1997; Pettitt and Wakelam, 1998). During the sustained phase, the concentration of mono­
unsaturated and saturated DAG rises. Molecular species analysis revealed that the DAGs 
produced during this second phase are derived from both PtdIns and PtdCho (Hermans et al.,
1996). It is proposed that PLD contributes to the production of DAG by promoting the 
formation of PtdOH, which is subsequently converted into DAG by PtdOH- 
phosphohydrolase. However, in IIC9 cells thrombin-induced DAG formation was not affected 
by ethanol, preventing the PLD-catalyzed formation of PtdOH (Wright et al., 1992). This 
suggests that in this system PLD does not contribute to the sustained increase in DAG.
The best-characterized function of receptor-stimulated DAG production is activation 
of PKCs. As mentioned above, the PKC family is a heterogeneous family of phospholipid- 
dependent kinases that can be divided into three subfamilies on basis of cofactor requirements 
(Jaken, 1996). There have been a number of attempts to correlate the generation of particular 
DAG species with the activation of specific PKC isoenzymes. It has been shown that PKC 
activation occurs during the first rather than the second phase of DAG formation in platelets 
and Swiss 3T3 cells (Hodgkin et al, 1998). In addition, LPA activated PLD independently of 
PLC and without activation of PKC in porcine aortic endothelial cells (Pettitt et al, 1997). 
These observations led to the conclusion that PLD-derived DAG does not activate PKC. 
However, other studies provided evidence that increased PLD activity does lead to PKC 
activation (reviewed in Nakashima and Nozawa, 1999).
The observation that ARF is an efficacious activator of PLD provoked interest in 
studies on the role of PLD in the regulation of protein trafficking (Singer et al., 1997). In 
HL60 cells, P-glucuronidase secretion was markedly inhibited by 1-butanol, demonstrating a 
role of PLD-induced PtdOH production (Stutchfield and Cockcroft, 1993). Similarly, in 
human fibrosarcoma cells metalloproteinase-9 secretion was inhibited by 1-propanol 
(Williger et al, 1999). It has been speculated that PLD acts by modifying the lipid bilayer to 
provide binding sites for coat proteins or to facilitate the process of vesicle fission and fusion 
(Liscovitch and Cantley, 1995). Because at present no sensitive anti-PLD antibodies are 
available it is not possible to demonstrate, by immunocytochemistry, that PLD is indeed 
present at places where vesicle transport occurs. On the other hand, fluorescence-localization 
studies employing recombinant PLD1 tagged with either green fluorescent protein or Flu- 
epitopes showed co-localization of PLD1 with markers for secretory granules (Liscovitch et
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al., 2000). Following subcellular fractionation of CHO cells, the bulk of PLD activity was 
found to be present in Golgi membranes, while a smaller amount of activity was detected in 
endoplasmic reticulum (Ktistakis et al., 1995). Accordingly, primary alcohols were shown to 
inhibit both protein transport from the endoplasmic reticulum to the Golgi complex and 
release of secretory vesicles from the trans-Golgi network (Chen et al., 1997; Bi et al., 1997). 
Initiation of coat assembly on Golgi membranes was demonstrated to occur independently of 
ARF in cell lines displaying a high constitutive PLD activity (Ktistakis et al., 1996; Bi et al., 
1997). The formation of coated vesicles was sensitive to ethanol at concentrations that 
inhibited the PLD-catalyzed production of PtdOH. Exogenous bacterial PLD, but not ARF- 
stimulated endogenous PLD, induced the binding of coatomers to Golgi membranes. This led 
to the idea that the PLD-catalyzed production of PtdOH is a key event in the formation of 
coatomer-coated vesicles. At present, two questions remain to be answered with respect to the 
role of regulated PLD activity in the process of secretion. First, does PtdOH interact with 
proteins or does it alter the lipid environment and therefore the biophysical properties of the 
membrane? Second, is the action due to PtdOH itself or to a product of its metabolism?
Although widely regarded as a regulator of stress fiber formation, RhoA has also been 
implicated in transcriptional regulation (Ridley and Hall, 1992; Hill et al., 1995). There are 
several lines of evidence suggesting a role of PLD in RhoA-mediated processes. For instance, 
differentiation of IIC9 fibroblasts from a semi-round to an elongated form can be induced by 
a-thrombin (Ha and Exton, 1993). This differentiation is accompanied by an increase in stress 
fibers and a similar increase in stress fibers was observed following incubation of these cells 
with exogenous PLD or PtdOH. In porcine aortic cells, LPA-induced stress fiber formation 
was inhibited by 1-butanol and mimicked by exogenous PtdOH (Cross et al., 1996). The 
formation of stress fibers in response to exogenous PtdOH was inhibited by C3-toxin, 
suggesting a role of RhoA downstream rather than upstream of PLD. PLD activity is 
markedly upregulated during differentiation of neutrophils and promyelocytic leukemia HL60 
cells into neutrophils-like cells (Nakashima et al., 1996; Nakashima et al., 1998; Ohguchi et 
al., 1999). In agreement with this the mRNA transcripts of both PLD 1a and PLD 1b were 
increased (Nakashima and Nozawa, 1999). Similar increases were observed in differentiating 
C6 glial and pheochromocytoma PC12 cells. At present, the significance of PLD activation 
during differentiation is unclear, but has been speculated that the enzyme stimulates the 
transport of phospholipid-containing vesicles in the extending neurites.
PLD is not only activated by differentiation signals but also by growth signals 
(Venable and Obeid, 1999). As mentioned above, it is suggested sustained PLD activation 
results in prolonged PKC stimulation. In gonadotropin-releasing hormone-stimulated pituitary 
cells, such a prolonged PKC activation has been associated with increased c-fos expression 
(Cesnjaj et al., 1995). In agreement with a role of PLD, c-fos expression was inhibited by 
ethanol and inhibition of PtdOH-phosphohydrolase activity.
In summary, circumstantial evidence suggests a crucial role of PLD in a multitude of 
cellular events. However, conclusive evidence has not been provided yet due to the lack of 
specific inhibitors and thus far evidence is predominantly based on experiments performed 
with primary alcohols. Recent developments with respect to the molecular structure and 
mechanism of catalysis should open the study of PLD function to rapid advances.
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Previous studies showed that PtdCho hydrolysis is increased during cholecystokinin (CCK)- 
induced DAG production in pancreatic acinar cells (Hermans et al., 1996). This suggests the 
involvement of PLD in the mechanism of action of CCK. In the first part of this thesis we 
tested this this idea. To this end, the CCKA receptor was stably expressed in CHO cells and 
the effect of CCK on PLD activity was investigated in the context of this mammalian
expression system (chapter 2). In addition, we investigated the relative importance of PKC
2+isoforms and cytosolic Ca in agonist-induced PLD ativation. In chapter 3, we used 
overexpression of PKCa and e in CHO cells to evaluate their role in regulated PLD activity in 
more detail. In a subsequent study, we used the putative PLC inhibitor U73122 and its 
inactive analogue U73343 to provide evidence that PLD activation occurs downstream of 
receptor-mediated PLC activation (chapter 4). The issue of the contribution of small 
GTPases in agonist-induced PLD activation is addressed in chapter 5. In this chapter we 
investigated the effects of Rac1 using overexpression of dominant negative and constitutively 
active mutants in CHO cells. Several studies suggest a role of Ral in PLD activation. Because 
R-Ras is a putative regulator of Ral, we investigated its effects on agonist-induced PLD 
activation. However, none of the interfering mutants affected CCK-induced PLD activation 
following overexpression in CHO cells (data not shown). On the other hand, confocal
imaging microscopy of cells loaded with a fluorescent Ca2+ indicator revealed marked effects
2+of constitutively active R-Ras on the pattern of CCK-induced Ca mobilization. This study is 
described in chapter 6.
The second part of this thesis deals with regulated PLD activity in freshly isolated
2+pancreatic acinar cells (chapter 7) and primary cultures of Ca reabsorbing connecting 
tubule and cortical collecting duct cells (chapter 8). In these studies RT-PCR was used to 
identify the expressed PLD transcripts. In addition, protein expression and subcellular 
localization was assessed by immunoblotting.
In the third part of this thesis we investigated a possible role of PLD in cancer 
development. PLD activity was determined in a panel of metastatic and non-metastatic human 
melanoma cell lines (chapter 9). In this study, special attention was paid to the Rho-like 
protein memB, which is preferentially expressed in the metastatic cells.
SCOPE OF THIS THESIS
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Receptor-mediated activation of phosphatidylcholine phosphatidohydrolase or phospholipase D 
(PLD) was studied in Chinese hamster ovary (CHO) cells expressing the cholecystokinin-A 
receptor (CCKA) receptor. Cells were labelled with [3H]myristic acid for 24 h and PLD-catalysed 
[3H]phosphatidylethanol formation was measured in the presence of 1% (v/v) ethanol. 
Cholecystokinin-(26-33)-peptide amide (CCK8) increased PLD activity both time- and dose- 
dependently. Maximal activation of protein kinase C (PKC) with 1 PMA or sustained 
elevation of the cytosolic free Ca2+ concentration ([Ca2+]i) with 1 ^M thapsigargin increased PLD 
activity to 50% and 70% of the maximal value obtained with 10 nM CCK8, respectively. The 
stimulatory effects of CCK8, PMA and thapsigargin were abolished in cells in which PKC was 
downregulated or inhibited by chelerythrine. PMA/Ca2+-stimulated PLD activity was absent in a 
homogenate of PKC-downregulated cells but could be restored upon addition of purified rat 
brain PKC. CCK8-induced PLD activation was inhibited by 90% in the absence of external Ca2+, 
demonstrating that receptor-mediated activation of PKC in itself does not significantly add to 
PLD activation but requires a sustained increase in [Ca +]i. Taken together, the results presented 
demonstrate that, in CHO-CCKA cells, receptor-mediated PLD activation is completely depen­
dent on PKC, but that the extent to which PLD becomes activated depends largely, if not 
entirely, on the magnitude and duration of the agonist-induced increase in [Ca +]i.
2 +
INTRODUCTION
Many hormones, neurotransmitters and growth factors use lipid-derived signalling molecules 
to exert their biological effects. A well-elucidated pathway involves the phospholipase C 
(PLC)-catalyzed hydrolysis of inositol phospholipids to yield inositol 1,4,5-trisphosphate 
(Ins(1,4,5P3)), releasing calcium from the endoplasmic reticulum (Berridge, 1993), and 1,2- 
diacylglycerol (DAG), which activates protein kinase C (PKC) (Nishizuka, 1992). This 
pathway is activated both via receptors that couple to a G-protein to activate PLC^ and via 
receptors that regulate intrinsic and extrinsic tyrosine kinases to activate PLCy (Exton, 1994; 
Noh et al., 1995; Natarajan et al., 1996a).
It is widely observed that agonists that stimulate the enzymic breakdown of inositol 
phospholipids to increase the concentration of cytosolic free Ca2+ ([Ca2+]i) and activate PKC 
also promote the hydrolysis of phosphatidylcholine (PtdCho) to yield choline and 
phosphatidic acid (Exton, 1994; Natarajan et al, 1996a). It has been suggested that 
phospholipase D (PLD) is responsible for this agonist-induced breakdown of PtdCho (Exton,
1994). Indeed, partially purified mammalian PLD has been shown to be highly selective for 
this phospholipid (Exton, 1994). Moreover, agonists which stimulate the hydrolysis of PtdCho
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also cause the formation of phosphatidylalcohols as a result of the PLD-catalyzed transphos- 
phatidylation reaction (Dawson, 1967). To date, the physiological relevance of agonist- 
induced PtdCho hydrolyis is unclear. However, it has been proposed that phosphatidic acid is 
rapidly converted into DAG to activate PKC (Nishizuka, 1992).
Although Ca2+ and PKC have been identified as important activators of PLD, their 
relative importance in agonist-induced PLD activation is still poorly defined (Exton, 
1994,1997c; Cockcroft, 1997a). In intact cells, receptor-mediated PLD activation can be 
mimicked by phorbol esters, which activate PKC, and Ca2+ ionophores, which increase [Ca2+]i 
(Kiss, 1996; Morris et al., 1996; Natarajan et al., 1996; Cockcroft, 1997a). It is generally 
observed that phorbol esters are much more effective than receptor agonists. However, 
preliminary experiments, using Chinese hamster ovary (CHO) cells stably expressing the 
cholecystokinin-A receptor (CHO-CCKA cells), revealed that in this cell type the phorbol 
ester PMA was less effective than cholecystokinin-(26-33)-peptide amide (CCK8). This might 
suggest the presence of an additional pathway in CCK-induced PLD activation. To investigate 
this possibility, we studied the mechanism of CCK8-induced PLD activation in CHO-CCKA 
cells in more detail.
The results presented demonstrate that PKC in itself is indispensable for receptor- 
mediated PLD activation and that the extent to which PLD becomes activated depends 
largely, if not entirely, on the duration and magnitude of the agonist-induced rise increase in
[Ca2+]i.
MATERIALS AND METHODS
Materials
CCK8, PMA, leupeptin and 2,2,4-trimethylpentane were obtained from Sigma (St. Louis, MO, USA) and 
thapsigargin from LC Services (Woburn, MA, USA). Phenylmethylsulfonyl fluoride (PMSF) was purchased 
from SERVA (Heidelberg, Germany) and [9,10(n)-3H]-myristic acid (53 Ci/mmol) from The Radiochemical 
Centre (Amersham, UK). Staurosporine was obtained from Boehringer (Mannheim, Germany) and chelerythrine 
from Research Biochemicals International (Köln, Germany). Aprotinin was purchased from Calbiochem (La 
Jolla, CA, USA) and dithiothreitol from Research Organics Inc. (Cleveland, Ohio, USA). HPTLC silica gel 60 
plates, ethylacetate and chloroform were obtained from Merck (Darmstadt, Germany), phospholipid standards 
from Avanti Polar Lipids (Birmingham, AL, USA) and isotype-specific PKC antibodies and tissue culture me­
dium with additives from Gibco (Paisley, Scotland, U.K.). Fura-2/acetoxymethyl ester was obtained from Mole­
cular Probes Inc. (Eugene, OR, USA). I-block reagent was purchased from Tropix (Bedford, MA, USA). All 
other chemicals were of reagent grade.
Development o f a stable CHO-CCKA cell line
The development of a stable CHO-CCKA cell line has been described in detail previously (Smeets et al, 1996). 
Phospholipase D measurements in CHO-CCKA cells
CHO-CCKa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal-calf serum (FCS), in a water saturated atmosphere containing 5% CO2 at 37°C. For PLD measurements, the 
cells were subcultured in 12 well plates (2.2 x 105 cells/well) and labelled with [3H]myristic acid (3 pCi/ml) for 
24 h. At the end of the labelling period, the cells were washed and incubated in DMEM without FCS for 3 h. In 
PKC downregulation experiments, PMA (0.1 pM) was added at the beginning of either the labelling (24 h PMA 
treatment) or the incubation with FCS-free DMEM (3 h PMA treatment). Subsequently, the cells were washed 
and incubated in DMEM containing 1% (v/v) ethanol for the indicated period of time. Ca2+-free experiments 
were performed with minimal essential medium to which no Ca2+ was added and which contained in addition 0.5 
mM EGTA. At the indicated time, the medium was aspirated and the reaction was quenched by the addition of 1
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ml ice-cold methanol. The cells were scraped off and the mixture was transferred into a lipid tube (Sarstedt, 
Essen, Germany). Lipids were extracted according to the method described by Bligh and Dyer (1959). Briefly, 
500 |j.l of chloroform and 400 |j.l of water were added and the mixture was mixed vigorously. Phase separation 
was achieved by addition of 400 |j.l of chloroform and 400 |j.l of water followed by centrifugation. After 
collection of the lower organic phase, the aqueous phase was extracted again and the combined organic phases 
were blown to dryness with N2 .
Separation o f labelled phospholipids
The dried extracts were dissolved in 20 |j.l chloroform/methanol (9:1, v/v) and the lipids were separated by TLC 
using potassium oxalate-treated silica gel 60 HPTLC plates. The plates were developed with the upper phase of a 
mixture of ethylacetate/2,2,4-trimethylpentane/acetic acid/water (13:2:3:10, by vol.). Radioactive spots 
corresponding to authentic lipid standards were visualised by I2 -staining and scraped off. Radioactivity was 
measured by liquid scintillation spectrometry.
Phospholipase D measurements in CHO-CCKA homogenates
PLD activity was measured in cell homogenates according to the method described by Ohguchi et al. (1996) as 
described previously (Bosch et al., 1998). Briefly, CHO-CCKA cells were grown to confluence in the presence of 
[3H]-myristic acid (2 |j.Ci/ml) for 48 h. Before homogenization, the cells were washed and incubated in DMEM 
without FCS for 3 h. In PKC downregulation experiments, PMA (0.1 |xM) was added either 3 or 24 h prior to 
homogenization. At the end of the incubation period, the cells were washed twice with an ice-cold 
homogenization solution containing 100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 5 mM 
dithiothreitol, 0.5 mM PMSF, 10 |J.g/ml leupeptin and 25 mM HEPES, adjusted with Tris to pH 7.4 and collected 
by scraping. The cells were subsequently homogenized at 4°C using a Potter-Elvehjem homogenizer (glass- 
teflon) by 10 strokes at 500 rev./min, 5 strokes at 1000 rev./min and 5 strokes at 1200 rev./min. Unbroken cells 
were removed by centrifugation at 50 g  for 5 min. For PLD measurements, aliquots of the homogenate were 
taken and 0.5 mM Mg-ATP and 1% (v/v) ethanol were added with or without PMA and CaCl2 at final 
concentrations of 0.1 |xM and 0.5 mM, respectively. The homogenate was incubated for 30 min at 37°C. The re­
action was quenched with 1 ml ice-cold methanol and lipids were extracted and separated as described above.
Partially purified PKC from rat brain
Partially purified PKC, to be added to homogenates of CHO-CCKA cells in which PKC was downregulated, was 
prepared from rat brain essentially as described previously (Ederveen et al, 1992). Briefly, rat brain tissue was 
homogenized in a buffer containing 20 mM Tris/HCl (pH 7.5), 0.25 M sucrose, 10 mM EGTA, 2 mM EDTA, 
0.2 mg/ml soybean trypsin inhibitor, 5 mM dithiothreitol, 1 mM PMSF, 10 |J.g/ml aprotinin and 10 |J.g/ml 
leupeptin. The homogenate was applied to a protamine-agarose column. Non-specifically bound protein was 
eluted with a buffer containing 20 mM Tris/HCl (pH 7.5), 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, 10 
mM MgCl2  and 1 M KCl. Subsequently, PKC was eluted with the same buffer containing 0.7 M KCl and 1 mM 
ATP. Western blot analysis revelead the presence of PKCa, 3, % 8, e, Z, n, and d.
Fluorescence measurements in suspensions ofCHO-CCKA cells
Measurement of the [Ca2+] in CHO-CCKA cells has been described in detail previously (Smeets et al, 1997, 
1998b, c). In brief, cells were loaded with the specific fluorescent calcium indicator, fura-2. Fluorescence 
measurements were carried out at 37°C and the fluorescence emission ratio was monitored as a measure of 
[Ca2+] at 490 nm after excitation at 340 and 380 nm.
PKC-isotype measurements in CHO-CCKA cells
PKC-isotype measurements were performed as described in detail previously (Smeets et al., 1996, 1998b).
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Figure 1. Time-dependence of 
CCKg- and PMA-stimulated 
formation of f.H]PtdEth in 
CHO CCKa cells. CHO-CCKa 
cells, labeled with [3H]myristic 
acid for 24 h, were stimulated 
with either 10 nM CCK8 (open 
circles), 0.1 |xM PMA (closed 
diamonds), 0.3 |xM PMA 
(closed triangles), 1 |jM PMA 
(closed squares), or the combi­
nation of 10 nM CCK8 and 1 
|xM PMA (closed circles) in the 
presence of 1% (v/v) ethanol.
At the indicated times, the 
reaction was quenched by the 
addition of ice-cold extraction 
medium. The lipids were 
separated by HPTLC, radio- T i m e  ( m i n )
active spots were scraped off
and radioactivity was measured by liquid scintillation spectroscopy. In each experiment, the amount of [3H]PtdEth 
present in cells stimulated with 10 nM CCK8 alone for 30 min is set at 100%, to which all other values are related. 
The values presented are the mean ± S.E.M of 3-6 experiments. At all three measuring points the values obtained 
with PMA alone were significantly different (P<0.05) from those obtained with CCK8 alone.
Analysis of the data
The results presented are the mean ± S.E.M. of the number of experiments indicated in the text. Paired Student's 
t-tests were used to determine statistical differences (P<0.05).
RESULTS
Time course of CCK8- and PMA-stimulated [3H]-Phosphatidylethanol (PtdEth) formation 
in CHO-CCKa cells
Both the peptide hormone CCK8 and the phorbol ester PMA increased the amount of
3 3[3H]PtdEth time-dependently when added to cells labelled with [3H]myristic acid and 
incubated in the presence of 1% (v/v) ethanol (Fig. 1). The time course of the stimulatory 
effect of 10 nM CCK8 revealed that the rate of [3H]PtdEth formation was highest during the 
first 3 min of stimulation, after which it decreased to the significantly lower levels reached at 
10 min and maintained for at least another 20 min. CCK8-induced [3H]PtdEth formation was 
dose-dependent and maximal stimulation was obtained with 10 nM CCK8 (data not shown).
With PMA the rate of [ H]PtdEth formation was relatively constant during the first 10 
min and, depending on the PMA concentration, either remained constant (0.1 ^M), decreased 
markedly (0.3 ^M), or even fell back to zero (1 ^M), thereafter. This finding shows that the 
PMA response rapidly desensitized with higher PMA concentrations. Compared with CCK8, 
the effect of PMA (1 ^M) was significantly lower at all three measuring points. When added 
simultaneously, PMA (1 ^M) neither potentiated nor inhibited the stimulatory effect of 10 nM
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Figure 2. Extracellular Ca2+ dependence of the CCK8 induced increase in average cytosolic free Ca2+ 
concentration in a suspension of CHO-CCKa cells. CHO-CCKA cells, loaded with fura-2, were resuspended in 
either normal or Ca2+-free HEPES/Tris medium (pH 7.4) and transferred to a cuvette placed in a spectrofluorophoto- 
meter. Ca2+-free medium contained in addition 0.5 mM EGTA. At the indicated time, the cells were stimulated with 
either 1 |xM thapsigargin or 10 nM CCKg and the fluorescence emission ratio at 490 nm was monitored as a measure 
of the average cytosolic free Ca2+ concentration after excitation at 340 and 380 nm.
CCK8. This observation demonstrates that the mechanism underlying desensitization of the 
PMA response did not affect the CCK8 response.
Comparison of the CCK8-, thapsigargin- and PMA-stimulated f  H]PtdEth formation in 
CHO-CCKa cells
In addition to stimulating PLD, 10 nM CCK8 evoked a rapid and sustained increase in the
2+ 2+ average cytosolic free Ca concentration ([Ca ]iav) in a suspension of CHO-CCKA cells
2+(Fig. 2). To study the relative importance of this sustained increase in [Ca2+]i in CCK8-
stimulated [3H]PtdEth formation, cells were stimulated with the sesquiterpene lactone thapsi-
2+gargin. Thapsigargin inhibits the endoplasmic reticulum Ca -ATPase (Lytton et al., 1991),
2+ 2+ leading to depletion of intracellular Ca stores and thus to an increase in store-regulated Ca
entry (Putney and Bird, 1993). As a result, [Ca2+]i remains elevated for a prolonged period of
time (Fig. 2). Figure 3 shows that 1 ^M thapsigargin alone markedly stimulated the formation
3 3of [ H]PtdEth. After correction for basal [ H]PtdEth formation, the thapsigargin-induced 
increase in [3H]PtdEth was calculated to be 70% of the value obtained with 10 nM CCK8. The 
effect of thapsigargin was not significantly different from that of PMA, which amounted to 
50% of the value obtained with 10 nM CCK8. The stimulatory effects of 1 ^M thapsigargin 
and 1 PMA were more than additive and the amount of [3H]PtdEth formed as a result of
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Figure 3. Inhibitory effect of staurosporine and chelerythrine on CCK8-, PMA- and thapsigargin-induced 
pHJPtdEth formation in CHOCCKA cells. CHO-CCKA cells, labeled with [3H]myristic acid for 24 h, were 
incubated in the absence (white bars) or presence of either 0.1 |jM staurosporine (black bars) or 50 |xM chelerythrine 
(hatched bars) for 5 min and subsequently, stimulated with either 10 nM CCK8, 1 |jM PMA, 1 |jM thapsigargin, or 
the combination of 1 |jM PMA and 1 |xM thapsigargin in the presence of 1% (v/v) ethanol for 10 min. The reaction 
was quenched at the indicated time and the lipids were separated by HPTLC. Radioactive spots were scraped off and 
radioactivity was measured by liquid scintillation spectroscopy. In each experiment, the amount of [3H]PtdEth 
present in cells stimulated with 10 nM CCK in the absence the two drugs is set at 100%, to which all other values 
are related. The values presented are the mean ± S.E.M. of 3-5 experiments. Significantly different (P<0.05) from 
the value obtained with 10 nM CCK8 alone. Significantly different (P<0.05) from corresponding stimulated cells. 
&Significantly different (p<0.05) from corresponding staurosporine-treated cells.
the combined action of both drugs was 1.4-fold higher than that obtained with 10 nM CCK8. 
Interestingly, PMA, when added at a 1000-fold lower concentration of 1 nM, did not increase 
PLD activity by itself, but significantly potentiated the stimulatory effect of 1 ^M 
thapsigargin to 100% (S.E.M.=10, n=3) of the value obtained with 10 nM CCK8.
Effect o f protein kinase inhibitors on the CCK8-, thapsigargin- and PMA-stimulated 
I3H]PtdEth formation, in CHO-CCKA cells
Both staurosporine (0.1 ^M), a general inhibitor of protein kinase activity (Ruegg and 
Burgess, 1989), and chelerythrine (50 ^M), a specific inhibitor of PKC (Herbert etal., 1990), 
completely inhibited the stimulatory effect of PMA (Fig. 3). However, when added in 
combination with either CCK8, thapsigargin or the combination of PMA and thapsigargin, 
staurosporine invariably reduced the increase in [3H]PtdEth above the basal level to 30% of 
the value obtained with CCK8 alone, whereas chelerythrine virtually completely blocked 
[3H]PtdEth formation under all stimulatory conditions. The inhibitors did not significantly 
affect basal [3H]PtdEth formation.
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Table 1. Effect of long-term stimulation with PMA on CCK8-, PMA- and thapsigargin induced fH]PtdEth 
formation andPKCa, £ and Z levels in CHO-CCKA cells. CHO-CCKA cells, labelled with [3H]myristic acid for 24 
h, were incubated in the absence (o h PMA) or presence of 0.1 |jM PMA for either 3 or 24 h. Subsequently, cells 
were stimulated with 10 nM CCK8, 0.1 |xM PMA or 1 |jM thapsigargin in the presence of 1% (v/v) ethanol for 10 
min. The reaction was quenched at the indicated time and the lipids were separated by HPTLC. Radioactive spots 
were scraped off and radioactivity was measured by liquid-scintillation spectroscopy. In each experiment, the amount 
of [3H]PtdEth present in untreated cells stimulated with 10 nM CCK8 is set at 100%, to which all other values are 
related. Except for thapsigargin and 24 h PMA, the values presented are the means±S.E.M. of three experiments. For 
PKC-isotype measurements, total cell lysates were subjected to SDS/PAGE followed by Western blotting. 
Membranes were incubated with protein kinase C isotype-specific antibodies in the presence (aspecific staining) and 
absence (total staining) of the corresponding isotype-specific peptides. PKC-specific bands were quantified 
densitometrically. In each experiment, the mean optical density of the untreated control is set at 100%, to which all 
other values are related. The results presented are the mean ± S.E.M. of three experiments. Significantly different 
(P<0.05) from corresponding unstimulated cells. Significantly different (P<0.05) from corresponding untreated (0 h 
PMA) cells. n.d., not determined.
0 h PMA 3 h PMA 24 h PMA
Relative PLD activity
Unstimulated 11.6±1.2- -
PMA 31.0±3.1* 13.0±2.1# 9.1
CCK8 100* 15.3±2.3# 10.7
PMA+CCK8 114±23* - -
Thapsigargin 83 15.3 n.d.
Relative PKC levels
PKCa 100 6.0±3.6# 3.3±3.3#
PKCe 100 68.7±18.5# 18.8±4.0#
PKCZ 100 90.0±13.8 101.2±4.8
Extracellular Ca2+ dependence of CCK8- and PMA-stimulated [3H]PtdEth formation in 
CHO CCKa cells 2+CCK8 (10 nM) transiently increased [Ca ]i,av in a suspension of CHO-CCKA cells incubated 
in the absence of extracellular Ca2+ (Fig. 2). Under these conditions the increase in [3H]PtdEth
in response to 10 nM CCK8 was dramatically reduced by 87.8% (S.E.M.=2.5, n=4). In con-
2+trast, the stimulatory effect of 1 |iM PMA was even enhanced in the absence of external Ca 
by 63.4% (S.E.M=9.8, n=4).
Effect o f PKC downregulation on C C K - PMA- and thapsigargin-induced [3H]PtdEth 
formation in CHO-CCKA cells
Immunoblotting revealed that CHO-CCKA cells contained detectable amounts of PKCa, 
PKCe and PKCZ These three PKC isotypes were differentially downregulated during 
prolonged PMA (0.1 ^M) treatment. The amount of PKCa was decreased by 94% after 3 h of 
incubation in the presence of PMA, whereas PKCe was maximally decreased after 24 h of 
PMA treatment (Table 1). In contrast, the amount of PKCZ remained unchanged. The
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Figure 4. Effect o f long-term PMA treatment on PMA- and Ca2 -induced formation of ¡3H]PtdEth in CHO- 
CCKa homogenates. CHO-CCKA cells, labeled with [3H]myristic acid for 24 h, were incubated in the absence (0 
h PMA) or presence of 0.1 |xM PMA for either 3 h or 24 h. Subsequently, cells were homogenized and 
homogenates were stimulated with 0.1 |xM PMA and 0.5 mM CaCl2 in the presence of 1% (v/v) ethanol and in 
the absence or presence of purified rat brain PKC for 30 min. The reaction was quenched at the indicated time 
and the lipids were separated by HPTLC. Radioactive spots were scraped off and radioactivity was measured by 
liquid scintillation spectroscopy. In each experiment, the amount of [3H]PtdEth formed in homogenates from 
untreated cells following incubation in the presence of PMA and Ca2+ is set at 100%, to which all other values 
are related. The values presented are the mean ± S.E.M. of 4 experiments. Significantly different (P<0.05) from 
the unstimulated conditions of untreated cells.
preferential decrease in PKCa was accompanied by a rapid decrease in CCK8-stimulated 
[3H]PtdEth formation. The response to 10 nM CCK8 was abolished 3 h after the onset of PMA 
treatment. Similarly, the stimulatory effect of thapsigargin was completely inhibited at 3 h of 
PMA treatment.
Effect of partially purified PKC on PMA/Ca2+-stimulated PLD activity in homogenates of 
PKC-downregulated CHO-CCKa cells
Preleminary experiments to determine the optimal concentrations of PMA and CaCl2  revealed 
that with CaCl2 alone a maximal increase above basal (65% of the value obtained with 0.1 
PMA and 0.5 mM CaCl2) was obtained at a concentration of 0.5 mM. In the presence of 
0.5 mM CaCl2, PMA further increased PLD activity to the maximum reached at 0.1 ^M. The 
increase above basal levels with 0.1 ^M PMA alone amounted to only 13% of the value 
obtained with 0.1 ^M PMA and 0.5 mM CaCl2. Importantly, this activation profile of PLD is 
identical with that of PKC.
Figure 4 shows that addition of 0.1 PMA and 0.5 CaCl2 resulted in a 2.5-fold
2+increase in PLD activity in a homogenate of CHO-CCKA cells. PMA/Ca -stimulated PLD
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activity dependend largely, but not entirely, on ATP, since without its addition only a 1.4-fold 
(S.E.M.=0.1, n=4) increase in PLD activity was observed. PMA/Ca2+-stimulated PLD activity 
was dramatically decreased in homogenates of cells pretreated with PMA for 3 h and 
abolished after 24 h of phorbol ester treatment (Fig. 4). Addition of partially purified PKC 
from rat brain did not affect PMA/Ca2+-stimulated PLD activity in untreated cells, while 
virtually completely restoring this activity in homogenates of PMA-treated cells. Addition of 
PKC had no significant effect on PLD activity measured in the absence of PMA and CaCl2.
DISCUSSION
This present study demonstrates that CCK8 increases PLD activity in CHO-CCKA cells solely
2+through PKC and an increase in [Ca ]i, and that no other pathway is involved. This 
conclusion is based on the following observations: (i) PKC, most probably PKCa, is 
indispensable for receptor-mediated PLD activation; (ii) receptor-mediated PKC activation in 
itself hardly increases PLD activity; and (iii) the extent to which PLD becomes activated
during receptor-mediated PLD activation depends largely, if not completely, on the duration
2+and magnitude of the agonist-induced increase in [Ca ]i.
(i) Evidence for the absolute requirement of CCK8-induced PLD activation for PKC 
comes from the following observations. First, neither CCK8 nor PMA increased PLD activity
in PKC downregulated cells, notwithstanding the fact that CCK8, as has been demonstrated
2+previously (Smeets etal., 1996), causes a sustained increase in [Ca ]i in PMA-treated cells. 
Consistent with the latter finding, thapsigargin did not increase PLD activity in cells in PKC 
downregulated cells. Secondly, the PKC inhibitor chelerythrine completely blocked the 
stimulatory effects of CCK8, PMA, thapsigargin and the combination of the latter two drugs. 
Thirdly, PMA/Ca2+-stimulated PLD activity was completely inhibited in a homogenate of 
PKC-downregulated cells but could be restored after addition of partially purified PKC from 
rat brain.
An absolute requirement of agonist-, phorbol ester- and Ca2+-induced PLD activation
for PKC has been reported in a wide variety of cell types (Pfeilschifter and Huwiler (1993);
Balboa etal., 1994; Gustavsson etal., 1994; Zheng et al., 1994), CHO cells expressing the
platelet-activating factor (PAF) receptor (CHO-PAF cells) (Liu et al., 1994). Noticeably,
these studies did not take into account the possibility that prolonged treatment with phorbol
ester might have led to downregulation of factors other than PKC that may play a role in
receptor-mediated PLD activation. However, given the finding that the effect of CCK8
2+ 2+ depends largerly on its effect on [Ca ]i, the observation that PMA/Ca -stimulated PLD
activity in a homogenate of PKC-downregulated cells was completely restored after addition
of partially purified PKC does not support this possibility.
Evidence has been provided that AlF4--insensitive monomeric G-proteins, such as
ARF and Rho, can directly activate PLD (Hammond et al., 1995). Thus far, however, the
mechanism by which agonists activate these small G-proteins is unknown. In a recent study it
was demonstrated that AlF4- stimulation of PLD activity in Saos-2 cells through heterotrimeric
G-proteins was accompanied by redistribution of ARF and RhoA to the membrane (Bourgoin
et al., 1996). Since the effects of AlF4- and phorbol ester were more than additive, and
preferential downregulation of PKCa by chronic phorbol ester treatment abolished the effect
of the phorbol ester, but not that of AlF4 -, it was proposed that these small G-proteins act
synergistically with PKC in receptor-mediated PLD activation. Of note is the similar additive
effect between agonist and phorbol ester that was observed in CHO cells expressing the V1a
vasopressin receptor (CHO-V1a cells) and regarded as indicative of the existence of different
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mechanisms of PLD activation (Garces et al., 1995). However, the present finding that 
preferential downregulation of PKCa completely inhibited the action of CCK8 supports the 
idea that no factors other than PKC are involved in agonist-induced PLD activation in CHO- 
CCKa cells.
Immunoblot analysis revealed that the loss of PMA- and CCK8-induced PLD activati­
on, as observed during chronic PMA treatment, correlated best with the disappearance of 
PKCa. In contrast with this study, preferential downregulation of PKCa in CHO-PAF cells 
by 6 h exposure to 0.1 ^M phorbol ester has previously been found not to completely inhibit 
agonist- and phorbol ester-induced PLD activation (Liu etal., 1995). Similarly, in CHO-V1a 
cells, 3 h exposure to 0.1 ^M phorbol ester did not even reduce agonist-induced PLD ac­
tivation by half (Garces etal., 1995), whereas the effect of the phorbol ester was virtually 
completely inhibited (Dunlop and Clark, 1993; Garces e ta l., 1995). The possibility that the 
V1a receptor activates an additional PKC-independent pathway leading to PLD activation is 
unlikely, since agonist-induced PLD activation was completely inhibited by calphostin-C 
(Garces etal., 1995).
Intriguingly, despite the fact that CCK8, thapsigargin and the combination of PMA and 
thapsigargin increased PLD activity to a different extent, staurosporine invariably reduced 
stimulated PLD activity to 30% of the value obtained with CCK8 alone. Given the absolute 
requirement for PKC and the fact that staurosporine acts as a competitive inhibitor at the 
ATP-binding site (Ruegg and Burgess, 1989), this suggests that the greater part of the agonist- 
induced increase in PLD activity occurs in a phosphorylation-dependent manner. The smaller 
staurosporine-resistant part may then reflect the ATP-independent PKC-mediated pathway 
originally postulated by Conricode et al. (1992). In agreement with this idea, PMA/Ca2 - 
stimulated PLD activity in a homogenate of CHO-CCKA cells was shown to depend largely, 
but not entirely, on the presence of ATP in the assay medium. Also in agreement with this 
idea, chelerythrine, which acts in a competitive fashion with respect to the phosphate acceptor 
(Herbert et al., 1990), completely inhibited CCK8-induced increase in PLD activity. 
Staurosporine abolished PMA-induced PLD activation, suggesting that the phorbol ester acts 
entirely via the phosphorylation-dependent pathway. This then suggest that the ATP- 
independent pathway is activated by the sustained increase in [Ca2+]i observed with CCK8 and 
thapsigargin.
ii) The observation that in the absence of external Ca2+ the effect of CCK8 was inhibi­
ted by 90% demonstrates that receptor-mediated PKC activation in itself only marginally
2+ 2+contributes to agonist-induced PLD activation. The absence of external Ca prevented [Ca ]i 
from being increased for prolonged periods of time, demonstrating that a sustained increase in 
[Ca2+]i is required for full activation of PLD. In contrast with the present study, agonist and 
phorbol ester displayed the same maximal effect in CHO-V1a (Garces etal., 1995) and CHO- 
PAF (Liu etal., 1994) cells. In view of the above discussion, however, this discrepancy might 
be explained by the higher magnitude of the sustained increase in [Ca2+]i in CHO-CCKA cells 
as compared with CHO-V1a cells.
iii) The finding that thapsigargin increased PLD activity to 70% of the value obtained 
with 10 nM CCK8 suggests that only 30% of receptor-induced PLD activation depends on 
DAG-mediated PKC activation. This is in agreement with the observation that low-level PKC 
activation by 1 nM PMA, which did not affect PLD activity by itself, potentiated the stimu­
latory effect of thapsigargin to a level similar to that obtained with 10 nM CCK8. The 
thapsigargin response was further increased to 138% of the value obtained with 10 nM CCK8 
by a PMA concentration (1 ^M) that was maximally effective in stimulating PLD activity by 
itself. Surprisingly, the response to the latter PMA concentration was also increased under
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2+ 2+ conditions when [Ca ]  was most likely to be decreased as a result of the omission of Ca
from the medium. At present, the reason for this apparent discrepancy is unclear.
Taken together, the present observations are consistent with the idea that agonist-
induced PLD activation in CHO-CCKA cells occurs in a PKC-dependent manner, most
problably involving both a phosphorylating and a non-phosphorylating mechanism. Despite
its indispensability, however, the contribution of PKC activation alone in receptor-mediated
2+PLD activation is low compared with that of the increase in [Ca ]i.
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Preliminary experiments revealed marked differences in relative expression levels of the protein 
kinase C (PKC) isoforms a  and e between metastatic and non-metastatic human melanoma cell 
lines (Bosch, Ahmadian, Langeslag, Jonsson, van Emst-de Vries, van Kempen, Swart, Willems, 
unpublished observations). In the non-metastatic cell lines 530 and 1F6-L the expression level of 
PKCe was relatively high as compared to the metastatic cell lines BLM and MV3, whereas, in 
contrast, the expression level of PK Ca was relatively low in 530 and 1F6-L cells as compared to 
BLM and MV3 cells. Moreover, phorbol ester (PMA)-induced phospholipase D (PLD) activation 
was shown to be more than halved in 530 cells as compared to BLM cells. The aim of the present 
study was to assess possible effects of PKCe on the expression level of PKCa and/or the PKCa- 
mediated activation of PLD. To this end, PKCe was overexpressed in Chinese hamster ovary 
cells expressing the cholecystokinin-A (CCKA) receptor. Western blot analysis revealed that 
overexpression of PKCe did not change the expression level of PK Ca and vice versa. However, 
PKCe overexpression abolished PMA-induced PLD activation, while partially inhibiting the 
stimulatory effects of thapsigargin, a potent elevator of cytosolic Ca2+, and cholecystokinin-(26- 
33)-peptide amide (CCK8). Addition of a cytosol fraction from PKCe overexpressing cells to a 
membrane fraction from mock-transfected cells resulted in virtually complete inhibition of 
PMA-induced PLD activation. PMA-induced translocation of PK Ca was not altered, indicating 
that PKCe did not act by sequestering PMA. In contrast, GTPyS-induced PLD activation was 
not altered. Consistent with this, PKCe overexpression did not alter the expression levels of 
PLD1, RhoA and ARF6. Taken together, these findings are compatible with a direct effect of 
PKCe on PKCa-mediated PLD activation. The present findings may provide a clue to the 
unraveling of the oncogenic potency of PKCe reported in the literature. Therefore, the present 
findings may be of eminent importance in cancer research.
INTRODUCTION
A common cellular event induced by many hormones, neurotransmittors, growth factors, 
cytokines and antigens is the enzymatic breakdown of membrane phospholipids to produce 
intracellular messengers (Exton, 1994, 1997a, 1999). Both, 1-phosphatidylinositol- 
phosphodiesterase (PLC) and phosphatidylcholine phosphatidohydrolase (PLD) are 
dominantly involved in the receptor-regulated production of lipid-derived signalling
molecules. PLC-catalyzed conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) yields
2+inositol 1,4,5-trisphosphate, which promotes the release of Ca from the endoplasmic 
reticulum (Berridge, 1993), and diacylglycerol, the endogenous activator of protein kinase C 
(PKC) (Nishizuka, 1992). PLD catalyzes the conversion of phosphatidylcholine (PtdCho) to
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phosphatidic acid (PtdOH). Although PtdOH in itself may act as a signalling molecule 
(Cockcroft, 1996a; Exton, 1997a), increasing evidence suggests that it also may serve as a 
precursor in the formation of diacylglycerol (Hermans et al., 1996; Hodgkin et al., 1998), 
implying that PLD, similarly to PLC, is involved in the activation of PKC. Importantly, 
because the diacylglycerols derived from Ptdlns and PtdCho differ in fatty acid composition 
and/or are generated in different subcellular compartments, it is very well possible that they 
may activate different PKC isoforms (Nishizuka, 1992; Jaken, 1996).
PLD activity is routinely measured by taking advantage of its characteristic feature to 
prefer primary short-chain alcohols to water in the catalysis reaction (Dawson, 1967; 
described in detail in Waite, 1999). The product formed in this transphosphatidylation 
reaction, phosphatidylethanol (PtdEth), is a unique phospholipid that can be separated by thin 
layer chromatography for quantification. Using this method it has been shown that phorbol 
esters, potent activators of PKC, can readily increase the activity of PLD in by far most of the 
cell types investigated (Cockroft, 1996a; Kiss, 1996). Moreover, circumstantial evidence was 
provided suggesting that certain PKC isoforms play a crucial role in the mechanism of action 
of most, but not all, of the stimuli that activate PLD (Billah et al., 1991; Kiss, 1996; Gomes- 
Cambronero and Keire, 1998; Exton, 1999). For instance, PKC downregulation was shown to 
abolish agonist-induced PLD activation in CHO cells expressing the CCKA receptor (Bosch et 
al., 1999), but not in MDCK-D1 cells stimulated with epinephrine (Balboa and Insel, 1998). 
Similarly, cAMP- and NaF-induced PLD activation were shown to be insensitive to PKC 
downregulation in FRTL-5 thyroid cells (Ginsberg et al., 1997) and osteoblast-like cells 
(Bourgoin et al., 1996), respectively. In the latter case, NaF-induced PLD activation was 
suggested to occur entirely through the small GTPases ARF and Rho. Importantly, the 
stimulatory effects of NaF and a phorbol ester were shown to be supra-additive suggesting a 
synergistic effect of PKC and the small GTPases on PLD activation in these cells. In a recent 
study, transposon mutagenesis was used to generate a pentapeptide insertion mutant of PLD1 
(PIM87) that was not activated by PKC in vitro or by the phorbol ester 12-0- 
tetradecanoylphorbol 13-acetate (PMA) in vivo but showed a wild-type response to RhoA and 
ARF1 in vitro (Zhang et al., 1999). Importantly, carbachol only minimally increased the 
activity of this PKC-insensitive PLD1 mutant following co-expression with the m1 
muscarinic receptor in HEK293 cells, whereas, in contrast, PLD activity was markedly 
increased following co-expression of wild-type PLD1 with this receptor. This finding 
demonstrates that a PKC-sensitive PLD is required for agonist-induced PLD activation.
At present, 11 isoforms of PKC have been identified (Jaken, 1996). Of these, the
conventional and novel, but not the atypical, isoforms are stimulated by diacylglycerol,
2+whereas only the conventional isoforms are sensitive to Ca . In vitro studies using 
recombinant PLD1 have shown that the activity of this enzyme is increased by the 
conventional isoforms a  and P, but not y (Min et al., 1998a). In addition, neither the novel nor 
the atypical PKC isoforms increased the activity of PLD1 in this artificial system.
Many cells, including CHO-K1 cells (Smeets et al., 1996), express substantial 
amounts of the novel PKCe in addition to PKCa. PKCe has unique properties among the PKC 
isoforms in that it contains motifs in the regulatory N-terminal region that are postulated to 
function as localization signals capable of anchoring this kinase within the cytoskeletal matrix 
(Prekeris et al., 1998) or to target it to either the Golgi or plasma membranes (Lehel et al.,
1995). PKCe has been implicated in the regulation of a wide variety of cellular functions 
(summarized in Prekeris et al., 1998). Of particular importance for this study, PKCe has been 
reported to act as an oncogene when overexpressed in rat fibroblasts (Cacace et al., 1993) and 
NIH 3T3 cells (Mischak et al, 1993). This latter observation has attracted our attention 
because preliminary experiments revealed marked differences in relative expression levels of
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PKCa and PKCe between metastatic and non-metastatic human melanoma cell lines (RR 
Bosch, MR Ahmadian, M Langeslag, MW Jonsson, SE van Emst-de Vries, LCLT van 
Kempen, GWM Swart, PHGM Willems, unpublished observations). Thus, in the non­
metastatic cell lines 530 and 1F6-L the expression level of PKCe was relatively high as 
compared to the metastatic cell lines BLM and MV3, whereas, in contrast, the expression 
level of PKCa was relatively low in 530 and 1F6-L cells as compared to BLM and MV3 
cells. Moreover, PMA-induced PLD activation was shown to be more than halved in 530 cells 
as compared to BLM cells. The aim of the present study was to investigate possible effects of 
PKCe on PKCa expression and/or PKCa-mediated PLD activation. To this end, PKCe was 
overexpressed in Chinese hamster ovary (CHO) cells expressing the cholecystokinin-A 
(CCKa) receptor. The data presented suggest that PKCe associates with PLD1 to prevent 
PKCa-mediated activation of the enzyme. The present findings may be of eminent 
importance in cancer research.
MATERIALS AND METHODS
Materials
CCK8, PMA, leupeptin, calpain inhibitor, soybean trypsin inhibitor, diacylglycerol, phosphatidylserine and 
2,2,4-trimethylpentane were obtained from Sigma (St. Louis, MO, USA) and thapsigargin from LC Services 
(Woburn, MA, USA). Phenylmethylsulfonyl fluoride was purchased from SERVA (Heidelberg, Germany) and 
dithiothreitol from Research Organics (Cleveland, OH, USA). Aprotinin was obtained from Fluka Chemie 
(Buchs, Switzerland) and [y-32P]ATP (3000 Ci/mmol) and [9,10(n)-3H]myristic acid (53 Ci/mmol) from The 
Radiochemical Centre (Amersham, UK). HPTLC silica-gel 60 plates, ethylacetate and chloroform were 
purchased from Merck (Darmstadt, Germany), phospholipid standards from Avanti Polar Lipids (Birmingham, 
AL, USA). Isotype-specific PKC antibodies and tissue culture medium with additives was obtained from Gibco 
(Paisley, Scotland) and I-block Reagent from Tropix (Bedford, MA, USA). All other chemicals were of reagent 
grade.
Development o f a stable CHO-CCKA cell line
The development of a stable CHO-CCKA cell line has been described in detail previously (Smeets et al., 1996). 
Transfection o f CHO-CCKA cells with PKC isoforms
CHO-CCKa cells were grown to confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) 
fetal calf serum (FCS) in a humidified atmosphere of 5% CO2 at 37 °C. For transfection, cells were trypsinized 
and transferred to a cuvette (5 x106 cells 300 ill-1). The cells were electroporated (250 V, 960 |xF) in the presence 
of 20 |j.g plasmid DNA (62.5 ng/ml). The cDNA encoded either bovine PKCa or mouse PKCe (Schaap et al, 
1989, 1993), subcloned in pcDNA3. As a control, cells were electroporated in the presence of the empty vector. 
Cells were used for experiments at 48 h post-transfection.
Protein kinase C activity measurements in CHO-CCKA homogenates
CHO-CCKA cells were washed 4 times with phosphate buffered saline (PBS), scraped off, and resuspended in a 
homogenization solution containing 10 mM EGTA, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 20 ^M 
leupeptin, 0.5 ^g/ml aprotinin, 1 ^M calpain inhibitor, 0.2 mg/ml trypsin inhibitor and 20 mM Tris, adjusted 
with HCl to pH 7.4. The cells were homogenized at 4 °C using a Potter-Elvehjem homogenizer (glass-teflon) by 
10 strokes at 500 rev./min, 5 strokes at 1000 rev./min and 5 strokes at 1200 rev./min and sucrose was added at a 
final concentration of 0.25 M. PKC activity was determined as described by Van der Hoeven et al. (2000). 
Briefly, cell lysate (0.40 ^g of protein) was mixed with a buffer containing 20 mM HEPES (pH 7.4), 10 mM 
MgCl2, 1 mM EGTA, 0.5 mM Na2VO4, 100 ^M [y-32P]ATP (spec. act. 0.2 Ci/mmol), 50 ^M e-peptide
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(ERMRPRKRQGSVRRRV) covalently bound to NHSLC-biotin (Pierce, Rockford, IL, USA), 100 ^g/ml 
phosphatidylserine and 10 ^g/ml diacylglycerol. The mixture (25 ^l) was incubated in the absence (PKCe 
overexpressing cells) or in the presence (PKCa overexpressing cells) of 0.5 mM CaCl2 for 25 min at 37 °C after 
which an excess of streptavidin-agarose beads (20 ^l) was added. At 30 min, the reaction was quenched with 3 
ml ice-cold stop solution containing 25 mM EDTA, 1 M NaCl and 25 mM HEPES (pH 7.4). The suspension was 
rapidly filtered (GF/A filter, Whatman, Maidstone, UK). The filters were washed thoroughly (10-12 times) with 
ice-cold stop solution, dissolved in scintillation fluid, and counted for radioactivity.
Phospholipase D measurements in intact CHO-CCKA cells
For PLD measurements, the cells were subcultured in 12-well plates (2.5 x 105 cells/well) and labelled with 
[3H]myristic acid (2 ^Ci/ml) for 24 h. At the end of the labelling period, the cells were washed and incubated in 
DMEM without FCS for 3 h. Subsequently, the cells were washed and incubated in DMEM containing 1% (v/v) 
ethanol for the indicated period of time. At the indicated time, the medium was aspirated and the reaction was 
quenched by the addition of 1 ml ice-cold methanol. The cells were scraped off and the mixture was transferred 
into a lipid tube (Sarstedt, Essen, Germany). Lipids were extracted according to the method described by Bligh 
and Dyer (1959). Briefly, 500 ^l chloroform and 400 ^l water were added and the mixture was mixed 
vigorously. Phase separation was achieved by addition of 400 ^l of chloroform and 400 ^l of water followed by 
centrifugation. After collection of the lower organic phase, the aqueous phase was extracted again and the 
combined organic phases were blown to dryness with N2. PLD activity is expressed as the percentage of lipid- 
incorporated label that is present in [3H]PtdEth.
Separation o f labelled phospholipids
The dried extracts were dissolved in 20 ^l chloroform/methanol (9:1, v/v) and the lipids were separated by thin- 
layer chromatography using potassium oxalate-treated silica-gel 60 HPTLC plates. The plates were developed 
with the upper phase of a mixture of ethylacetate/2,2,4-trimethylpentane/acetic acid/water (13:2:3:10, by vol.). 
Radioactive spots corresponding to authentic lipid standards were visualized by I2-staining and scraped off. 
Radioactivity was measured by liquid-scintillation spectrometry.
Phospholipase D measurements in membranes o f CHO-CCKA cells
CHO-CCKa cells were electroporated in the presence of 2 |j.g of pGFP-N1 (Clontech, Palo Alto, CA, USA) and 
18 |j.g of either pcDNA3-PKCe or empty vector. After 24 h of culturing, GFP-positive and -negative cells were 
separated by fluorescence-activated cell sorting (FACS). Subsequently, cells were grown in DMEM containing 
10% (v/v) FCS and 2 ^Ci/ml [3H]myristic acid for another 24 h. PLD activity was measured in cell membranes 
according to the method described by Ohguchi et al. (1996). Before homogenization, the cells were washed and 
incubated in DMEM without FCS for 3 h. At the end of this incubation period, the cells were washed twice with 
an ice-cold homogenization solution containing 100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 5 mM 
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 ^M leupeptin and 25 mM HEPES, adjusted with Tris 
to pH 7.4, and collected by scraping. The cells were transferred to a Potter-Elvehjem homogenizer (glass-teflon) 
and homogenized at 4 °C by 10 strokes at 500 rev./min, 5 strokes at 1000 rev./min and 5 strokes at 1200 
rev./min. The homogenate was centrifuged at 100,000 g for 1 h and the supernatant (cytosolic fraction) was 
collected. The pellet (membrane fraction) was resuspended in an equal volume of homogenization buffer. For 
PLD measurements, aliquots of the membrane fraction were taken and either homogenization buffer or cytosol 
fraction was added. Mg-ATP (0.5 mM), CaCl2 (0.5 mM) and 1% (v/v) ethanol were added. The reaction mixture 
was incubated in the absence or presence of either PMA (0.1 |xM) or GTPyS (10 |xM) for 30 min at 37 °C. The 
reaction was quenched with 1 ml ice-cold methanol and the lipids were extracted and separated as described 
above.
Determination o f PLD1, RhoA, ARF6, PKCa and PKCe
CHO-CCKa cells overexpressing either PKCa or PKCe were grown in DMEM containing 10% (v/v) FCS for 48 
h post-transfection. Where indicated, total cell lysates or membrane and cytosol fractions were prepared,
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subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to polyvinylidine difluoride 
membranes (Immobilon P, Millipore) by Western blotting. For the determination of PLD1, membranes were 
blocked for 1 h at RT with PBS (pH 7.4) containing 1% (w/v) milkpowder and 0.1% (v/v) Tween-20 (PBST- 
MLK). Then, the membranes were incubated overnight at 4°C with the rabbit anti-hPLD1 antibody described by 
Muller-Wieprecht et al. (1998) diluted 1:1000 in PBST-MLK. The antibody was kindly provided by Prof. dr. 
C.C. Geilen (University Medical Center Benjamin Franklin, The Free University of Berlin, Germany). 
Immunoreactive protein was detected by incubating the blots for 1 h at RT with goat anti-rabbit IgG conjugated 
to alkaline phosphatase diluted 1:1000 in PBST-MLK. Membranes were washed with PBS (pH 7.4) containing 
0.1% (v/v) Tween-20 and stained with 0.1 M diethanolamine, 0.34 mg/ml Nitroblue tetrazolium, 0.18 mg/ml 5- 
bromo-4-chloro-3-indolylphosphate and 50 mM MgCl2. For the determination of RhoA and ARF6, membranes 
were blocked for 1 h at RT in TBST-buffer containing 10 mM Tris/HCl (pH 8.0), 85 mM NaCl, 0.05% (v/v) 
Tween-20, 0.1% (w/v) BSA and 5% (w/v) milkpowder. Membranes were washed twice in TBST and incubated 
for 1 h at RT with either mouse anti-RhoA antibody (1:500, Santa Cruz Biochtechnology Inc., Santa Cruz, CA, 
USA) or the rabbit anti-ARF6 antibody described by Song et al. (1998) diluted 1:500 and 1:1000 in TBST, 
respectively. Membranes were washed 5 times in TBST and incubated overnight at 4°C with either rabbit anti­
mouse IgG (1:1000 in TBST) or goat anti-rabbit IgG (1:1000 in TBST) both conjugated to alkaline phosphatase. 
Membranes were washed 5 times in TBST before staining. PKC-isotype detection was performed as described in 
detail previously (Smeets etal., 1996,1998a,1998b). The membranes were scanned by an Imaging Densitometer 
(Biorad, Munich, Germany).
Analysis of the data
The results presented are the mean ± S.E.M. of the number of experiments indicated in the text. Overall 
statistical significance was determined by analysis of variance. In the case of significance (P<0.05), individual 
groups were compared according to Fisher.
RESULTS
Overexpression ofPKCa and PKCe in CHO-CCKA cells
The present study investigates the effects of PKCa and PKCe overexpression on CCK8-,
PMA- and thapsigargin-induced PLD activation in CHO-CCKA cells. Thapsigargin inhibits
the endoplasmic reticulum Ca2+-ATPase (Lytton et al, 1991), leading to depletion of 
2+ 2+ intracellular Ca2+ stores and thus to an increase in store-regulated Ca2+ entry (Putney and
Bird, 1993). Cells were electroporated in the presence of the cDNA of either PKCa (Fig. 1, 
lanes B and E) or PKCe (Fig. 1, lanes C and F) and used for PLD measurements at 48 h post­
transfection. Western blot analysis of total cell lysates revealed a marked increase of PKCa 
(Fig. 1, lane B) and PKCe (Fig. 1, lane F). Comparison of lanes A (mock-transfected cells) 
and C (PKCe-overexpressing cells) and of lanes D (mock-transfected cells) and E (PKCa- 
overexpressing cells) shows that overexpression of PKCe did not affect the endogenous 
expression level of PKCa and vice versa. Figure 2 shows that in both cases the increase of the 
amount of immunoreactive protein was paralleled by a significant increase in enzyme activity. 
Relative to mock-transfected cells, phosphorylation of e-peptide was increased 16-fold 
(S.E.M.=5.6; n=3) in a total cell lysate of PKCa overexpressing cells. On the other hand, 
phosphorylation of e-peptide was increased 2.9-fold (S.E.M.=1.0; n=3) in a total cell lysate of 
PKCe overexpressing cells. These data clearly demonstrate that CHO-CCKA cells express 
elevated levels of functionally active PKC-isoform at 48 h post-transfection with either PKCa 
or PKCe. FACS analysis of cells co-electroporated with the cDNAs of PKC and GFP-N1 at a 
molar ratio of 10 to 1 revealed a transfection efficiency of approximately 50% (data not 
shown). This indicates that approximately half of the cells overexpressed the PKC isoform.
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Figure 1. Overexpression o f PKCa and PKCe in 
CHO-CCKa cells. CHO-CCKA cells were 
electroporated with plasmid DNA containing the 
cDNA of either bovine PKCa (lanes B and E) or 
mouse PKCe (lanes C and F) subcloned in pcDNA3 
and grown for 48 h. As a control, cells were 
electroporated in the presence of empty vector 
(mock-transfected cells; lanes A and D). At the end 
of this culturing period, total cell lysates were 
prepared and subjected to SDS-polyacrylamide gel 
electrophoresis. Proteins were transferred to 
polyvinylidine difluoride membranes by Western 
blotting and probed with either rabbit anti-PKC 
(lanes A, B and C) or rabbit anti-PKC (lanes D, E 
and F).
Figure 2. Isoform-specific enzyme activities in 
homogenates o f PKCa and PKCe overexpressing 
cells. CHO-CCKa cells overexpressing either 
PKC or PKC were cultured for 48 h and 
homogenized. The homogenate was used for 
measurement of the PKC isoform-specific 
phosphorylation of e-peptide (ERMRPRKR- 
QGSVRRRV). In each experiment, 
phosphorylation of the -peptide in mock- 
transfected cells was set at 100% to which the 
values obtained with PKC and PKC 
overexpressing cells were related. The left bar 
shows phosphorylation of the -peptide in a total 
cell lysate of PKC overexpressing cells. The right 
bar shows phosphorylation of the -peptide in a 
total cell lysate of PKC overexpressing cells.
Significantly different from the corresponding 
value in mock-transfected cells (P < 0.05).
0
CCK8-, PMA-, and thapsigargin-stimulated fHJPtdEth formation is inhibited in CHO- 
CCKa cells overexpressing PKCe
CCK8 (10 nM), PMA (1 ^M) and thapsigargin (1 ^M) increased the amount of [3H]PtdEth, 
expressed as the percentage of lipid-incorporated label that is present in PtdEth, time- 
dependently when added to mock-transfected CHO-CCKA cells labelled with [ H]myristic 
acid and incubated in the presence of 1% (v/v) ethanol (Fig. 3). With all three stimulants, the 
rate of [3H]PtdEth formation was highest during the first 10 min. The kinetics of CCK8-, 
PMA- and thapsigargin-stimulated [ H]PtdEth formation was not altered at 48 h post-
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Figure 3. CCK8-, PMA-, and thapsigargin- 
stimulated ¡3H]PtdEth formation in CHO- 
CCKa cells overexpressing PKCa or PKCs. 
Mock-transfected CHO-CCKA cells (circles) 
or CHO-CCKa cells overexpressing either 
PKCa (squares) or PKCe (triangles) were 
cultured for 48 h. The cells were labelled with 
[3H]myristic acid during the last 24 h of 
culturing. At the end of the culturing period, 
cells were incubated in the absence (closed 
symbols) or presence (open symbols) of 10 nM 
CCK8, 1 |xM PMA, or 1 |xM thapsigargin in 
the presence of 1% (v/v) ethanol. At the 
indicated times, the reaction was quenched by 
the addition of ice-cold methanol. The lipids 
were separated by HPTLC, radioactive spots 
were scraped off, and radioactivity was 
measured by liquid scintillation spectroscopy. 
In each experiment, the amount of [3H]PtdEth 
present in mock-transfected cells stimulated 
for 10 min is set at 100%, to which all other 
values are related. The values presented are the 
mean ± S.E.M of 3 experiments. Significantly 
different from the corresponding value 
obtained with mock-transfected cells (P < 
0.05).
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transfection with PKCa. However, overexpression of PKCe markedly reduced the stimulatory 
effects of these three stimulants. At 10 min, CCK8-, PMA- and thapsigargin-stimulated 
[3H]PtdEth formation was inhibited by 30%, 44% and 22%, respectively, and in all three 
cases the percentage inhibition remained virtually the same during the next 20 min. Basal 
[3H]PtdEth formation did not significantly increase during 30 min of incubation. Moreover, 
basal [3H]PtdEth formation was not altered in cells overexpressing PKCa or PKCe. After 30 
min of incubation in the absence of any stimulant, the percentage [3H]PtdEth amounted to 
0.070% (S.E.M.=0.007, n=4), 0.063% (S.E.M.=0.009, n=4) and 0.060% (S.E.M.=0.003, n=4) 
in mock-transfected, PKCa-overexpressing and PKCe-overexpressing cells, respectively. 
These data indicate that overexpression of PKCe affects primarily the initial rapid phase of 
CCK8-, PMA- and thapsigargin-induced PLD activation.
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Figure 4. Comparison of the expression
levels of PKCs, PLD1, RhoA and Arf6 mock PKCe
between mock-transfected cells and cells n r n .  _  -U _  4-
overexpressing PKCs. CHO-CCKA cells 
expressing GFP alone (mock-transfected 
cells) or co-expressing GFP and PKCe 
(PKCe overexpressing cells) were cultured 
for 24 h after which GFP-positive and - 
negative cells were separated by 
fluorescence-activated cell sorting (FACS). 
At the end of another 24 h period of 
culturing, total cell lysates were prepared 
and subjected to SDS-polyacrylamide gel 
electrophoresis. Proteins were transferred to 
polyvinylidine difluoride membranes by 
Western blotting and probed with either 
rabbit anti-PKCe (1:500), rabbit anti- 
hPLDl (1:1000), mouse anti-RhoA (1:500) 
or rabbit anti-ARF6 (1:1000). /  «gggfÉÉ*
—  ARF6
PMA-, but not GTPyS-, stimulated PLD activity is absent in membranes from PKCe 
overexpressing cells
To study the mechanism(s) underlying the inhibitory action of PKCe overexpression on 
CCK8-, PMA-, and thapsigargin-induced PLD activation in more detail a procedure was 
developed to obtain a cell preparation enriched in PKCe-overexpressing cells. To this end, 
cells were co-transfected with the cDNAs of PKCe and GFP-N1 and cultured for 24 h. At the 
end of this culturing period, GFP-positive and -negative cells were separated by means of 
fluorescence activated cell sorting (FACS). Figure 4 (upper panel) shows that the GFP- 
positive cells expressed significantly more PKCe than the corresponding GFP-negative cells. 
GFP-positive cells were grown in the presence of [ H]myristic acid for another 24 h, 
homogenized, and subjected to centrifugation at 100,000 g for 1 h. The resultant supernatant 
(cytosol fraction) and pellet (membrane fraction) were used for PLD measurements. Neither 
PMA (0.1 ^M) nor GTPyS (10 ^M) increased the amount of [3H]PtdEth in a membrane 
fraction alone (data not shown). Figure 5 shows that in the case of mock-transfected cells 
recombination of the cytosol and membrane fraction resulted in a significant PMA- and 
GTPyS-induced increase in [ H]PtdEth. In the case of PKCe-overexpressing cells, however, 
the formation of [ H]PtdEth was increased only by GTPyS and not by PMA. Addition of the 
cytosol from PKCe-overexpressing cells to membranes from mock-transfected cells did not 
result in a PMA-stimulated PLD activity. Similarly, no PMA-induced PLD activity was 
observed following addition of cytosol from mock-transfected cells to membranes from 
PKCe-overexpressing cells. These findings are consistent with a direct effect of PKCe on 
PKCa-mediated PLD activation. In agreement with this idea, PKCe overexpression did not 
affect the expression levels of PLD1 (Fig. 4, panel two), RhoA (Fig. 4, panel three) and ARF6 
(Fig. 4, panel four). We investigated the expression level of ARF6 because, in contrast to 
ARF1, 3, 4 and 5, it is present at the plasma membrane in CHO-cells (Cavenagh et al., 1996).
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Figure 5. PMA- and GTPyS-stimulated PLD activity in a cell-free system following recombination of a cytosol 
and membrane fraction from mock-ransfected cells and cells overexpressing PKCs. CHO-CCKA cells 
expressing GFP alone (mock-transfected cells) or co-expressing GFP and PKCe (PKCe-overexpressing cells) 
were cultured for 24 h after which GFP-positive cells were collected by FACS and cultured in the presence of 
[3H]myristic acid for another 24 h. Subsequently, cells were homogenized and centrifuged at 100,000 g for 1h to 
prepare a cytosol and membrane fraction. Cytosol and membrane fractions were recombined as indicated and 
PMA (0.1 |xM)- or GTPyS (10 |xM)-induced PLD activity was measured in the presence of 1% (v/v) ethanol for 
30 min at 37 °C. The reaction was quenched with 1 ml ice-cold methanol. The lipids were separated by HPTLC, 
radioactive spots were scraped off and radioactivity was measured by liquid scintillation spectroscopy. In each 
experiment, the amount of [3H]PtdEth formed in the unstimulated condition is set at 100% to which all other 
values are related. The values presented are the mean ± S.E.M. of 3 experiments. Significantly different from 
the value obtained following homologous recombination of a cytosol and mebrane fraction from mock- 
transfected cells (P < 0.05).
Subcellular distribution and PMA-induced translocation of PKCa are not altered in CHO 
cells overexpressing PKCe
We previously showed a close relationship between the disappearance of PKCa and the loss 
of CCK8-, PMA- and thapsigargin-induced PLD activation during chronic PMA treatment of 
CHO-CCKa cells (Bosch et al., 1999). This finding stresses the importance of PKCa in the 
mechanism of action of these stimuli. Overexpression of PKCe did not change the overall 
expression of PKCa (see Fig. 1). However, it might very well have changed the subcellular 
distribution and/or stimulus-induced translocation of PKCa. Figure 6A shows that PKCa was 
exclusively present in the cytosol fraction of unstimulated mock-transfected cells and that this 
localization was not changed following overexpression of PKCe. The figure also shows that
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Figure 6. Effect o f PKCe overexpression on the subcellular distribution and PMA-induced translocation of
PKC . CHO-CCKA cells expressing GFP alone (mock-transfected cells) or co-expressing GFP and PKC 
(PKC overexpressing cells) were cultured for 24 h after which GFP-positive cells were collected by FACS and 
cultured for another 24 h. At the end of this culturing period, the cells were incubated in the absence (A) or 
presence (B) of 0.1 |xM PMA for 3 min at 37 °C. Next, the cells were homogenized and the homogenate was 
centrifuged at 100,000 g for 1h to prepare a cytosol and membrane fraction. The cytosol fraction was treated 
with trichloroacetic acid to precipitate the proteins. Precipitate and membrane fraction were taken up in sample 
buffer, subjected to SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidine difluoride 
membranes by Western blotting. In A the membranes were probed with either rabbit anti-PKC (lanes indicated 
with a) or rabbit anti-PKCe (lanes indicated with e). In B the membranes were probed with rabbit anti-PKCa.
PKCe is predominantly present in the membrane fraction of mock-transfected cells. However, 
in cells overexpressing PKCe this isoform was found to be present in both the membrane and 
cytosol fraction. Importantly, incubation of cells overexpressing PKCe with PMA (0.1 ^M) 
for 3 min still resulted in a marked translocation of PKCa from the cytosol to the membrane 
fraction (Fig. 6B). This demonstrates that overexpression of PKCe did not interfere with the 
PMA-induced translocation of PKCa.
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DISCUSSION
The results obtained in this study demonstrate the potential of PKCe to inhibit hormone- 
stimulated PLD activity in CHO cells. The cells stably expressed the CCKA receptor and 
previous work revealed that upon agonist binding this receptor promotes the phospholipase C-
mediated cleavage of PIP2 to yield DAG, the endogenous activator of PKC, and Ins 1,4,5-P3,
2+the physiological regulator of Ca release from the endoplasmic reticulum (Smeets et al., 
1996,1998c). In addition, we showed that CCK8-induced PLD activation is completely
dependent on PKC, but that the extent to which the enzyme becomes activated depends
2+largely on the magnitude and duration of the agonist-induced increase in cytosolic Ca 
(Bosch et al., 1999). PKCe overexpression also inhibited PMA- and thapsigargin-induced 
PLD activation. At 30 min, the percentage inhibition amounted to 31%, 49% and 26%, for 
CCK8, PMA and thapsigargin, respectively. Importantly, when taking into account that only 
half of the cells is transfected (as indicated by co-expression with GFP) the inhibitory effect 
on PMA-induced PLD activation was complete, whereas the stimulatory effects of CCK8 and 
thapsigargin were no more than halved. Because PKCa is absolutely required for PMA- 
induced PLD activation (Bosch etal., 1999) this suggests that PKCe can completely prevent 
PKCa from exerting its stimulatory effect in the context of the intact cell. However, also the 
stimulatory effects of CCK8 and thapsigargin were shown before to depend completely on the 
presence of PKCa (Bosch etal., 1999). Together with the present finding that both CCK8 and 
thapsigargin can still partially activate PLD in cells in which PMA-induced PLD activation 
was abolished, this suggests the existence of a second pathway leading to PLD activation that 
is also PKCa-dependent but insensitive to PKCe overexpression.
It may be argued that the inhibition by PKCe overexpression is due to sequestration of 
PMA thus preventing the PMA-induced activation of PKCa. However, this is not supported 
by the present finding that this maneuver has no effect on the PMA-induced translocation of 
PKCa. Moreover, it would not explain the inhibitory effect of PKCe overexpression on 
thapsigargin-induced PLD activation because thapsigargin activates PKCa by increasing of 
the cytosolic Ca2+ concentration (Conricode et al., 1994). Therefore, the present findings 
rather suggest that PKCe acts by preventing PKCa from exerting its stimulatory effect. 
Importantly, the data presented in this study exclude the possibility that overexpression of 
PKCe leads to downregulation of PKCa and/or PLD1.
Inhibition of PLD activation by PMA and platelet-derived growth factor (PDGF) has 
also been observed in NIH 3T3 cells (Kiss et al., 1999). In the latter study it was shown that 
overexpression of both the regulatory domain fragment and the cysteine-rich zinc finger 
domain, but not of the catalytic domain, of PKCe inhibited PMA- and PDGF-induced PLD 
activation. Importantly, it was demonstrated that PKCe overexpression did not interfere with 
the PMA-induced translocation of PKCa, indicating that PKCe did not act by sequestering 
PMA. In contrast, overexpression of PKCe failed to affect PMA-induced 
phosphatidylethanolamine breakdown in R6 rat fibroblasts and NIH 3T3 fibroblasts 
(Mukherjee et al., 1996).
The present study shows that PKCe overexpression did not change GTPyS-induced 
PLD activation in a cell-free system, whereas it virtually abolished the stimulatory action of 
PMA. This is in agreement with preliminary results showing that prolonged treatment of CHO 
cells with PMA (0.1 ^M) for 24 h did not change GTPyS-induced PLD activation while 
abolishing the stimulatory effect of PMA in a broken cell preparation obtained from these 
cells (RR Bosch, BJLJ Joosten, SE van Emst-de Vries, JJHHM De Pont and PHGM Willems, 
unpublished observations). Moreover, inhibition of PMA-induced PLD activation in intact 
cells was already close to maximal after 3 hours of PMA treatment and Western blot analysis
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revealed a virtually complete disappearance of PKCa, but not PKCe or PKCZ, at this time 
point (Bosch et al., 1999). Taken together these findings suggest the existence of two 
independent pathways leading to PLD activation, one that is stimulated by PMA, requires 
PKCa, and is inhibited by PKCe overexpression and a second one that is stimulated by 
GTPyS, does not require PKCa, and is insensitive to PKCe overexpression. The latter 
pathway is different from the PKCe-insensitive pathway involved in CCK8- and thapsigargin- 
induced PLD activation in intact cells, which is completely dependent on the presence of 
PKCa (see above). The present finding that PKCe overexpression did not increase PMA- 
induced PLD activation in a cell-free system is in agreement with the finding that this PKC 
isoform did not activate recombinant rat PLD1 (Conricode etal., 1994; Min et al., 1998a). 
Moreover, it is in agreement with the finding that PMA and agonists did not significantly 
increase PLD activity in CHO cells in which PKCa, but not PKCe, was downregulated by 2 
to 3 h of phorbol ester treatment (Liu et al., 1995; Bosch et al., 1999).
The exchange of cytosol and membrane fractions between mock-transfected cells and 
cells overexpressing PKCe revealed that whenever PKCe is present, PMA-, but not GTPyS-, 
induced PLD activation is abolished. The observation that the cytosol fraction from PKCe 
overexpressing cells inhibited PMA-induced PLD activation in membranes from mock- 
transfected cells is consistent with the idea that PKCe overexpression does not act by 
downregulation of membrane-bound stimulatory factors but rather exerts a direct effect. Such 
a direct effect also explains the finding that the cytosol of mock-transfected cells was unable 
to confer the stimulatory effect of PMA on membranes from PKCe overexpressing cells. In 
addition, such a direct effect is in agreement with the observation that overexpression of 
PKCe did not change the expression level of PKCa thus excluding the possibility that the loss 
of PMA-inducable PLD activity was due to downregulation of this PKC isoform. 
Overexpression of PKCe did not affect the PMA-induced translocation of PKCa from the 
cytosol to the membrane, indicating that PKCe does not act by sequestering PMA (see also, 
Kiss et al., 1999). Similarly, the finding that the expression levels of the small GTPases RhoA 
and ARF6 were not changed in cells overexpressing PKCe is in agreement with the 
observation that GTPyS-stimulatable PLD activity was not altered in these cells. Finally, 
PKCe overexpression did not change the expression levels of the PLD1 protein. Taken 
together, the present findings indicate that PKCe inhibits PMA-induced PLD activation in a 
direct manner and that its overexpression does not interfere with either the PMA-induced 
translocation of PKCa or the expression levels of PKCa, RhoA, ARF6 and PLD1.
The direct action of PKCe on PMA-induced PLD activation in a cell-free system is in 
agreement with the idea that PKCe acts by preventing PKCa from interacting with PLD. One 
possibility is that PKCe binds to PLD thus hindering the binding of PKCa. A second 
possibility is that PKCe phosphorylates PLD to decrease its activity and/or stimulatability by 
PKCa. Thus far, inhibition of PLD activity by PKC-dependent phosphorylation has been 
demonstrated for PKCa and PKC^2 (Min et al., 1998a). Therefore, the possibility exists that 
PMA stimulation induces the association of both PKCe and PKCa with PLD1 and that in case
of a relative overabundance of PKCe the PMA-induced association of PKCa with PLD will
2+be reduced or even abolished. In the physiological situation, however, Ca2+ mobilizing 
hormones increase the activity of PKCa by both increasing of the cellular diacylglycerol 
content and the cytosolic Ca2+ concentration, whereas the activity of PKCe is increased only 
by the increase in diacylglycerol. In CHO cells the hormone-induced increase in Ca2+ is large 
and sustained and therefore its relative contribution to PLD activation is high (Bosch et al., 
1999). This explains the present observation that PKCe overexpression only partially 
inhibited CCK8- and thapsigargin-induced PLD activation. This may also explain the
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observation that selective downregulation of PKCe did not affect PDGF-induced PLD
activation in a mouse embryo fibroblast line (Kiss and Anderson, 1994). However, this
2+relative importance of cytosolic Ca may be completely different in other cells types showing
2+a less prominent rise in cytosolic Ca . In these cells, the effect of a relative overexpression of 
PKCe is likely to be much more pronounced. Finally, as far as the activation of PKCe is 
concerned recent studies suggest that in some cell types agonists may also activate this PKC 
isoform via the cAMP pathway (Graness et al., 1997).
Of note, PKCe has been implicated in regulated PLD activity in some cell types. For 
instance, in rat renal mesangial cells angiotensin II-induced PLD activition was found to be 
abolished only after 24 h of phorbol ester treatment when PKCe was also downregulated 
(Pfeilschifter and Huwiler, 1993). No inhibition was observed after 8 h when both PKCa and
PKC8 had disappeared. Moreover, thapsigargin only slightly increased PLD activity in these
2+cells, whereas chelation of cytosolic Ca2+ did not affect the angiotensin II-induced PLD 
activation. This stimulation pattern is opposite to that observed in CHO cells and most 
probably reflects the involvement a PLD isoform other than PLD1.
The present findings may be of eminent importance in cancer research because recent 
studies have revealed marked differences in relative expression levels of PKCa and PKCe 
between metastatic and non-metastatic human melanoma cell lines (RR Bosch, MR 
Ahmadian, M Langeslag, MW Jonsson, SE van Emst-de Vries, GWM Swart, PHGM 
Willems, unpublished observations). Thus, in the non-metastatic cell lines 530 and 1F6-L the 
expression level of PKCe was relatively high as compared to the metastatic cell lines BLM 
and MV3, whereas, in contrast, the expression level of PKCa was relatively low in 530 and 
1F6-L cells as compared to BLM and MV3 cells. Intriguingly, PMA-induced PLD activation 
was shown to be more than halved in 530 cells as compared to BLM cells. Moreover, 530 
cells were observed to grow considerably slower than BLM and MV3 cells. Based on the 
present findings and the preliminary data discussed above we propose that the relative 
overexpression of PKCe as compared to PKCa leads to inhibition of regulated PLD activity, 
which, at its turn, results in growth inhibition. This model is in agreement with a recent report 
showing that the growth-inhibitory effect of ethanol in astrocytes is related to the specific, 
ethanol-induced disruption of the PLD signalling pathway (Kotter and Klein, 1999).
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The aminosteroid 1-(6-{[17B-3-methoxyestra-1,3,5(10)-trien-17-yl]-amino}hexyl)-1H-pyrrole-2,5- 
dione (U73122) and its inactive analogue 1-(6-{[17B-3-methoxyestra-1,3,5(10)-trien-17-yl]- 
amino}hexyl-2,5-pyrrolidine-dione (U73343) are widely used to study the involvement of G 
protein-coupled 1-phosphatidylinositol-phosphodiesterase, or phospholipase C, in receptor- 
mediated cell activation. The present work shows that both aminosteroids inhibit 
cholecystokinin-(26-33)-peptide amide (CCK8)-induced phospholipase D activation equipotently 
in Chinese hamster ovary cells expressing the cholecystokinin-A receptor (CHO-CCKA cells). In 
addition, the two aminosteroids virtually completely inhibited thapsigargin- and 1 2 -0  
tetradecanoylphorbol 13-acetate (PMA)-induced phospholipase D activation. Since the latter two 
drugs mimic inositol 1,4,5-trisphosphate-mediated Ca2+ mobilization and 1,2-diacylglycerol- 
mediated protein kinase C activation, respectively, this suggests that both U73122 and U73343 
act downstream of phospholipase C to inhibit receptor-mediated phospholipase D activation. 
U73122, but not U73343, effectively inhibited both PMA/Ca2+-stimulated phospholipase D 
activation and PMA/phosphatidylserine-stimulated protein kinase C activation in a homogenate 
of CHO-CCKa cells. The data presented suggest that U73122 may act at the level of protein 
kinase C to inhibit activation of phospholipase D. The exact site of action of U73343 is presently 
unknown.
INTRODUCTION
There is growing evidence that G protein-coupled receptors may interact with more than one
type of G protein (Raymond, 1995). For instance, cholecystokinin-(26-33)-peptide amide
(CCK8) increases both the cellular cyclic AMP content and the cytosolic free Ca2+ 
2+concentration ([Ca ]i) in Chinese hamster ovary cells expressing the cholecystokinin-A 
receptor (CHO-CCKA cells) (Yule and Williams, 1992). However, the potency with which 
CCK8 stimulates both signal transduction pathways differs considerably in these cells (Smeets 
et al., 1998b). This suggests that coupling to different G proteins is a dose-dependent 
phenomenon.
The potential of receptors to couple to multiple G proteins and consequently activate 
multiple signalling pathways enables extracellular stimuli to differentially regulate a variety 
of cellular activities. As a consequence, specific blockers and/or activators of G proteins and 
their effectors are needed to elucidate the intracellular pathway(s) used by a receptor to 
control a particular cellular activity.
One of the drugs frequently used in this type of investigation is the aminosteroid (1-(6- 
|[17B-3-methoxyestra-1,3,5(10)-trien-17-yl]-amino}hexyl)-1H-pyrrole-2,5-dione or U73122 
(Bleasdale et al., 1990; Smith et al., 1990; Yule et al., 1993; Babich et al., 1994; Martin et al., 
1994; Hellberg et al., 1996). U73122 was originally described as a potent inhibitor of agonist-
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induced platelet aggregation (Bleasdale et al., 1990). Since the drug inhibited the guanosine 
5'-[y-thio]triphosphate-stimulated hydrolysis of phosphatidylinositol 4,5-bisphosphate by a 
soluble fraction from platelets it was concluded that the aminosteroid exerted its effect by 
inhibiting the activity of 1-phosphatidylinositol-phosphodiesterase or phospholipase C. The 
inhibitory action of U73122 was found to be completely abolished by substitution of the 
maleimide group for the less electrophilic succinide group. The latter analogue of U73122, 
referred to as U73343 (1-(6-{[17B-3-methoxyestra-1,3,5(10)-trien-17-yl]-amino}hexyl-2,5- 
pyrrolidine-dione), should therefore be included as a negative control in this type of study.
In recent years, many stimuli have been demonstrated to promote the hydrolysis of 
phosphatidylcholine (Exton, 1994, 1997c; Natarajan et al., 1996a). Most probably, this 
stimulatory action involves the increased activity of phosphatidylcholine phosphatido- 
hydrolase or phospholipase D rather than phosphatidylcholine cholinephosphohydrolase. A 
number of studies used U73122 to demonstrate the involvement of phospholipase C in 
receptor-mediated phospholipase D activation (Wu et al., 1992; Sugiyama et al., 1994; Zheng 
et al., 1994; Freeman et al., 1995). However, preliminary experiments revealed that not only 
U73122 but also its inactive analogue U73343 inhibited CCK8-induced phospholipase D 
activation in CHO-CCKA cells. This finding urged us to investigate the effects of the two 
aminosteroids in more detail. From the data obtained it is concluded that both U73122 and 
U73343 act downstream of phospholipase C to inhibit receptor-mediated phospholipase D 
activation in Chinese hamster ovary cells.
MATERIALS AND METHODS
Materials
CCK8, PMA, histone-H1 (type III-S), leupeptin, soybean trypsin inhibitor and 2,2,4-trimethylpentane were 
obtained from Sigma (St. Louis, MO, USA) and thapsigargin from LC Services (Woburn, MA, USA). 
phenylmethylsulfonyl fluoride was obtained from SERVA (Heidelberg, Germany), calpain inhibitor was from 
Boehringer (Mannheim, Germany) and aprotinin from Fluka (Buchs, Switzerland). U73122 and U73343 were 
purchased from Calbiochem (La Jolla, CA, USA) and [y-32P]ATP (3000 Ci/mmol) and [9,10(n)-3H]myristic acid 
(53 Ci/mmol) from The Radiochemical Centre (Amersham, UK). Silica gel 60 high performance thin layer 
chromatography plates, ethylacetate and chloroform were obtained from Merck (Darmstadt, Germany) and 
phospholipid standards from Avanti Polar Lipids (Birmingham, AL, USA). Fura-2/AM was purchased from 
Molecular Probes Inc. (Eugene, OR, USA) and tissue culture medium with additives from Gibco (Paisley, 
Scotland). All other chemicals were of reagent grade. Stock solutions of U73122 (1 mM) and U73343 (1 mM) 
were prepared in dimethyl sulfoxide.
Development o f a stable CHO-CCKA cell line
The development of a stable CHO-CCKA cell line has been described in detail previously (Smeets et al., 1996). 
Phospholipase D measurements in CHO-CCKA cells
CHO-CCKa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% 
fetal calf serum in a water saturated atmosphere containing 5% CO2 at 37°C. For phospholipase D measure­
ments, the cells were subcultured in 12 well plates (2.5 x 105 cells/well) and grown to confluence in the presence 
of [3H]myristic acid (3 ^Ci/ml) for 24 h. At the end of the labeling period, the cells were washed and incubated 
in DMEM without fetal calf serum for 3 h. Labeled cells were preincubated in the absence or presence of 
aminosteroid for 5 min before being stimulated with either 10 nM CCK8, 1 |xM 12-O-tetradecanoylphorbol 13- 
acetate (PMA) or 1 |xM thapsigargin in the presence of 1% (v/v) ethanol. After 10 min, the medium was 
aspirated and the reaction was quenched by the addition of 1 ml ice-cold methanol. The cells were scraped off 
and the mixture was transferred into a lipid tube (Sarstedt, Essen, Germany). Lipids were extracted according to
64
Chapter 4
the method described by Bligh and Dyer (1959). Briefly, 500 |j.l chloroform and 400 |j.l H2O were added and the 
mixture was vigorously mixed. Phase separation was obtained by addition of 400 |j.l chloroform and 400 |j.l 
water followed by centrifugation. After collection of the lower organic phase, the aqueous phase was extracted 
again and the combined organic phases were blown to dryness with N2 .
Separation o f labeled phospholipids
The dried extracts were dissolved in 20 |j.l chloroform/methanol (9:1, v/v) and the lipids were separated by thin- 
layer chromatography using potassium oxalate-treated silica gel 60 high performance thin layer chromatography 
plates. The plates were developed with the upper phase of a mixture of ethylacetate/2,2,4-trimethylpentane/acetic 
acid/water (13:2:3:10, v/v/v/v). Radioactive spots corresponding to authentic lipid standards were visualised by 
I2 -staining and scraped off. Radioactivity was measured by liquid scintillation spectrometry.
Phospholipase D measurements in CHO-CCKA homogenates
Phospholipase D activity was measured in cell homogenates according to the method described by Ohguchi et al. 
(1996). Briefly, CHO-CCKA cells were grown to confluence in the presence of [3H]myristic acid (2 ^Ci/ml) for 
48 h, washed, and incubated with DMEM without fetal calf serum for another 3 h. At the end of the incubation 
period, the cells were washed twice with an ice-cold homogenization solution containing 100 mM KCl, 3 mM 
NaCl, 5 mM MgCl2, 1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride, 10 |J.g/ml leupeptin and 25 mM 
HEPES, adjusted with Tris to pH 7.4 and collected by scraping. The cells were transferred to a Potter-Elvehjem 
(glass-teflon) homogenizer and homogenized by 10 strokes at 500 rev./min, 5 strokes at 1000 rev./min and 5 
strokes at 1200 rev./min, successively. Unbroken cells were removed by centrifugation at 50 g  for 5 min. For 
phospholipase D measurements, aliquots of the homogenate were removed and preincubated for 5 min at 37°C 
in the presence of either 1% (v/v) dimethyl sulfoxide (control), U73122 (10 |xM) or U73343 (10 |xM). 
Subsequently, 0.5 mM Mg-ATP and 1% (v/v) ethanol was added with or without PMA and CaCl2 at final 
concentrations of 100 nM and 0.5 mM, respectively, and the homogenate was incubated for another 25 min. The 
reaction was quenched by the addition of 1 ml ice-cold methanol and the lipids were extracted and separated as 
described above.
Protein kinase C measurements in CHO-CCKa homogenates
CHO-CCKA cells were washed 4 times with phosphate buffered saline, scraped off, and resuspended in a 
homogenization solution containing 10 mM EGTA, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 20 |xM 
leupeptin, 0.5 |J.g/ml aprotinin, 1 |xM calpain inhibitor, 0.2 mg/ml trypsin inhibitor and 20 mM Tris, adjusted 
with HCl to pH 7.4. The cells were homogenized as described above and sucrose was added to a final 
concentration of 0.25 M. Homogenization medium was added to reach a final protein concentration of 0.1 
mg/ml. Protein kinase C activity was determined in a reaction mixture containing 20 mM HEPES (pH 7.1), 1 
mM EGTA, 0.2 mM EDTA, 10 mM MgCl2, 1.3 mM CaCl2 (approximately 0.3 mM free Ca2+), 0.5 mM 
phenylmethylsulfonyl fluoride, 0.05 mg/ml histone-H1 (type III-S) and 50 |xM [y-32P]ATP (spec. act. 0.05 
Ci/mmol) with or without 1 |xM PMA and 0.05 mg/ml phosphatidylserine at 30°C. After a 2 min preincubation 
period in the absence or presence of either 10 |xM U73122 or 10 |xM U73343, the reaction was started by the 
addition of 10% (v/v) homogenate. At 10 min, the reaction was quenched by the addition of ice-cold stop 
solution containing 5% (w/v) trichloroacetic acid and 0.1 M H3PO4. The acid-precipitable material was collected 
on a Schleicher & Schull ME-27 membrane filter (pore size 0.8 |j.m) and washed three times with stop solution. 
Radioactivity was determined by liquid scintillation counting. Protein kinase C activity was defined as the 
PMA/phosphatidylserine-dependent increase in histone-H1 phosphorylation.
Fluorescence measurements in suspensions ofCH0-CCKA cells
CHO-CCKa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% 
fetal calf serum in a water saturated atmosphere containing 5% CO2 at 37°C. For fluorescence measurements, the 
cells were trypsinized, washed twice, and resuspended in a HEPES(10 mM)/Tris medium (pH 7.4) containing 
133 mM NaCl, 4.2 mM KCl, 1.0 mM CaCl2, 1.0 mM MgCl2, 5.8 mM glucose, 0.2 mg/ml soybean trypsin
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Figure 1. Effect o f U73122 and U73343 on 
CCK8 induced phospholipase D activation in 
CHO-CCKa cells. [3H]myristic acid-labeled 
CHO-CCKa cells were preincubated with the 
indicated concentrations of either U73122 or 
U73343 for 5 min and subsequently stimulated 
with 10 nM CCK8 in the presence of 1% (v/v) 
ethanol. The final dimethyl sulfoxide 
concentration was 1% (v/v). The reaction was 
quenched at 10 min following the onset of 
stimulation and the amount of [3H]PtdEth was 
determined. In each experiment, the value 
obtained with 10 nM CCK8 alone is set at 
100%, to which all other values are related. The 
data presented are the mean ± S.E.M. of 3 and 6 
experiments in the case of U73122 and U73343, 
respectively.
-log [aminosteroid] (M)
inhibitor, an amino acid mixture according to Eagle and 1% (w/v) bovine serum albumin. The cells were 
incubated in the presence of 2 |xM 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'- 
methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid pentaacetoxy methylester (fura-2/AM) for 20 min at 37°C. 
Excess fura-2/AM was removed by washing 2 times with HEPES/Tris medium containing 0.1% (w/v) bovine 
serum albumin. The fura-2-loaded cells were transferred to a cuvette placed in a Shimadzu RF-5000 
spectrofluorophotometer equipped with a magnetic stirrer and a thermostatic cuvette holder. Fluorescence 
measurements were carried out at 37°C and the fluorescence emission ratio at 490 nm was monitored after 
excitation at 340 and 380 nm.
Analysis of the data
The results presented are the mean ± S.E.M. of the number of experiments indicated in the text. IC50 values were 
calculated by means of the nonlinear regression computer programme InPlot (Graphpad Software for Science, 
San Diego, CA, USA).
RESULTS
In order to study the effects of the putative phospholipase C inhibitor U73122 and its inactive 
analogue U73343 on CCK8-induced phospholipase D activation, [3H]myristic acid-labeled 
CHO-CCKa cells were preincubated with either U73122 or U73343 for 5 min and subse­
quently stimulated with 10 nM CCK8 in the presence of 1% (v/v) ethanol. The reaction was 
quenched at 10 min following the onset of stimulation and the amount of 
[3H]Phosphatidyl ethanol (PtdEth) was determined. CCK8 evoked a 7.5-fold increase in the 
amount of [ H]PtdEth when added at a concentration of 10 nM (Fig. 1). In each experiment, 
this value was set at 100% to which all other values were related. Basal [3H]PtdEth formation 
amounted to 13.4% ± 3.2% (n=6) of the value obtained with 10 nM CCK8. Neither U73122 
(10 ^M) nor U73343 (10 ^M) had an effect on basal [3H]PtdEth formation (15.6% ± 3.3%, 
n=3 and 13.9% ± 2.5%, n=6 of the value obtained with CCK8 alone for U73122- and U73343- 
treated cells, respectively). However, both aminosteroids inhibited CCK8-induced [ H]PtdEth
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Figure 2. Effect o f U73122 and U73343 on 
[Ca2+]j in resting and CCK8 stimulated CHO- 
CCKa cells. CHO-CCKa cells, loaded with fura- 
2, were transferred to a cuvette placed in a 
spectrofluorophotometer equipped with a magne­
tic stirrer and a thermostatic (37°C) cuvette 
holder. Cells were allowed to equilibrate for 3 
min before addition of 1% (v/v) dimethyl 
sulfoxide (DMSO), U73343 or U73122. At 5 min 
following the onset of aminosteroid treatment the 
cells were stimulated with 10 nM CCK8. The 
fluorescence emission ratio at 490 nm was 
monitored as a measure of [Ca2+]i after excitation 
at 340 and 380 nm.
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formation dose-dependently and half-maximal inhibitory concentrations were calculated to be 
3.9 and 4.5 ^M for U73122 and U73343, respectively.
The cholecystokinin-A receptor couples to phospholipase C to promote the release of
Ca2+ from intracellular stores. In accordance with this, CCK8 (10 nM) evoked a rapid increase
2+ 2+of the average cytoplasmic free Ca concentration ([Ca ]i) in a suspension of CHO-CCKA 
cells (Fig. 2A). Addition of 10 ^M U73343, which by itself led to a minor increase in [Ca2+]i,
did not influence the response to CCK8 added thereupon (Fig. 2B). U73343 did not affect
2+[Ca ]i when added at concentrations at or below 7 ^M (data not shown). Conversely, U73122 
markedly increased [Ca2+]i in a dose-dependent fashion and the response to CCK8 added 
thereupon decreased with increasing aminosteroid concentration (Fig. 2C-E). The response to 
CCK8 was abolished in cells pretreated with 7 ^M U73122 (Fig. 2E). A relatively small effect 
of higher concentrations of U73343 is in agreement with the observation that, in some 
instances, the inhibitory action of U73122 was not completely abolished by substitution of the 
maleimide group for the the succinide group (Bleasdale et al., 1990).
The observation that U73343 and U73122 are equipotent in inhibiting CCK8-induced
phospholipase D activation suggests that both aminosteroids act through the same mechanism.
2+Assuming that this is the case, the finding that U73343 does not affect CCK8-induced Ca 
mobilization then suggests that both aminosteroids act downstream of phospholipase C to 
inhibit CCK8-induced phospholipase D activation. To address this idea, the two aminosteroids
were tested in combination with drugs that mimic the stimulatory effects of CCK8 on [Ca2+]i
2+and protein kinase C activity. Table 1 shows that both thapsigargin, which increases [Ca ]i by
|iM U73343
10 nM CCK8
10 nM CCK8
C 1 |iM U73122
3 |iM U73122 10 nM CCK8
D
7 |iM U73122
10 nM CCK8
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Treatment [3H]PtdEth
(% of CCK8-stimulated untreated cells)
control +10 |iM U73122 +10 |iM U73343
unstimulated 14±3 13±2 19±4
thapsigargin (1 ^M) 82±7
*
21±3
*
22±1
PMA (1|iM) 60±7 35±5* 19±1*
Table 1. Effect o f U73122 and U73343 on thapsigargin- and PMA-induced phospholipase D activation in 
CHO-CCKa cells. [3H]myristic acid-labeled ChO-CCKa cells were preincubated in the presence of either 1% 
(v/v) dimethyl sulfoxide (control), 10 |xM U73122 or 10 |xM U73343 for 5 min and subsequently stimulated with 
10 nM CCK8, 1 |xM thapsigargin or 1 |xM PMA in the presence of 1% (v/v) ethanol. The reaction was quenched 
at 10 min following the onset of stimulation and the amount of [3H]PtdEth was determined. In each experiment, 
the value obtained with 10 nM CCK8 is set at 100%, to which all other values are related. The data presented are 
the mean ± S.E.M. of 3 experiments. Significantly different from stimulated control (P<0.05).
2+inhibiting endoplasmic reticulum Ca -ATPase activity (Lytton etal., 1991), and the phorbol - 
ester 12-0-tetradecanoylphorbol 13-acetate (PMA), which activates protein kinase C (Takai et 
al., 1984), readily increased the amount of [ H]PtdEth. These findings are in agreement with
the idea that CCK8 increases both [Ca2+]i and the activity of protein kinase C to activate
2+phospholipase D. A concerted action of [Ca ]i and protein kinase C in the process of 
receptor-mediated phospholipase D activation has been suggested in a wide variety of cell 
types (Exton, 1994, 1997c). Both U73122 (10 ^M) and U73343 (10 ^M) virtually completely 
inhibited the thapsigargin- and PMA-induced increases in [3H]PtdEth (Table 1). These 
findings demonstrate that both U73122 and U73343 act downstream of the receptor-mediated 
increase in [Ca2+]i and protein kinase C activity in inhibiting CCK8-induced phospholipase D 
activation.
To further elucidate the mechanism underlying the inhibitory action of both 
aminosteroids on phospholipase D activition we studied the effects of U73122 and U73343 on 
PMA/Ca2+-stimulated phospholipase D activity in homogenates of CHO-CCKA cells. Figure 3 
shows that addition of 0.1 PMA and 0.5 mM CaCl2 to the assay medium virtually 
doubled phospholipase D activity. This stimulatory effect of PMA is in agreement with the
idea that protein kinase C plays a pivotal role in agonist-induced phospholipase D activation.
2+U73122 (10 ^M) significantly reduced PMA/Ca -stimulated phospholipase D activity by 
68% (S.E.M.=13%, n=3). By contrast, U73343 (10 ^M) did not significantly affect
PMA/Ca2+-stimulated phospholipase D activity. To examine the possibility that U73122 acts
2+directly at protein kinase C to inhibit PMA/Ca2+-induced phospholipase D activation we 
measured the effect of the aminosteroid on PMA/phosphatidylserine-stimulated histone-H1 
phosphorylation. Figure 4 shows that U73122 (10 ^M) markedly inhibited protein kinase C 
activity by 45% (S.E.M.=5%, n=3), whereas U73343 (10 ^M) did not affect 
PMA/phosphatidylserine-stimulated protein kinase C activation.
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control U73122 U73343
Figure 3. Effect o f U73122 and U73343 on 
phospholipase D activity in a homogenate of  
CHO-CCKa cells. Homogenates of [3H]myristic 
acid-labeled CHO-CCKA cells were preincubated in 
the presence of either 1% (v/v) dimethyl sulfoxide 
(control), 10 |xM U73122 or 10 |xM U73343 for 5 
min at 37 °C. The PMA/Ca2+-dependent increase in 
[3H]PtdEth, was measured at 25 min. In each 
experiment, the value obtained with the stimulated 
control homogenate is set at 100%, to which all 
other values are related. The data presented are the 
mean ± S.E.M. of 3 experiments. Significantly 
different from stimulated control (P<0.05).
Figure 4. Effect o f U73122 and U73343 on protein 
kinase C activity in a homogenate o f CHO-CCKA 
cells. Homogenates of CHO-CCKA cells were 
preincubated in the presence of either 1% (v/v) 
dimethyl sulfoxide (control), 10 |xM U73122 or 10 
|jM U73343 for 2 min at 30°C. Protein kinase C 
activity, defined as the PMA/phosphatidylserine- 
dependent increase in histone-H1 phosphorylation, 
was measured at 10 min. For each condition, basal 
phosphorylation is set at 100%, to which the value 
obtained in the presence of PMA/ 
phosphatidylserine is related. The data presented 
are the mean ± S.E.M. of 3 experiments.
Significantly different from stimulated control 
(P<0.05).
DISCUSSION
The present study shows that the putative inhibitor of phospholipase C activity, U73122, and
its inactive analogue, U73343, inhibit receptor-mediated phospholipase D activation
downstream of phospholipase C in Chinese hamster ovary cells. More precisely, the data
presented demonstrate that both aminosteroids act downstream of agonist-induced Ca2+
mobilization and protein kinase C activation and evidence is provided that U73122 might act
at the level of protein kinase C. On the other hand, the exact site of action of U73343
remained unclear.In the present study we made use of Chinese hamster ovary cells stably
expressing the cholecystokinin-A receptor. This receptor, which belongs to the superfamily of
G protein-coupled receptors, is coupled to phospholipase C to promote the hydrolysis of
phosphatidylinositol 4,5-bisphosphate, leading to the increased production of inositol 1,4,5­
2+trisphosphate, releasing Ca from intracellular stores, and 1,2-diacylglycerol, activating 
protein kinase C (Wank, 1995). The present study shows that CCK8, acting through this 
receptor, readily increased phospholipase D activity and that this process was inhibited
equipotently by the two aminosteroids. Together with the observation that U73343 did not
2+affect CCKg-induced Ca mobilization, and therefore phospholipase C activation, this led us 
to suggest that the two aminosteroids exerted their inhibitory effects downstream of 
phospholipase C.
The data obtained with thapsigargin and PMA, which mimic the stimulatory effects of
2+CCK8 on [Ca ]i and protein kinase C activity, respectively, demonstrate that both routes lead 
to phospholipase D activation. The present study shows that each of these routes was 
effectively inhibited by the two aminosteroids. The same observation was reached in vascular 
smooth muscle cells (Freeman et al., 1995) and is in agreement with the idea that both
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U73122 and U73343 act downstream of phospholipase C to exert their inhibitory effect on 
receptor-mediated phospholipase D activation.
The present study demonstrates that phospholipase D activity can be increased in a
2+PMA/Ca -dependent fashion in a homogenate of Chinese hamster ovary cells. Preliminary 
experiments, performed to establish the optimal Ca2+ concentration, revealed that Ca2+ alone 
is a poor stimulator of phospholipase D activity. However, addition of PMA at the optimal 
Ca2+ concentration virtually doubled phospholipase D activity. This finding is in agreement 
with the idea that protein kinase C plays a pivotal role in receptor-mediated phospholipase D
activation (Exton, 1994, 1997c). The data presented demonstrate that U73122, but not
2+U73343, effectively inhibited both the PMA/Ca -stimulated phospholipase D activity and the 
PMA/phosphatidyl-serine-stimulated protein kinase C activity. This suggests that U73122 
might act at the level of protein kinase C to inhibit phospholipase D activation. By contrast, 
neither of the two activities was affected by U73343. The latter finding is inconsistent with 
the observation that U73343 completely inhibits PMA-induced phospholipase D activation in 
intact cells. At present, we have no explanation for this discrepancy. However, it suggests that 
the action of PMA on phospholipase D in intact cells is different from that in broken cells.
Inhibitory effects of U73122 on agonist-induced phospholipase D activation have been 
described in osteoblast-like MC3T3-E1 cells (Sugiyama et al., 1994), rat gonadotrophs 
(Zheng et al., 1994) and human erythroleukemia cells (Wu et al., 1992) and have been 
interpreted as evidence for the involvement of phospholipase C in receptor-mediated 
phospholipase D activation. However, the present finding that U73122 can directly inhibit 
phospholipase D activity in a cell-free system clearly demonstrates that experimental data 
obtained with this aminosteroid have to be regarded with caution.
Serious side effects of U73122 have been reported before. For instance, U73122- 
evoked increases in [Ca2+]i, similarly to those observed in the present study, have been 
reported before in freshly isolated pancreatic acinar cells (Wank, 1995). With respect to the
possible mechanism by which U73122 acts on [Ca2+]i, it was demonstrated that the
2+aminosteroid stimulated the release of Ca from intracellular stores by inhibiting intracellular
Ca2+-ATPase activity (Willems et al., 1994; Wank, 1995). In doing so, U73122 resembles
2+thapsigargin. The fact that U73122, despite its Ca mobilizing effect, did not increase
phospholipase D activity is fully compatible with the idea that the aminosteroid exerts its
2+inhibitory effect downstream of the rise in [Ca ]i. The inability of CCK8 to evoke an increase
in [Ca2+]i following treatment with U73122 can be explained by the Ca2+ mobilizing activity
2+of this aminosteroid, which leads to emptying of agonist-sensitive Ca stores. By contrast, in 
freshly isolated hepatocytes U73122 was found to abolish the receptor-mediated increase in
[Ca2+]i without affecting resting [Ca2+]i (De Moel etal., 1995). At present, it is unclear why
2+U73122 increases [Ca ]i in some cells but not in other cells (Mogami etal., 1997).
In summary, the data presented are in agreement with the idea that both U73122 and 
U73343 act downstream of phospholipase C to inhibit receptor-mediated phospholipase D 
activation in CHO-CCKa cells. Regarding the mechanism underlying the inhibitory action of 
the two aminosteroids evidence is provided that U73122 might act at the level of protein 
kinase C, whereas the exact mechanism of action of U73343 remains unknown.
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Phospholipase D (PLD) is expressed in a wide range of mammalian cells and its activity is increased 
by a multitude of extracellular signalling molecules including hormones, neurotransmitters, growth 
factors, cytokines and antigens. In vitro studies have identified certain PKC isozymes and members 
of the ARF and Rho families of small GTPases as potential mediators in regulated PLD activity. At 
present, however, the relative importance of these PLD regulators in the mechanism of action of 
these various stimuli is poorly understood. Here we show that transient overexpression of a 
constitutively active mutant of the Rho family member Racl, Rac1-V12, significantly inhibits 
agonist-induced PLD activation in a Chinese hamster ovary (CHO) cell line expressing the wild 
type rat cholecystokininA receptor. Rac1-V12 did not change PLD activation in response to the 
potent PKC activator, PMA, or the inhibitor of the endoplasmic reticulum Ca2+-ATPase, 
thapsigargin, which exerts its effects through an increase in cytosolic Ca +. In contrast to Rac1-V12, 
a dominant negative Rac1 mutant, Rac1-N17, did not interfere with agonist-induced PLD 
activation. Importantly, Rac1-V12 inhibition was removed following overexpression of Rac1-V12 in 
a CHO cell line expressing a CCKA receptor engineereed to have mutations in the consensus sites 
for protein kinase C (PKC) phosphorylation. Given the evidence in the literature that Rac1 is less 
efficacious than RhoA in activating PLD in vitro we propose that Rac1-V12 interacts with CCKA 
receptors in which key PKC sites are phosphorylated to compete with RhoA in receptor-induced 
PLD activation. From a cell physiological point of view this opens the possibility for a regulatory 
mechanism in which PLD activation through one receptor is controlled by the concerted action of 
receptors that increase PKC activity and receptors that activate Rac1.
INTRODUCTION
Many extracellular stimuli promote the enzymatic cleavage of membrane phospholipids to 
generate intracellular signalling molecules. An important enzyme in transmembrane signalling is 
phosphatidylcholine-specific phospholipase D (PLD), which catalyses the breakdown of 
phosphatidylcholine to yield phosphatidic acid (PtdOH) and choline (reviewed in Exton, 1999 
and Frohman ef al., 1999). Initially, PtdOH, produced by the action of PLD, was thought to be 
converted to diacylglycerol, a proces catalyzed by phosphatidate phosphohydrolase, to cause 
long-term activation of PKC (Nishizuka, 1992). However, modern insights implicate PtdCho- 
derived PtdOH as an important messenger in regulated exocytosis, membrane delivery and 
vesicle budding (reviewed in Jones ef al., 1999), cytoskeleton reorganization (reviewed in 
Liscovitch et al., 1999) and cell proliferation (reviewed in Daniel et al., 1999).
PLD activity is routinely measured by taking advantage of its characteristic feature to 
prefer primary short-chain alcohols to water in the catalysis reaction (Dawson, 1967; described 
in detail in Waite, 1999). The product formed in this transphosphatidylation reaction, 
phosphatidylethanol (PtdEth), is a unique phospholipid that can be separated by thin layer
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chromatography for quantification. Using this method it has been demonstrated that almost all 
mammalian cells contain a regulated PLD activity (listed in Exton, 1999). In recent years, in vivo 
studies provided circumstantial evidence for a role of PKC in regulated PLD activity. Thus, in 
many, but not all systems, agonist-induced PLD activation was found to be enhanced by PKC 
overexpression or inhibited by PKC inhibitors, prolonged phorbol ester treatment to 
downregulate novel and conventional PKC isozymes, or transfection with antisense cDNA to 
deplete PKC (summarized in Exton, 1999). Similarly, the involvement of members of the ADP- 
ribosylating factor (ARF) and Rho families of small GTPases in regulated PLD activity was 
demonstrated by the use of Brefeldin A and botulinum C3 exozyme, inhibitors of ARF and Rho, 
respectively, or by transfection with interfering mutants (Rumenapp ef al., 1995; Malcolm et al., 
1996a,b; Mitchell ef al., 1998; Zhang et al, 1999).
In parallel, in vitro studies identified a number of potential regulators of agonist- 
stimulated PLD activity including the conventional PKC isozymes, PKCa and PKC^, and 
members of the ADP-ribosylation factor (ARF) and Rho (RhoA, Rac1 and Cdc42) families of 
small GTPases (reviewed in Exton, 1999 and Frohman etal., 1999). Initially, these studies used 
whole cell homogenates in which phorbol esters, potent activators of PKC, and GTPyS, a non- 
discriminatory activator of all GTPases, were shown to increase PLD activity in a synergistic 
manner. Subsequently, the use of reconstitution systems based on cytosol-depleted cells allowed 
to identify the different effectors of PLD. More recently, the cloning of two mammalian PLD 
isozymes, PLD1 (Hammond etal., 1995) and PLD2 (Colley etal., 1997; Kodaki and Yamashita,
1997), enabled to use recombinant PLD isozymes in reconstitution assays. In these studies, it 
was demonstrated that the activity of PLD1, but not PLD2, is under control by the above PLD 
regulators (Lee et al, 1998; Exton, 1999; Frohman et al., 1999). Moreover, evidence was 
provided that these PLD regulators interact directly with specific sites on the enzyme to exert 
their stimulatory effect (Sung etal., 1997; Sung etal., 1999a; Sung etal., 1999b; Yamazaki et 
al, 1999).
Insight in how these different effectors of PLD may cooperate in agonist-induced PLD 
activation comes from a recent study employing a pentapeptide insertion mutant of PLD1 that 
was not activated by PKC in vitro or by PMA in vivo but showed a wild-type response to RhoA 
and ARF1 in vitro (Zhang et al, 1999). HEK293 cells, co-expressing this PKC-insensitive PLD1 
mutant and the m1 muscarinic receptor, responded with only a minimal increase in PLD activity, 
whereas a marked stimulation was observed following co-expression with wild-type PLD1. This 
finding demonstrates that a PKC-sensitive PLD is required for agonist-induced PLD activation. 
Moreover, expression of dominant active RhoA increased PLD activity to a level that was further 
increased by carbachol in cells co-expressing wild-type PLD1 but not in cells co-expressing the 
PKC-insensitive mutant. This finding is in agreement with the concept that PKC and RhoA act 
synergistically in agonist-induced PLD activation.
In vitro studies revealed that the Rho family member Rac1 is less efficacious than RhoA 
in restoring GTPyS-stimulated PLD activity in membranes depleted from Rho proteins by the 
action of Rho-GDI (Siddiqi et al, 1995). In the present study we have used this given to 
investigate the possibility that Rac1 competes with RhoA in agonist-induced PLD activation. It 
was observed that overexpression of constitutively active Rac1-V12, but not dominant negative 
Rac1-N17, in CHO cells expressing the cholecystokininA receptor (CCKA cells) reduced the 
CCK-induced increase in PLD activity. Importantly, this inhibition was found to be removed 
following overexpression of Rac1-V12 in CHO cells expressing a CCKA receptor engineered to 
have mutations in the consensus sites for PKC phosphorylation. It is concluded that agonist- 
induced phosphorylation of key PKC phosphorylation sites on G protein-coupled receptors is 
required for Rac1, activated by other signalling systems, to compete with RhoA in agonist- 
induced PLD activation.
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MATERIALS AND METHODS
Materials
Cholecystokinin-(26-33)-peptide amide (CCK8), 12-O-tetradecanoylphorbol 13-acetate (PMA), bovine serum 
albumin, leupeptin and 2,2,4-trimethylpentane were obtained from Sigma (St. Louis, MO, USA), phenylme- 
thylsulfonyl fluoride (PMSF) from SERVA (Heidelberg, Germany), aprotinin from Calbiochem (La Jolla, CA, 
USA), dithiothreitol from Research Organics Inc. (Cleveland, OH, USA), t-butyloxycarbonyl-Tyr(SO3H)-Nle-Gly- 
Trp-Nle-Asp-2-phenylethyl ester (JMV-180) from Research Plus Inc. (Bayonne, NJ, USA) and thapsigargin from 
LC services (Woburn, MA, USA). Fura-2/acetoxymethyl ester (Fura-2/AM) and pluronic F-127 were purchased 
from Molecular Probes Inc. (Eugene, OR, USA), HPTLC silica gel 60 plates, ethylacetate and chloroform from 
Merck (Darmstadt, Germany) and [9,10(n)-3H]myristic acid (53 Ci/mmol) from The Radiochemical Centre 
(Amersham, UK). Phospholipid standards were obtained from Avanti Polar Lipids (Birmingham, AL, USA) and 
tissue culture medium with additives from Gibco (Paisley, Scotland). PcDNA3-myc-Rac1-V12 and pcDNA3-myc- 
Rac1-N17 were kindly provided by Prof. dr. J.L. Bos (Laboratory for Physiological Chemistry, Utrecht University, 
The Netherlands). All other chemicals were of reagent grade.
Development of CHO cell lines expressing the wild-type CCKA receptor and a receptor lacking the consensus sites 
for PKC action
The development of CHO cell lines expressing either the wild type rat CCKA receptor (CHO-CCKA WT cells) or a 
rat CCKA receptor engineered to have mutations in the consensus sites for PKC action (CHO-CCKA MT cells) has 
been described in detail elsewhere (Smeets et al., 1996, 1998c). The rat CCKA receptor contains four potential 
phosphorylation sites for PKC, three on serine (S260, S264 and S275) in the large intracellular third loop and one on 
threonine (T424) in the cytoplasmic carboxyl-terminal tail (Wank et al, 1992). Previous work demonstrated that 
CCKA receptors engineered to have mutations in two (S260 and S264) of the four consensus sites for PKC action 
were not phosphorylated in response to CCK (Rao et al, 1997). In the receptor mutant used in our studies, all four 
consensus sites for PKC action have been changed in an alanine.
Transfection of CHOCCKA WT and CHO CCKAMT cells with Racl mutants
CHO-CCKaWT and CHO-CCKAMT cells were grown to confluence in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% (v/v) fetal calf serum (FCS) in a humidified atmosphere of 5% CO2 at 37°C. For 
transfection, cells were trypsinized and transferred to a cuvette (5x106 cells 300 ill-1). The cells were electroporated 
(250 V, 960 |jF) in the presence of 2 |j.g of plasmid pGFP-N1 (Clontech, Palo Alto, CA, USA) and 18 |j.g of either 
pcDNA3-myc-Rac1-V12 or pcDNA3-myc-Rac1-N17. At 24 h after electroporation, GFP-positive and GFP-negative 
cells were separated by means of fluorescence activated cell sorting (FACS) and cultured for another 24 h.
Western blotting
Total cell lysates were subjected to SDS-polyacrylamide gel electrophoresis. Proteins were transferred overnight 
to polyvinylidene difluoride membranes (Immobillon P, Millipore, Bedford, MA, USA). For detection of PLD1, 
blots were incubated with the rabbit anti-hPLD1 antibody described by Muller-Wieprecht et al. (1998). The 
antibody was kindly provided by Prof. dr. C.C. Geilen (University Medical Center Benjamin Franklin, The Free 
University of Berlin, Germany). For the detection of myc-Rac1-V12 and myc-Rac1-N17, blots were incubated 
overnight with the anti-myc monoclonal antibody 9E10. Immunoreactive bands were detected with alkaline 
phosphatase-conjugated rabbit anti-mouse IgG. Immunoreactive protein was detected with goat anti-rabbit IgG 
antibody conjugated to alkaline phosphatase.
Phospholipase D measurements in intact CHO-CCKA WT and CHO CCKAMT cells
PLD measurements were performed as described previously (Bosch etal, 1998,1999). Briefly, FACS separated cells 
were subcultured in 12 well plates (105 cells/well) and labelled with [3H]myristic acid (2 ^Ci/ml) for 24 h. At the end 
of the labelling period, cells were washed and incubated in DMEM without FCS for 3 h. Subsequently, the cells were 
washed and stimulated with the indicated concentrations of either CCK8, PMA and thapsigargin in DMEM
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containing 1% (v/v) ethanol. After 10 min, the medium was aspirated and the reaction was quenched by the addition 
of 1 ml ice-cold methanol. The cells were scraped off and the mixture was transferred into a lipid tube (Sarstedt, 
Essen, Germany). Lipids were extracted according to the method described by Bligh and Dyer (1959). Briefly, 500 
^l of chloroform and 400 ^l of water were added and the mixture was mixed vigorously. Phase separation was 
obtained by addition of 400 ^l of chloroform and 400 ^l of water followed by centrifugation. The lower organic pha­
se was collected and blown to dryness with N2.
Separation of labelled phospholipids
The dried extracts were dissolved in 20 ^l of chloroform/methanol (9:1, v/v) and the lipids were separated by thin- 
layer chromatography using potassium oxalate-treated silica-gel 60 HPTLC plates. The plates were developed with 
the upper phase of a mixture of ethylacetate/2,2,4-trimethylpentane/acetic acid/water (13:2:3:10, by vol.). Ra­
dioactive spots corresponding to authentic lipid standards were visualised by I2 -staining and scraped off. Radioacti­
vity was measured by liquid-scintillation spectrometry.
Phospholipase D measurements in a broken cell preparation of CHO-CCKA WT cells
Phospholipase D activity was assayed in cell homogenates according to the method of Ohguchi etal. (1996) as 
described previously (Bosch etal, 1998, 1999). CHO-CCKAWT cells were grown to confluence in the presence of 
[3H]myristic acid (2 ^Ci/ml) for 24 h. In PKC downregulation experiments, PMA (0.1 |xM) was present during the 
entire labelling period. We previously demonstrated that this treatment leads to a rapid disappearance of PMA- 
sensitive PKC isoforms (Smeets etal, 1996, 1998a,b). Prior to homogenization, cells were washed and incubated in 
DMEM without FCS for 3 h. At the end of this incubation period, cells were washed twice with an ice-cold 
homogenization solution containing 100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 5 mM dithiothreitol, 
0.5 mM phenylmethylsulfonyl fluoride, 20 ^M leupeptin and 25 mM HEPES, adjusted with Tris to pH 7.4 and 
collected by scraping. The cells were subsequently homogenized at 4°C using a Potter-Elvehjem homogenizer (glass- 
teflon) by 10 strokes at 500 rev./min, 5 strokes at 1000 rev./min and 5 strokes at 1200 rev./min. Unbroken cells were 
removed by centrifugation at 50 g  for 5 min. For PLD measurements, aliquots of the resultant supernatant were 
incubated in the presence of Mg-ATP (0.5 mM), CaCl2 (0.5 mM) and 1% (v/v) ethanol and in the absence or 
presence of PMA (1 ^M ) and/or GTPyS (100 ^M) for 30 min at 37°C. The reactions were quenched with 1 ml of 
ice-cold methanol and the lipids were extracted and separated as described above.
Fluorescence measurements in individual CHO CCKA WT and CHO CCKAMT cells
Cells, electroporated in the presence of 2 |j.g of plasmid pGFP-N1 and 18 |j.g of pcDNA3-myc-Rac1-V12, were 
seeded on a glass cover slip (15.000 cells 30 ^l-1) and allowed to attach for 30 min. Culture medium was added and 
cells were grown for 48 h. In PKC downregulating experiments, PMA (0.1 |xM) was added 24 h prior to the 
measurements. Cells were loaded with Fura-2 in the presence of 3 |jM Fura-2/AM and 0.025% (w/v) pluronic F-127 
for 30 min at 37°C. Excess Fura-2/AM was removed by washing twice with HEPES/Tris medium containing 133 
mM NaCl, 4.2 mM KCl, 1.0 mM CaCl2, 1.0 mM MgCl2, 5.8 mM glucose, an amino acid mixture according to Eagle, 
0.1% (w/v) bovine serum albumin and 10 mM HEPES, adjusted with Tris to pH 7.4. Cover slips were subsequently 
mounted in a thermostatic (34°C) perfusion chamber, placed on the stage of an inverted microscope (Nikon, 
Diaphot). An epifluorescent x40 magnification oil immersion objective was used, allowing simultaneous monitoring 
of close to 50 individual cells. GFP-positive cells were identified at 490 nm excitation. Subsequently, cells were 
superfused with HEPES/Tris medium and the indicated concentration of agonist. Digital imaging microscopy was 
carried out using the MagiCal hardware and TARDIS software provided by Joyce Loebl (Dukesway, Team Valley, 
Gateshead, UK) as described previously (Willems et al, 1993). The fluorescence emission ratio at 492 nm was 
monitored as a measure of the intracellular calcium concentration after excitation at 340 and 380 nm. Of note, GFP 
did not interfere with the Fura-2 fluorescence measurements.
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Figure 1. Expression of PLD1 in Chinese hamster ovary cells. 
The figure shows a Western blot of total cell lysate of CHO cells 
probed with a rabbit anti h-PLD antibody directed against the C­
and N-terminal sequences of human PLD1. The positive band is 
of the expected size (~110 kD).
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Analysis of the data
The results presented are the mean ± S.E.M. of the number of experiments indicated. Unless indicated otherwise, 
overall statistical significance was determined by analysis of variance (ANOVA). In the case of significance (P < 
0.05), individual groups were compared according to Fisher. P  values of less than 0.05 were considered significant.
RESULTS
Expression ofPLDl in CHO cells
Western blot analysis of total cell lysate was performed to examine the expression of PLD1. 
Using an antibody directed against the C- and N-terminal sequences of human PLD1 we 
observed a positive band of expected size (~110 kD) (Fig. 1). This shows that CHO cells 
express substantial amounts of PLD1 at the protein level.
PMA- and GTPyS- induced PLD activation in a broken cell preparation of CHOCCKA cells
In a previous study we showed that PMA evokes a significant increase in PLD activity in a 
homogenate of CHO-CCKA cells (Bosch et al., 1998, 1999). Figure 2 shows that a similar 
increase in PLD activity can be obtained with GTPyS (100 ^M) and that the effects of PMA and 
GTPyS are additive. We previously demonstrated that pretreatment of the cells with PMA (0.1 
^M) to downregulate PKC abolished the stimulatory effect of PMA (Bosch et al., 1999). Here 
we show that this treatment did not affect GTPyS-induced PLD activation. Moreover, the 
increase in PLD activity obtained with the combination of these two drugs was reduced to the 
level obtained with GTPyS alone.
Overexpression o f Rac1 mutants in CHO-CCKAWT cells
CHO cells expressing the wild-type rat CCKA receptor (CHO-CCKAWTcells) were co­
transfected with GFP and either dominant negative myc-Rac1-N17 or constitutively active myc- 
Rac1-V12 and cultured for 24 h. After this first culturing period, GFP-positive cells and GFP- 
negative cells were separated by FACS and cultured for another 24 h. At the end of this second 
culturing period, total cell lysates were prepared and subjected to Western blot analysis using the 
monoclonal anti-myc antibody 9E10. Figure 3 shows a significant expression of the myc-tagged 
Rac1 mutants in the GFP-positive CHO-CCKAWT cells. No signal was obtained with the GFP- 
negative cells, demonstrating the utility of GFP co-expression and subsequent FACS to obtain an 
enriched preparation of Rac1 mutant overexpressing cells.
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Figure 2. PKC downregulation inhibits 
PMA-, but not GTPyS-, induced PLD 
activation in a broken cell preparation 
of CHO cells. CHO cells were labelled 
with [3H]myristic acid in the absence 
(open bars) or presence (closed bars) of 
0.1 |xM PMA for 24 h (o/n; overnight).
Subsequently, the cells were 
homogenized and unbroken cells were 
removed by centrifugation. For PLD 
measurements, aliquots of the 
supernatant were incubated in the 
presence of 0.5 mM MgATP, 0.5 mM 
CaCl2 and 1% (v/v) ethanol for 30 min at 
37°C. Where indicated, PMA (0.1 |xM) 
and/or GTPyS (100 |xM) were added to the reaction mixture. At the end of the incubation period, the lipids were 
extracted, separated by thin layer chromatography and counted for radioactivity. PLD activity is expressed as the 
percentage of total lipid-incorporated label that is present in PtdEth. The data presented are the mean ± S.E.M. of 3 
experiments. * Significantly different from the corresponding untreated control (P< 0.05).
Increased PLD activity in CHO-CCKa WT cells overexpressing constitutively active Rac1-V12
For PLD measurements, cells labelled with [3H]myristic acid were incubated in the presence 
of 1% (v/v) ethanol for the indicated period of time after which lipids were extracted and 
separated by HPTLC. PLD activity is expressed as the percentage of lipid-incorporated label 
that is present in PtdEth. CHO-CCKAWT cells transiently expressing constitutively active 
Rac1-V12 accumulated significantly more [3H]PtdEth than the corresponding GFP-negative 
cells when incubated in the presence of ethanol for 30 min (0.15 ± 0.01 vs. 0.11 ± 0.01 % of 
lipid-incorporated label in GFP-positive and GFP-negative cells, respectively; n=5; P  <0.05). 
In contrast, [3H]PtdEth was not increased in cells transiently expressing dominant-negative 
Rac1-N17 (0.10 ± 0.01 vs. 0.11 ± 0.02 of lipid-incorporated label in GFP-positive and GFP- 
negative cells, respectively; n=5; P  >0.5). Of note, in subsequent experiments PLD activity 
was measured over a period of 10 min during which [3H]PtdEth accumulation was not 
significantly different between unstimulated CHO-CCKAWT cells overexpressing Rac1-V12 
and the corresponding GFP-negative cells (Fig. 4).
Inhibition of CCK8-induced PLD activation in CHO-CCKAWT cells overexpressing 
constitutively active Rac1-V12
The peptide hormone CCK8 increased the amount of [3H]PtdEth dose-dependently when added 
to GFP-negative CHO-CCKAWT cells (Fig. 4). The CCK8-induced increase in [3H]PtdEth was 
not changed in cells overexpressing dominant-negative Rac1-N17 (Fig. 4A). In contrast, PLD 
activation by 1 nM and 10 nM CCK8 was significantly inhibited by 28% and 17%, respectively, 
in CHO-CCKaWT cells transiently expressing constitutively active Rac1-V12 (Fig. 4B).
Overexpression of Rac1-V12 is without effect on phorbol ester- and thapsigargin-induced 
PLD activation in CHO-CCKA WT cells
We previously reported that both PMA, a potent activator of PKC, and thapsigargin, a specific 
inhibitor of the endoplasmic reticulum Ca2+-ATPase which increases the cytosolic free Ca2+ 
concentration by stimulating store-regulated Ca2+ entry, can markedly increase the amount of
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Figure 3. Co-expression of GFP and Racl 
mutants in CHO cells. CHO-CCKaWT cells 
(5x106 cells 300 jil-1) were electroporated in the 
presence of 2 jig pGFP-N1 and 18 jig of either 
pcDNA3-myc-Rac1-N17 or pcDNA3-myc- 
Rac1-V12. The cells were cultured for 48 h 
after which GFP-positive and GFP-negative 
cells were separated by FACS and grown for 
another 24 h. Total cell lysates were prepared 
and subjected to SDS/PAGE followed by 
Western blotting. The membranes were probed 
with the anti-myc monoclonal antibody 9E10.
The figure shows a Western blot of total cell 
lysates from GFP-negative and GFP-positive 
cells. The mock lane represents total cell lysate 
from non-transfected CHO-CCKa WT cells.
The blot is representative of three experiments.
[3H]PtdEth in CHO-CCKaWT cells (Bosch et al, 1999). Figure 5 shows that PMA (1 iM)- 
induced PLD activation was not altered in CHO-CCKaWT cells overexpressing constitutively 
active Rac1-V12. Similarly, the increase in [ H]PtdEth in response to thapsigargin (1 iM ) was 
not affected in these cells. These findings demonstrate that the effect of constitutively active 
Rac1-V12 is specific for CCK8-induced PLD activation.
Removal of Rac1-V12 inhibition of CCK8 induced PLD activation following expression of a 
CCKa receptor engineered to have mutations in the consensus sites for PKC action
Rac1-V12 did not inhibit CCK8-induced PLD activation in CHO cells expressing a CCKa 
receptor in which the four potential sites for PKC action were changed in an alanine (Fig. 6). 
Comparison of figures 4 and 6 furthermore shows that the increase in [ H]PtdEth in response to 
0.1 nM CCK8 was significantly higher in CHO-CCKaMT cells as compared to CHO-CCKaWT 
cells. In CHO-CCKaWT cells transfected with Rac1-N17 the percentage lipid-incorporated label 
present in [3H]PtdEth increased with 0.21 ± 0.02 and 0.21 ± 0.04 % (n = 3) for GFP-negative and 
GFP-positive cells, respectively (Fig. 4A), in Rac1-V12-transfected CHO-CCKaWT cells with 
0.28 ± 0.02 and 0.22 ± 0.04 % (n = 4), respectively (Fig. 4B), and in Rac1-V12-transfected 
CHO-CCKaMT cells with 0.54 ± 0.06 and 0.54 ± 0.06 % (n = 4), respectively (Fig. 6). No 
significant difference was observed with 1 nM and 10 nM CCK8.
Removal of Rac1-V12 inhibition of JMV-180-induced Ca2+ mobilization by PKC 
downregulation in CHO-CCKa cells
We previously provided evidence for the operation of an inhibitory feedback regulation during 
CCK8 stimulation in CHO-CCKaWT cells (Smeets et al, 1998c). This feedback inhibition was 
abolished by PKC inhibitors and PKC downregulation. Moreover, feedback inhibition was 
absent in CHO cells expressing a mutated CCKa receptor in which the four potential sites for 
PKC phosphorylation were changed in an alanine (CHO-CCKaMT cells). It was suggested that 
stimulation with CCK8 results in an increase in PKC activity leading to an increase in receptor 
phosphorylation and consequent decrease in receptor affinity. The finding that PLD activity is 
increased in CHO-CCKaWT cells overexpressing Rac1-V12 (see above) suggests that this PKC- 
dependent feedback mechanism may be activated in these cells. To test this possibility we
kDa 
30 —
21 —
\
cv.
79
Regulation of CCK-induced PLD activation by Rac1-V12
T3
CL
I
T3
¡1
I
CCK8 (nM) CCK8 (nM)
Figure 4. Effect ofoverexpression ofRac1 mutants on CCK8 induced fHJPtdEth formation in CHO-CCK-A WT 
cells. GFP-negative and -positive CHO-CCKaWT cells were separated by FACS and subsequently cultured in 
the presence of [3H]myristic acid for 24 h. At the end of the labelling period, cells were stimulated with the 
indicated concentration of CCK8 in the presence of 1% (v/v) ethanol for 10 min. The lipids were extracted, 
separated by thin layer chromatography and counted for radioactivity. PLD activity is expressed as the 
percentage of total lipid-incorporated label that is present in PtdEth. The figure shows the effects of Rac1-N17 
(a) and Rac1-V12 (b) on the dose-response curve for CCK8 stimulation of PLD activity. The data presented are 
the mean ± S.E.M. of 3 experiments. *Significantly different from the corresponding GFP-negative control (P < 
0.05).
determined the effect of Rac1-V12 on the percentage of cells that responded with an increase in
2+cytosolic Ca following stimulation with the CCK8 analogue JMV-180. We previously 
demonstrated that JMV-180 (f-butyloxycarbonyl-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-2- 
phenylethyl ester), which acts as a partial agonist at the CCKA receptor, increases cytosolic Ca2+ 
in an average of 50% of the cells when added at a concentration of 0.3 nM (Smeets et al, 1996). 
Figure 7 shows that the percentage of CHO-CCKAWT cells that responded with an increase in 
cytosolic Ca2+ was significantly lowered following overexpression of Rac1-V12 (49 ± 9 vs. 28 ± 
8 % in GFP-positive and GFP-negative cells, respectively; n = 12; P  <0.05). This inhibitory 
action of Rac1-V12 was absent in CHO-CCKAWT cells in which PKC was downregulated. 
Similarly, Rac1-V12 overexpression did not decrease the percentage of responding CHO- 
CCKaMT cells.
Broadening ofthe CCK8-induced Ca2+ oscillations in CHO-CCKaMT cells
In a previous study we provided evidence that the extent to which PLD becomes activated in 
CHO-CCKAWT cells depends largely, if not entirely, on the magnitude and duration of the 
CCK8-induced increase in cytosolic free Ca2+ concentration (Bosch ef al., 1998). Therefore, the 
present finding that the increase in PLD activity in response to 0.1 nM CCK8 was significantly 
higher in CHO-CCKAMT cells as compared to CHO-CCK8WT cells urged us to study the 
profile of CCK8-induced Ca2+ mobilization in individual CHO-CCKAWT cells and CHÜ- 
CCKAMT cells in more detail. Figure 8 (upper trace) shows the induction of repetitive changes 
in cytosolic free Ca2+ concentration, or Ca2+ oscillations, in response to continuous stimulation of 
CHO-CCKAWT cells with 3 pM CCK8. The duration of the individual Ca2+ oscillations was 
markedly increased in CHO-CCKAMT cells (Fig. 8; lower trace). Calculation of the peak-width 
at half-maximal peak-height revealed average durations of 11.4 ± 0.6 sec (n=39) and 16.9 ± 1.1
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Figure 5. PMA- and thapsigargin-induced PLD 
activition in CHO CCKAWT cells overexpressing 
Rac1-V12. CHO-CCKaWT cells overexpressing 
Rac1-V12 (GFP-positive cells) and the 
corresponding GFP-negative cells were labelled with 
[3H]myristic acid for 24 h. Subsequently, the cells 
were stimulated with either PMA (1 |jM) or 
thapsigargin (1 |xM) in the presence of 1% (v/v) 
ethanol for 10 min. At the end of the stimulation 
period, the lipids were extracted, separated and 
counted for radioactivity. PLD activity is expressed 
as the percentage of total lipid-incorporated label 
that is present in PtdEth. The data presented are the 
mean ± S.E.M. of 3-4 experiments.
CCK8 (nM)
Figure 6. Removal of Rac1-V12 inhibition of CCK8- 
induced PLD activation in CHO cells expressing a 
CCKa receptor engineered to have mutations in the 
four potential PKC phosphorylation sites. CHO- 
CCKaMT cells overexpressing Rac1-V12 (GFP- 
positive cells) and the corresponding GFP-negative 
cells were labelled with [3H]myristic acid for 24 h 
and subsequently stimulated with the indicated 
concentration of CCK8 in the presence of 1% (v/v) 
ethanol for 10 min. At the end of the stimulation 
period, the lipids were extracted, separated and 
counted for radioactivity. PLD activity is expressed 
as the percentage of total lipid-incorporated label 
that is present in PtdEth. The values presented are 
the mean ± S.E.M. of 3 experiments.
sec (n=67) in CHO-CCKa WT cells and CHO-CCKa MT cells, respectively. Similarly, 
stimulation with 10 pM CCKg yielded average peak-widths of 10.6 ± 0.2 sec (n=86) and 50.2 ± 
4.1 sec (n=178) in CHO-CCKa WT and CHO-CCKa MT cells, respectively. In both cases, the 
difference was statistically significant (P<0.05).
DISCUSSION
Small GTPases are distributed widely in eukaryotic cells and elucidation of their regulation and 
roles in cell function is a challenge in modern cell biology. Here, we provide evidence that Rac1, 
a member of the Rho family of small GTPases, attenuates G protein-coupled receptor (GPCR) 
signalling via a mechanism that involves the consensus sites for PKC action on the receptor 
protein. This conclusion is based on the following observations: (i) agonist-induced PLD 
activition was significantly inhibited in CHO-CCKaWT cells overexpressing constitutively 
active Rac1-V12; (ii) Rac1-V12 inhibition was removed following overexpression in CHO cells 
expressing a CCKa receptor engineered to have mutations in the four potential sites for PKC 
phosphorylation.
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Figure 7. Effect o f Rac1-V12 on JMV- 
180-induced Ca2+ mobilization in CHO- 
CCKaWT cells and CHO-CCKAMT 
cells. CHO cells were electroporated in 
the presence of pGFP-N1 and pcDNA3- 
myc-Rac1-V12, seeded on a glass cover 
slip, and cultured for 48 h. In PKC 
downregulation experiments, 0.1 |xM 
PMA was present during the last 24 h of 
culturing. Cells were loaded with the 
fluorescent Ca2+ indicator fura-2 after 
which the cover slip was mounted in a 
thermostatic (34°C) perfusion chamber, 
placed on the stage of an inverted 
microscope. After identification of GFP-
positive cells at 490 nm excitation, cells were superfused with 0.3 nM JMV-180 and changes in cytosolic Ca2+ 
were monitored simultaneously in close to 50 individual cells. Each measurement enclosed GFP-positive as well 
as -negative cells and for both the number of responding cells was expressed as a percentage of the 
corresponding total. The data presented are the mean ± S.E.M. of at least 5 measurements. *Significantly different 
(P < 0.05 ) from the corresponding GFP-negative control (Student’s t-test for paired samples).
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Multiple PLD activities have been characterized in mammalian cells and, more 
recently, two isoforms, PLD1 (Hammond et al., 1995) and PLD2 (Colley et al., 1997; Kodaki 
and Yamashita 1997), have been cloned. These two isoforms show different regulatory 
properties, e.g. PLD1 activity is increased by several PKC isoforms and members of the ARF 
and Rho families of small GTPases, whereas the activity of PLD2 is not influenced by these 
regulators (Lee et al., 1998; Exton, 1999; Frohman et al, 1999). It has been demonstrated that 
recombinant Rac1, Cdc42, and RhoA restore GTPyS-stimulated PLD activity in HL60 
membranes from which Rho proteins were previously extracted by means of Rho-GDI 
(Siddiqi et al., 1995). This demonstrates that Rac1 and CDC42, similarly to RhoA, can 
interact with membrane-bound PLD to increase its activity in a GTPyS-dependent manner. Of 
relevance to this discussion is the finding that Rac1 was considerably less efficacious than 
RhoA in restoring GTPyS-stimulated PLD activity (30% and 70% recovery of PLD activity 
for Rac1 and RhoA, respectively). Evidence that Rac1-V12 can activate PLD in intact cells 
comes from the present finding that PLD activity is significantly (1.4-fold) increased in CHO 
cells overexpressing this Rac1 mutant. A similar increase in PLD activity was observed 
following overexpression of Rac1-V12 in Rat1 fibroblasts (Hess et al., 1997). This latter 
study also provided evidence that some agonists activate PLD through Rac1 (EGF), whereas 
others act through RhoA (PDGF). Using a specific antibody raised against N- and C-terminal 
sequences of human PLD1 (Muller-Wieprecht et al, 1998) we now demonstrate that CHO 
cells express substantial amounts of this isoform. Consistent with this finding, PMA increased 
PLD activity in intact cells (Bosch et al., 1999), whereas both PMA and GTPyS increased 
PLD activity in a broken cell preparation of these cells (this study). Intriguingly, 
downregulation of PKC was found to abolish the stimulatory effect of PMA while leaving 
that of GTPyS intact. This indicates that PKC and the small GTPases can regulate PLD 
activity in an independent fashion in vitro.
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Figure 8. CCKg-induced cytosolic Ca2+ signalling in individual CHO-CCKaWT cells and CHO-CCKaMT cells. 
CHO cells were loaded with fura-2 and stimulated with 3 pM and 10 pM CCK8 for the indicated periods of time. 
The fluorescence emission ratio at 492 nm was monitored as a measure of the cytosolic Ca2+ concentration after 
excitation at 340 and 380 nm. Representative recordings from a single CHO-CCKAWT cell (upper recording) and a 
single CHO-CCKaMT cell (lower recording).
2+Recent work showed that Ca mobilizing GPCRs that increase PLD activity in an ARF- 
and RhoA-dependent manner form functional complexes with these small GTPases on ligand 
binding in human astrocytoma cells (Mitchell ef a/., 1998). Moreover, mutational analysis 
revealed that the presence of a NPXXY motif in the seventh transmembrane domain of the 
GPCR is a prerequisite for agonist-induced complex formation and PLD activation. The rat 
CCKa receptor contains the NPXXY motif, suggesting that CCK8 increases PLD activity in an 
ARF- and RhoA-dependent manner. The present finding that CCK8-induced PLD activation is 
reduced in CHO-CCKAWT cells overexpressing Rac1-V12 together with the given that Racl is 
less efficacious than RhoA in activating PLD (see above) provides a rationale to propose that 
constitutively active Rac1-V12 competes with RhoA to form a functional complex with the 
CCKa receptor on CCK8 binding. The Rac1-V12 complex is less efficacious than the RhoA 
complex in activating PLD thus explaining the reduced CCK8-induced increase in PLD activity. 
Overexpression of Rac1-V12 did not affect the increase in PLD activity in response to PMA and 
thapsigargin. This is consistent with our proposal that Rac1-V12 does not exert its effect 
downstream of the CCKA receptor. Similarly to the present study, overexpression of Rac1-V12 
was found to attenuate PDGF-induced PLD activation in Rati fibroblasts (Hess et al, 1997). 
Importantly, PDGF acts through RhoA which is consistent with our idea that Rac1-V12 exerts its 
inhibitory effect by competing with RhoA in agonist-induced PLD activation.
The major finding of this study is that Rac1-V12 inhibition of CCK8-induced PLD 
activation is abolished in cells expressing a mutated CCKA receptor in which the four consensus 
sites for PKC phosphorylation are changed in an alanine. This receptor mutant is not
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phosphorylated in response to CCK8 as can be deduced from the work of Miller and co-workers 
who demonstrated that CCK8-induced receptor phosphorylation was abolished following 
expression of a CCKA receptor engineered to have mutations in only two of the four potential 
sites for PKC action (Rao et al, 1997). According to the above model, this finding suggests that 
phosphorylation of key PKC sites on the receptor is required for Rac1-V12 to compete with 
RhoA to form a functional complex with the CCKA receptor. Of note, the increase in PLD 
activity in response to the higher CCK8 concentrations, 1 nM and 10 nM, was not different 
between the untransfected (GFP-negative) CHO-CCKAWT cells and the CHO-CCKAMT cells. 
This indicates that CCK8 does not activate endogenous Rac1. This is furthermore supported by 
the finding that Rac1-N17 did not affect CCK8-induced PLD activation in CHO-CCKAWT cells. 
Therefore, from a regulatory point of view, it is tempting to speculate that factors other than 
CCK8 activate endogenous Rac1 to promote the formation of Rac1/CCKA receptor complexes 
during CCK8 stimulation thus attenuating CCK8-induced PLD activation.
Rac1-V12 overexpression did not significantly inhibit the increase in PLD activity in 
response to 0.1 nM CCK8 in CHO-CCKAWT cells. According to our hypothesis, this suggests 
that the lower (< 0.1 mM) CCK8 concentrations do not induce phosphorylation of the key PKC 
sites on the CCKA receptor for complex formation with Rac1-V12. As a consequence, PLD 
activation will occur entirely via RhoA. We previously reported that CCK8 at concentrations < 
0.1 mM does not significantly increase mass inositol 1,4,5-trisphosphate in CHO-CCKAWT cells 
(Smeets et al, 1998c). Accordingly, the increase in mass diacylglycerol will be too low for 
sufficient PKC-mediated phosphorylation of the CCKA receptor for association with Rac1-V12 . 
Intriguingly, the increase in PLD activity in response to 0.1 nM CCK8 was significantly
higher in CHO-CCKAMT cells as compared to cells expressing the wild-type receptor. We
2+previously reported that cytosolic Ca is an important determinant in CCK8-induced PLD 
activation in these cells (Bosch et al, 1999). In agreement with this, we observed that the 
duration of the repetitive increases in cytosolic Ca2+, as evoked by the lower (< 0.1 nM) CCK8
concentrations, is significantly increased in cells expressing the PKC-insensitive CCKA receptor
2+mutant. In contrast, CCK8 concentrations > 1 nM evoke a sustained increase in cytosolic Ca 
(Bosch et al, 1999) the size of which is not different between CHO-CCKAWT and CHO-
CCKAMT cells (Smeets et al, 1998c). The finding that the duration of the CCK8-induced
2+periodic increases in cytosolic Ca is increased in CHO cells expressing the CCKA receptor 
lacking the four potential PKC phosphorylation sites indicates that in case of the wild-type 
receptor low-level PKC activation during stimulation with <0.1 nM CCK8 is sufficient to
phosphorylate the receptor thus decreasing inositol 1,4,5-trisphosphate production, which, in
2+turn, leads to shortening of the duration of the periodic Ca rises.
Overexpression of Rac1-V12 significantly increased PLD activity in unstimulated CHO- 
CCKaWT cells. It has been suggested that PtdOH, formed as a result of PLD action, is converted 
to diacylglycerol, the physiological activator of PKC. The present study shows that the number 
of cells that responded with an increase in cytosolic Ca2+ to stimulation with the CCK8 analogue, 
JMV-180, which acts as a partial agonist at the CCKA receptor, was decreased in CHO-CCKA 
cells overexpressing Rac1-V12. This effect of Rac1-V12 was not observed in CHO-CCKAMT 
cells, indicating that Rac1-V12 increases the phosphorylation state of the receptor via low-level 
activation of PKC. This finding provides evidence for a role of PLD, activated by Rac1 or other 
factors, in the regulation of receptor signalling. It has been reported that EGF-, but not GPCR-,
induced Ca2+ signalling is abolished in Rat1 fibroblasts overexpressing Rac1-N17
2+(Peppelenbosch et al, 1996). This demonstrates that EGF-induced Ca mobilization occurs
2+through Rac1, whereas the present study shows that Rac1-V12 inhibition of CCK8-induced Ca 
mobilization occurs through PKC.
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We previously showed that CCK8-induced PLD activation is abolished in CHO- 
CCKaWT cells in which PKC is downregulated by prolonged PMA treatment (Bosch et al, 
1999). In addition, this study shows that PMA-, but not GTPyS-, stimulated PLD activity is 
abolished in a broken cell preparation of PKC downregulated cells. According to our model, 
CCK8-induced PLD activation requires the formation of a complex of the CCKA receptor with 
RhoA and ARF. Apparently, this complex requires PKC to become functional. In a recent study, 
transposon mutagenesis was used to generate a pentapeptide insertion mutant of PLD1 (PIM87) 
that was not activated by PKC in vitro or by PMA in vivo but showed a wild-type response to 
RhoA and ARF1 in vitro (Zhang et al, 1999). Importantly, carbachol only minimally increased 
the activity of this PKC-insensitive PLD1 mutant following co-expression with the m1 
muscarinic receptor in HEK293 cells, whereas, in contrast, PLD activity was markedly increased 
following co-expression of wild-type PLD1 with this receptor. This finding demonstrates that a 
PKC-sensitive PLD is required for agonist-induced PLD activation. This is in agreement with 
our finding that agonist-induced PLD activation is abolished in cells in which PKC is 
downregulated. Therefore, we conclude that CCK8 interacts with its receptor to stimulate the 
translocation of PKC, RhoA and ARF to the plasma membrane (Rumenapp et al., 1996; Keller 
et al, 1997) where RhoA and ARF form a complex with the receptor that in conjunction with 
PKC increases the activity of PLD.
Finally, many studies have shown that both PMA and thapsigargin, which increases 
cytosolic Ca2+, evoke a marked increase in PLD activity. However, it is very well possible that 
this receptor-independent activation of PLD reflects a situation of non-physiological PKC 
activation and that PMA and thapsigargin concentrations that evoke a physiological level of PKC 
activation and cytosolic Ca2+ mobilization do not increase PLD activity.
In conclusion, the data presented in this study are consistent with the idea that binding of
CCK8 to the CCKa receptor initiates a sequence of events including, activation of phospholipase
C, increases in cellular levels of diacylglycerol and, through the action of inositol 1,4,5­
2+trisphosphate, cytosolic free Ca2+, activation and translocation of PKC, PKC-dependent 
phosphorylation of the receptor, translocation of ARF and RhoA, formation of a complex of 
CCKA receptors with ARF and RhoA, and, finally, a PKC-dependent increase in PLD activity. 
Rac1, which is less efficacious than RhoA in increasing PLD activity, when activated by some 
other signalling pathway, inhibits CCK-induced PLD activation by competing with RhoA for 
association with the CCKA receptor. Rac1 inhibition requires phosphorylation of key PKC sites 
on the CCKA receptor, which is achieved either by high CCK concentrations (homologous 
phosphorylation) or by agonists other than CCK that interact with receptors coupled to 
phospholipase C to increase PKC activity (heterologous phosphorylation). Taken together, the 
model proposed here provides a mechanism by which PLD activation through one receptor can 
be controlled by the concerted action of receptors that increase PKC activity and receptors that 
activate Rac1.
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The role of small GTP-binding proteins in signal transduction cascades is currently widely 
studied. However, their involvement in Ca + signaling is poorly understood. We transfected 
Chinese hamster ovary (CHO) cells, stably expressing the rat cholecystokinin-A (CCKA) 
receptor, with either a dominant negative (N43) or constitutively active (V38) form of Ras-like 
Ras (R-Ras). Co-transfection of green fluorescent protein with the R-Ras interfering mutants 
allowed easy discrimination between transfected and non-transfected cells. At 48 h post­
transfection, videospeed confocal laser scanning microscopy was used to evaluate the effects of 
R-Ras-N43 and R-Ras-V38 expression on cytosolic Ca + dynamics and shape of the cells. It was 
found that cells expressing the R-Ras interfering mutants were more spherical than control cells, 
whereas the cellular area in the confocal plane was not affected. CCK8-induced cytosolic Ca2+ 
changes were recorded in the absence of extracellular Ca + by using the UV Ca + indicator indo- 
1 and video rate confocal microscopy. Interestingly, 0.1 C C K  evoked a different Ca2+ 
transient in R-Ras-V38 expressing cells, compared to control cells. This phenomenon was not 
observed in R-Ras-N43 expressing cells. R-Ras-V38 expression was associated with a less wide 
Ca2+ transient and an increased Ca2+ removal rate. For Ca2+ transients evoked with thapsigargin 
(1 ^M), a specific sarco-, endoplasmic reticulum calcium ATPases (SERCA)-inhibitor, similar 
differences were found. In contrast, the kinetics of the Ca + oscillations, induced with a lower 
concentration of CCK8 (0.1 nM), were not different between R-Ras-V38 expressing and control 
cells. In addition, expression of R-Ras-V38 did not affect the amount of Ins(1,4,5)P3 generated 
during CCK8 stimulation. Because R-Ras interacts with Bcl-2, an anti-apoptotic protein that has 
been shown to affect intracellular Ca2+ sequestration, we propose that the R-Ras-V38-induced 
modulation of Ca2+ signaling contributes to the anti-apoptotic effects described for R-Ras. This 
implies that an increased Ca + storage capacity in cells expressing constitutively active R-Ras is 
responsible for the observed findings.
INTRODUCTION
The superfamily of Ras-like GTPases contains several members, one of which is the Ras family 
(Bos, 1997, 1998). This family consists of, among others, Ras, Rap, Ral and Ras-like Ras (R- 
Ras) proteins, which share an identical effector domain. The Ras protein is frequently mutated in 
human tumors, which urged investigators to study this small GTP- binding protein in great detail. 
Several extracellular ligands activate Ras, thereby initiating a multi-component signaling 
network responsible for the mitogenic action of Ras. At present, the function of the other Ras 
family members and how they are intertwined with other signal transduction pathways is largely 
unknown. Rap proteins can antagonize the oncogenic transformation of cells by Ras. Recently, it
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has been demonstrated that Rap on its turn, is activated by Epac (exchange protein directly 
activated by cAMP) (De Rooij ef al, 1999). Effectors of Ral are Cdc42 (Cantor et al., 1995) and 
phospholipase D (Jiang et al, 1995). Ral on its turn, is reported to be regulated by Ras (for 
review see Bos, 1998), although Ras-independent pathways have also been reported (Wolthuis et 
al, 1998).
R-Ras, which is also a member of the Ras family, was initially found to be involved in 
integrin regulation (Zhang et al., 1995). R-Ras-V38-expressing mouse 32D.3 and human U937 
myeloid cells bind more strongly to fibronectin, an effect mediated by integrin. R-Ras-mediated 
integrin activation has also been demonstrated in other mammalian cells (Keely et al, 1999; 
Sethi et al, 1999; Zou et al, 1999; Wang et al, 2000). Thus far, no specific R-Ras activating 
protein has been identified which makes it difficult to place R-Ras within elucidated signal 
transduction cascades. It can bind several Ras-effector proteins in vitro, such as Raf, RalGDS, 
Rlf and PI-3-kinase (for review see Bos, 1998), but it is unclear whether these interactions do 
occur in vivo. It has been reported, however, that R-Ras activates the PI-3-kinase pathway but 
not the Raf pathway (Marte et al, 1997), suggesting that not all Ras-effector proteins are 
stimulated by R-Ras.
Because R-Ras binds to the anti-apoptosis protein Bcl-2 (Fernandez-Sarabia and 
Bischoff, 1993), it could exert its apoptosis-inhibiting function (Suzuki et al, 1997,1998; Osada 
et al, 1999) via this association. Bcl-2 has been identified to overrule apoptotic signals (for 
review see: Vaux and Strasser, 1996) via increasing the capacity of intracellular calcium storage
(Zhu et al, 1999). In this mechanism, Bcl-2 stimulates the expression of sarco-, endoplasmic
2+reticulum calcium ATPases (SERCAs) and leads to an increased mitochondrial Ca
sequestration (either by increasing the mitochondrial mass or the membrane potential of
individual mitochondria). Since apoptosis is generally accompanied by sustained high cytosolic 
2+ 2+Ca concentrations ([Ca ]i), this increased calcium storage capacity functions as a protection
mechanism against toxically high Ca2+ levels. However, during prolonged pathological 
2+ 2+ conditions of high [Ca ]i, mitochondria become overloaded with Ca leading to opening of the
mitochondrial permeability transition (PT) pore, a key process in programmed cell death (for
review see Crompton, 1999). Given that R-Ras binds to Bcl-2, a role for R-Ras in the regulation
2+of cellular Ca levels is not unlikely. At present, however, evidence is lacking for such a role.
2+Therefore, we studied whether constitutively active R-Ras-V38 affected cellular Ca dynamics.
To this end, Chinese hamster ovary (CHO) cells, stably expressing the cholecystokinin-A
2+receptor (CCKA), were challenged with high Ca loads, 48 h post-transfection with R-Ras-V38
2+and R-Ras-N43. Interestingly, removal of Ca from the cytosol after cholecystokinin 
octapeptide (CCK8) stimulation was considerably enhanced in R-Ras-V38-transfected cells
but not in R-Ras-N43 transfected cells. Therefore, we propose that the anti-apoptotic effect
2+reported for R-Ras is due to its ability to increase the mitochondrial Ca storage, most likely 
by activating Bcl-2.
MATERIALS AND METHODS
Materials
CCKg was obtained from Sigma (St. Louis, MO, USA) and thapsigargin from LC services (Woburn, MA, USA). 
Tissue culture medium with additives from Gibco (Paisley, Scotland). Indo-1/acetoxymethyl ester and pluronic F- 
127 were purchased from Molecular Probes Inc. (Leiden, ZH, The Netherlands). D-myo [3H] inositol 1,4,5- 
trisphosphate (51.4 Ci/mmol) was obtained from Amersham (Buckinghamshire, UK). All other chemicals were of 
reagent grade.
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Transient transfection of CHOCCKA cells with R-Ras mutants
The development of a stable CHO cell line expressing the CCKA receptor (CHO-CCKA) has been described in detail 
elsewhere (Smeets et al., 1998c). CHO-CCKA cells were grown to confluence in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal calf serum (FCS) in a humidified atmosphere of 5% CO2 at 37°C. 
For transfection, cells were trypsinized and transferred to a cuvette (3x106 cells/300 ill). The cells were 
electroporated (280 V, 975 |jF) in the presence of 2 |j.g of plasmid pGFP-N1 (Clontech,Palo Alto, CA, USA) and 18 
|j.g of either pMT2-HA-R-Ras-V38 or pMT2-HA-R-Ras-N43 (Spaargaren et al, 1994). Subsequently, cells were 
seeded on a glass cover slip (15,000 cells/30 |jl) and allowed to attach for 30 min. Culture medium was added and 
the cells were grown for 48 h.
Detection o f R-Ras mutants in CHOCCKA cells
To analyze the efficiency of co-transfection with green fluorescence protein (GFP), cells were monitored for 
GFP expression and subsequently separated into a GFP-positive and a GFP-negative fraction by means of 
fluorescence activated cell sorting. After 24 h of culture, total cell lysates (50 |j.g) were prepared and subjected to 
SDS-polyacrylamide gel electrophoresis. Proteins were transferred overnight to polyvinylidine difluoride 
membranes (Immobilon P, Millipore, Bedford, MA, USA). For detection of HA-R-Ras-V38 and HA-R-Ras- 
N43, blots were incubated overnight with the anti-HA monoclonal antibody 12ca5. Immunoreactive bands were 
detected with alkaline phosphatase-conjugated rabbit anti-mouse IgG.
Imaging of indo-1 and GFP fluorescence in single cells
Cells were loaded with indo-1 for 30 min at 37oC in DMEM containing 10% FCS, 3 |xM indo-1/AM and 0.025% 
(w/v) pluronic F-127. Excess indo-1 was removed by washing twice with calcium-free HEPES/Tris medium 
containing 133 mM NaCl, 4.2 mM KCl, 1.0 mM MgCl2, 5.8 mM glucose, an amino acid mixture according to 
Eagle, 0.1% (w/v) bovine serum albumin and 10 mM HEPES, adjusted with Tris to pH 7.4. Cover slips (22 
mm) were subsequently mounted in a Leiden chamber (Ince et al., 1985) and placed on the stage of an inverted 
microscope (Nikon, Diaphot), attached to a videorate confocal microscope (Noran instruments, Middleton, WI, 
USA). A water immersion objective (x40, NA 1.2) was used, allowing a field of view of about 15 cells. Within 
each field (165x155^m), cells of comparable size were selected. GFP-positive cells were identified by recording 
its green emission at 525 + 25nm after 488 nm excitation (delivered by an Argon- ion laser, Omnichrome Inc., 
Chino, CA, USA). Specific excitation of indo-1 (at 351 nm) was provided by a high power argon ion laser 
(Coherent Enterprise, Santa Clara, CA, USA). Indo-1 fluorescence emission was monitored at 405 + 45 nm and 
485 + 45 nm by using a 455 nm DCLP dichroic mirror. The OZ hardware set-up and acquisition was controlled 
with Intervision software (Version 1.6, Noran instruments) running under IRIX 6.2 on an Indy workstation 
(Silicon Graphics Inc., Mountain View, CA, USA) equipped with 128 Mb of RAM. Fluorescence signals were 
collected in real-time from eight rectangular regions of interest (including a background signal) drawn on full- 
frame images (512x480 pixels, 30 Hz, 5-10 min total recording time) at a zoom factor of 0.6 (pixelsize: 0.323 
^m). To reduce noise and to ensure that each cell was fully within the confocal volume no slit was applied, 
resulting in an optical sections thickness of 10.53 ^m. Between recordings, hardware settings (i.e. brightness, 
contrast and laser power) were kept constant. The laser power used (28 ^W at the back of the objective lens) was 
minimal to prevent cytotoxic and/or heating artifacts. Cells were incubated for 2 minutes in calcium free 
HEPES/Tris medium containing EGTA (0.5 mM) prior to the start of the recording. Subsequently, cells were 
stimulated with CCK8 (100 pM or 0.1 |xM) or 1 |xM thapsigargin.
Ins(1,4,5)P3 measurements in cell suspensions
GFP-negative control cells and transfected GFP-positive cells were plated out in 12-well plates (100,000 
cells/well) 24 hours previous to hormonal stimulation and Ins(1,4,5)P3 measurement. Subsequently, cells were 
washed in HEPES/Tris medium containing 1% (w/v) bovine serum albumin. Each well was stimulated 
separately by the addition of 125 HEPES/Tris medium containing the indicated concentration of CCK8. After 
20 sec, the reaction was stopped by addition of 31 trichloroacetic acid (50 %). The cells were scraped off and 
transferred to an eppendorf test tube. The samples were centrifuged for 4 min at 10,000 g and a 120 |jl aliquot of
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Figure 1. Co-expression of GFP and HA- 
R-Ras mutants in CHO-CCKA cells. CHO-
CCKa cells (5x106 cells 300 ^l-1) were 
electroporated in the presence of 2 ^g 
pGFP-N1 and 18 ^g of either pMT2-HA- 
R-Ras-V38 or pMT2-HA-R-Ras-N43. The 
cells were cultured for 48 h after which 
GFP-positive and GFP-negative cells were 
separated by FACS and grown for another 
24 h. Total cell lysates were prepared and 
subjected to SDS/PAGE followed by 
Western blotting. The membranes were 
probed with the anti-HA monoclonal
mock V38 N43
kDa
43
30
20
GFP
antibody 12ca5. The figure shows that expression of R-Ras mutants (indicated with arrow) is predominantly in the 
total cell lysates of GFP-positive cells. The mock lane represents total cell lysate from non-transfected CHO-CCKA 
cells. The blot is representative of three experiments.
the supernatant was removed, which was extracted three times with 2 ml of water-saturated diethyl ether. 
Subsequently, 75 ^l was taken to which 2 ^l KHCO3 (50%) was added to increase pH above 7.5. The 
Ins(1,4,5)P3 content of the extract was determined by isotope dilution assay as previously described (Willems et 
al, 1994).
Data analysis
Numerical data was analyzed by using a spreadsheet (Excel 2000, Microsoft, Redmond, USA), dedicated 
visualization/fitting software (Microcal, Northampton, MA, USA) and an image-analysis program (Media 
Cybernetics, Silver Spring, MD, USA). The results presented are the mean ± S.E.M. of the number of experiments 
indicated in the text. Overall statistical significance was determined by analysis of variance (ANOVA). In case of 
significance, individual groups were compared according to Fischer. P values of less than 0.05 were considered 
significant.
RESULTS
Overexpression ofR-Ras interfering mutants in CHO-CCKa cells affects cellular shape
CHO cells expressing the rat CCKA receptor (CHO-CCKa) were co-transfected with GFP and 
either constitutively active HA-R-Ras-V38 or dominant negative HA-R-Ras-N43 and cultured 
for 24 h. After this first culture period, GFP-positive cells and GFP-negative cells were separated 
by FACS and cultured for another 24 h. At the end of this second culturing period, total cell 
lysates were prepared and subjected to Western blot analysis using the monoclonal anti-HA 
antibody 12ca5. Figure 1 shows a significant expression of the HA-tagged R-Ras mutants in the 
GFP positive CHO-CCKa cells. In case of HA-R-Ras-V38, hereafter referred to as R-Ras-V38, a 
minimal signal was obtained with the GFP-negative cells and in case of HA-R-Ras-N43, 
hereafter referred to as R-Ras-N43, no signal was obtained with the GFP-negative cells. Based 
on these results we used GFP co-expression to identify individual R-Ras mutant-expressing 
CHO-CCKa cells during subsequent calcium recordings. Figure 2 shows a representative 
recording of fluorescence data obtained from CHO-CCKa cells 48 h post-transfection with R- 
Ras-V38 and GFP. The fluorescence images of GFP (Fig. 2A) and indo-1 (Fig. 2B) were 
color-coded using either a linear green (GFP) or red (indo-1) lookup table (LUT). GFP- 
positive cells were designated as transfected cells that express the interfering R-Ras mutants.
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Figure 2. Identification of R-Ras interfering mutants transfected cells. (A) Fluorescence image recorded at 525 
nm (excitation: 488 nm), showing the GFP signal of cells co-transfected with GFP and R-Ras-V38. (B) Same cells 
as in (A) recorded at 405 nm (excitation: 351 nm) showing indo-1 emission of GFP-positive, as well as GFP- 
negative cells.
GFP-negative cells were designated as non-transfected cells. The intensity of the GFP signal 
was not different for R-Ras-V38 and R-Ras-N43 transfected cells (see table 1). In order to 
assess whether R-Ras expression affects cellular shape, two parameters were defined. First, 
the cellular area in the plane of focus was determined from the indo-1 images after a threshold 
operation (needed to distinguish cells from background). The pixel dimensions for the applied 
zoom and objective were obtained with a graticule and used to calculate the area in |im . It 
was found that control cells had a somewhat smaller area than transfected (GFP-positive) 
cells. This difference was only significant between R-Ras-N43 and control cells. Second, the 
‘roundness’-value, which is defined as (perimeter) /(4narea), of each cell was determined. 
This implies that spherical cells, which have a perimeter of 2nr and an area of nr in the 
confocal plane, have a roundness of unity. Cells expressing either R-Ras-V38 or R-Ras-N43 
displayed a significantly smaller roundness-value compared to non-transfected cells (table 1). 
Moreover, cells transfected with R-Ras-N43 had a significantly smaller roundness-value than 
R-Ras-V38-transfected cells. Taken together, this finding demonstrates that cells expressing 
the R-Ras interfering mutants are more spherical than non-transfected cells.
Expression ofR-Ras-V38accelerates Ca2 extrusion after CCKs- and thapsigargin treatment
To investigate whether R-Ras affects Ca2+ signaling, cells were stimulated with a high
2+concentration of CCK8 in the absence of extracellular Ca at 48 h post-transfection. CCK8 
(0.1 ^M) induced a transient Ca2+-rise both in transfected and control cells (Fig. 3A). This 
transient consisted of a rapid increase that was followed by a biphasic return which was 
composed of a slow and a subsequently more rapid decline to basal levels. This return was not 
observed in the presence of extracellular Ca2+, where after the rapid increase a plateau of high
[Ca2+]i was maintained (Bosch et al. 1999). Figure 3A, shows a typical example of kinetic
2+differences between a Ca transient recorded from R-Ras-V38-expressing cell (GFP+) and a 
corresponding control cell (GFP-). The recording shows that the duration of the Ca2+ transient
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Parameter Control/GFP- R-Ras-V38/GFP+ R-Ras-N43/GFP+
N 41 31 23
GFP intensity 
(greyvalue) 0 130±11 157±11
Area
(Mm2) 376±20 429±46 475±25*
Roundness 4.27±0.30 2.51±0.20* 1.83±0.06*
Table 1. Morphological parameters o f control and transfected cells. The GFP intensity and the area of 
untransfected control (GFP-) cells and cells expressing either R-Ras-V38 or R-Ras-N43 (GFP+) was determined 
(for details see text). The roundness was defined as (perimeter)2/(47iA), with A being the area of the region of 
interest. Significantly different from control (GFP-) cells.
was affected in case of R-Ras-V38 expression. In contrast, no differences in Ca2+ kinetics
were found between control cells and cells expressing the dominant negative R-Ras-N43
2+mutant (Fig. 3A: inset). Thapsigargin, a specific inhibitor of SERCA-ATPases, releases Ca 
from the endoplasmic reticulum and stimulates store-regulated Ca2+ entry in CHO-CCKA cells
(Bosch et al. 1999). Similar as CCK8, it induces a Ca2+ transient in the absence of
2+extracellular Ca (Fig. 3B). In addition, the duration of this transient was affected, similarly 
as with CCK8, in case of R-Ras-V38 expression.
Figure 4 shows the relation between the amplitude of the CCK8-induced [Ca2+]i increase
2+and the subsequent linear decrease in [Ca ]i during the fastest removal rate (second phase) (A) 
and peak width (B) for each individual cell. Both control and R-Ras-V38 expressing cells display 
a more rapid removal rate of [Ca2+]i and a smaller peak width at higher amplitudes. The average 
amplitude of control and transfected cells was not different. The variance in removal rate and 
peak width for each condition was corrected by dividing the two parameters of each recording 
with the corresponding amplitude. Figure 5 shows that control cells belonging to experiments 
performed with either R-Ras-V38 or R-Ras-N43 have similar corrected peak width and removal 
rate values. Control R-Ras-V38 and control R-Ras-N43 cells had a corrected removal rate of 
0.0094 (S.E.M.=0.0005; n=27) and 0.0081 (S.E.M.=0.0007; n=18) and a corrected peak width of 
54.5 (S.E.M.=4.0; n=27) and 63.2 (S.E.M.=5.9; n=18), respectively. Expression of R-Ras-N43 
did not significantly affected the removal rate, which was 0.0092 (S.E.M.=0.0006; n=18), or the 
peak width, which was 57.7 (S.E.M.=5.8; n=18), of the Ca2+ transient. In contrast, expression of 
R-Ras-V38 resulted in a significantly higher removal rate, which was 0.013 (S.E.M.=0.0006; 
n=27), and a significantly lower peak width, which was 44.7 (S.E.M.=3.3; n=27). These results
indicate that the Ca2+ transient in cells expressing R-Ras-V38 is faster nullified, as the transient
2+lasted shorter and is accompanied with a more rapid second phase Ca removal. Similarly, the 
rate of Ca2+ removal of thapsigargin-induced Ca2+ transients was significantly increased 
following R-Ras-V38 expression and amounted 0.007 (S.E.M.=0.0004; n=35) in case of control 
cells and 0.010 (S.E.M.=0.001; n=29) in case of R-Ras-V38 expressing cells. Because the 
increase in [Ca2+]i is immediate upon CCK8 application, the peak width reflects the time required
to return to basal level. The increase in [Ca2+]i was relatively slow upon application of
2+thapsigargin. As a consequence, the Ca extrusion mechanism already operates during the 
increase phase of the Ca2+ transient. This implicated that the period during which the maximal
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Figure 3. agonist-induced Ca + transients in R-Ras- V38 and R-Ras-N43 expressing cells. Representative recording 
of a indo-1 loaded R-Ras-V38 expressing (GFP+) and control (GFP-) cell upon treatment with 0.1 CCK8 (A) and 
1 |jM thapsigargin (B) (basal ratio was normalized to 1; addition of agonist shown by arrow). Inset of A: 
representative recording of a R-Ras-N43 expressing (GFP+) and control (GFP-) cell upon stimulation with 0.1 |xM 
CCK8.
95
R-Ras and Ca2+ signaling
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Figure 4. Removal rate and peak width are a function of amplitude of the CCK-nduced Ca2+ transient. The 
amplitude (x-axis), rate of Ca2+ removal (y-axis, A) and peak width (y-axis, B) of the Ca2+ transient following 
application of 0.1 |jM CCK was determined of R-Ras-V38 (GFP+) and corresponding control (GFP-) cells. The 
continuous line was fitted for the GFP- cells and the dotted line for GFP+ cells. The linear correlation coefficient r of 
the continuous (GFP-) and dotted (GFP+) line in case of removal rate is 0.87 and 0.85, respectively. The linear 
correlation coefficient r of the continuous (GFP-) and dotted (GFP+) line in case of peak width is -0.38 and -0.51, 
respectively.
2+ 2+ [Ca ]i returned to basal level was in part dominated by the period during which [Ca ]
increased. Therefore, determination of the peak width is an invalid parameter to assess in case of
thapsigargin treament.
Expression of R-Ras-V38 does not affect the kinetics o f the Ca2+ oscillations
To investigate whether R-Ras-V38 expression affects the kinetic of the Ca2+ oscillations, 
induced with low concentrations CCK8, cells were loaded with indo-1 and subsequently 
stimulated with 100 pM CCK8 in the absence of extracellular Ca2+, 48 h post-transfection. 
Each Ca2+ oscillation consisted of a rapid increase followed by a biphasic decline (see 
enlargement of peak I in Fig. 6A). During the time course of the recording, the amplitude of 
the oscillations recorded from a control cell, decreased (Fig. 6A). This decrease is well 
described by a mono-exponential function (Y = Yo+C*e-X/^ , |i = 533 ± 54.3 s-1, R2 = 0.999; 
graph not shown). The rate of decline in amplitude of the consecutive oscillations was not 
affected by transfection with R-Ras-V38 (Fig. 6B). The oscillation pattern induced with 100 
pM CCK8 starts with high amplitudes and rapid declines and this pattern shifts with 
increasing number of oscillations to low amplitude and slower decline (see inset figure 6A). 
Given the more rapid decline observed with high CCK8 concentrations in R-Ras-V38 
expressing cells, we investigated whether this increased rate of Ca2+ removal was also present 
during consecutive oscillations. However, the relation between amplitude and decline rates 
was similar between R-Ras-V38 expressing cells and control cells (Fig. 6C). Moreover, GFP- 
positive and GFP-negative cells had a similar corrected removal rate value (given by removal 
rate/amplitude) which was 0.067 (S.E.M.=0.001; n=25) and 0.062 (S.E.M.=0.0004; n=38), 
respectively. This shows that across the full oscillation range the rate of Ca2+ removal was not 
affected by R-Ras-V38 expression.
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Figure 5. Determination of the corrected 
removal rate and peak width values.
Removal rate and peak width values of each 
recorded Ca2+ transient was divided with the 
corresponding amplitude. Corrected 
removal rate (x-axis) and corrected peak 
width (y-axis) of control cells (GFP-) from 
R-Ras-V38 and R-Ras-N43 experiments 
and of cells expressing R-Ras-43 or R-Ras- 
V38 (GFP+) are plotted. * Significantly 
different (P<0.05) from corresponding GFP- 
control. Significantly different (P<0.05) 
from R-Ras-N43 / GFP-. Significantly 
different (P<0.05) from corresponding R- 
Ras-N43 / GFP+.
Expression of R-Ras interfering mutants does not affect CCKs-mediated Ins(1,4,5)P3 
synthesis
To investigate whether R-Ras-V38-mediated differences in Ca2+ kinetics are caused by altered 
Ins(1,4,5)P3 levels, we evaluated whether R-Ras-V38 expression interfered with CCK8- 
mediated Ins(1,4,5)P3 production. To this end, 24 h post-transfection GFP-positive cells and 
GFP-negative cells were separated by FACS and cultured for another 24 h. Subsequently, the 
amount of Ins(1,4,5)P3 produced during 20 sec was determined for both R-Ras-interfering 
mutants as a function of CCK8 concentration (Fig. 7). The stimulatory effect of CCK8 was dose- 
dependent and did not differ between control and transfected cells.
DISCUSSION
2+Uptake of Ca by the endoplasmic reticulum (ER) and the mitochondria is important in 
maintaining normal Ca2+ homeostasis and protection of cells from apoptotic insult (Bian etal.,
1997; Preston etal., 1997; Zhu etal., 1999). We studied the role of R-Ras in Ca2+ homeostasis
2+and found that large cytosolic Ca loads are removed faster from R-Ras-V38-expressing cells
than from non-transfected cells. Because CHO cells possess a powerful capacitative Ca2+ entry
2+mechanism (Bosch et al, 1999) that prevented to assess the kinetics of Ca extrusion, we
2+removed extracellular Ca shortly (1-2 min) before application of CCK8 or thapsigargin.
During CCK8 application, the cytosolic Ca2+ concentration [Ca2+]i is determined by the balance
2+ 2+between intracellular Ins(1,4,5,)P3-induced Ca release, Ca sequestration (by SERCAs and 
2+ 2+ the Ca2+-activated mitochondrial uniporter) and Ca2+ extrusion across the plasma membrane
(PMCAs). It was found that in R-Ras-V38-transfected cells, CCK8-induced Ca2+ transients
lasted shorter than in control cells. This shortening was accompanied by a more rapid removal
2+of Ca2+. In addition, R-Ras-V38 transfected cells were more spherical than control cells and
tended to have a smaller area. However, the differences in morphology are unlikely to be
2+responsible for the enhanced Ca extrusion rate, since R-Ras-N43 transfected cells had similar
2+morphology characteristics as R-Ras-V38 transfected cells, but similar kinetics of Ca2+ 
extrusion as control cells. Also, the amount of Ins(1,4,5)P3 produced during CCK8 treatment
was equal for R-Ras-V38 expressing and control cells. This implies that the observed
2+differences in Ca dynamics are not mediated via Ins(1,4,5)P3. By stimulating with a
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Figure 6. CCK8induced Ca2+ 
oscillations in R-Ras- V38 
transfected cells. (A) Application 
of 0.1 nM CCK8 induced Ca2+ 
oscillations (indo-1 recording) in 
R-Ras-V38 cells. Since no 
extracellular Ca2+ was present, the 
amplitude of the oscillations 
gradually decreased. The change 
in kinetics during the recording is 
shown in the inset, which is a 
magnified superimposition of the 
first (marked I) and last (IX) 
oscillation. (B) No difference was 
found between R-Ras-V38 
expressing (GFP+) and control 
(GFP-) cells for the mono­
exponential decrease in amplitude 
(n = 8 GFP- and GFP+ cells). (C) 
Lack of difference between R-Ras- 
V38 expressing (GFP+) and 
control (GFP-) cells in the relation 
between amplitude and rate of 
decline (n=8). The continuous line 
was calculated from the GFP- cells 
and the dotted line was calculated 
from the GFP+ cells. The linear 
correlation coefficient r of the 
continuous (GFP-) and dotted 
(GFP+) line is 0.83 and 0.86, 
respectively.
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Figure 7. Effect o f R-Ras expression on CCK8 induced Ins(1,4,5,)P3 production. R-Ras-V38 (A) and R-Ras- 
N43 (B) transfected cells (GFP+) were stimulated with different concentrations of CCK8 and the amount of 
Ins(1,4,5)P3 produced during 20 s was estimated. The stimulatory effect was dose-dependent and no difference 
was found between R-Ras interfering mutants and control (GFP-) cells.
2+supramaximal concentration of CCK8 (0.1 |iM), Ca efflux from the ER was maximized. This 
prevented store refilling by SERCAs leading to emptying of the ER and a maximal cytosolic 
Ca2+ response. Under these conditions, it is expected that Ca2+ is not extruded from the cytosol
by SERCAs but only by PMCAs and the extremely rapid mitochondrial uniporter. Indeed, the
2+faster Ca removal was also observed using the SERCA inhibitor thapsigargin, showing that
the more rapid Ca2+ removal in R-Ras-V38 transfected cells is not SERCA mediated and also
2+does not depend the Ca release mechanism.
2+During oscillatory changes in [Ca ]i, induced with 100 pM CCK8 no differences in the
kinetic of the oscillations between R-Ras-V38 expressing and non-transfected cells were found
2+ 2+ indicating that R-Ras-V38 affects Ca extrusion only during prolonged Ca increases. In
2+addition, these observations suggest that the duration and/or amplitude of the Ca
transient/oscillation determine the mechanism of Ca2+ removal. In Ca2+ free medium, the Ca2+
2+oscillations were eventually abolished, indicative of PMCA-mediated Ca extrusion. Since 
their affinity for Ca2+ is high (Km=0.2-0.3 |iM; Carafoli, 1992) we expected that the PMCAs 
were maximally activated during oscillatory Ca2+ changes. This hypothesis is confirmed by a 
recent study in endothelial cells (Sedova etal., 1999) showing that PMCAs are activated in a 
Ca2+-dependent manner. Since no differences in Ca2+ removal during Ca2+ oscillations were 
found between R-Ras-V38 and control cells, it is unlikely that the accelerated Ca2+ extrusion
observed with 0.1 ^M CCK8 in R-Ras-V38 transfected cells is caused by enhanced PMCA-
2+mediated Ca extrusion.
In general, mitochondria rapidly sequester cytosolic calcium through a uniporter
+ 2+followed by a much slower release via the mitochondrial Na /Ca exchanger (Gunter et al.,
1994; Herrington, et al., 1996). These observations are in line with the proposal that the
mitochondria act as a temporary store of Ca2+ during cytosolic Ca2+ peaks, thereby blunting the
2+ 2+ cytoplasmic response and releasing the Ca back to the cytosol when [Ca ]i recovered below a
certain setpoint (Nicholls and Budd, 2000). Depending on the timecourse of the CCK8-induced
cytosolic Ca2+ signal, the return of [Ca2+]i to basal levels can either be slowed down by release
2+of the sequestered Ca from the mitochondria (Gunter etal., 1994) or increased by the action of
2+the fast uniporter (Babcock etal., 1997). Given the Ca affinity of the uniporter (reported to be
~10 |iM; Bernardi etal., 1999), uniporter activation will be minimal during fast oscillatory Ca2+
2+ 2+ changes. Therefore, the increased Ca removal rate observed for large Ca transients in R-Ras-
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V38 cells is in agreement with a rapid uniporter-mediated mitochondrial uptake. This is in line
with observations in chromaffin cells, where carbonyl cyanide m-chloro-phenylhydrazone
2+(CCCP) that collapses the mitochondrial membrane potential essential for uniporter Ca2+
2+transport (Gunter et al, 1994), blocked rapid Ca clearance (Babcock et al., 1997). Earlier 
research has shown that the anti-apoptosis protein Bcl-2 associates with R-Ras (Fernandez- 
Sarabia and Bischoff, 1993) and is capable of increasing the capacity of both mitochondrial and 
ER Ca2+ sequestration (Kuo et al., 1998; Zhu et al., 1999). Since R-Ras also inhibits
physiological cell death (Suzuki etal., 1997,1998; Osada etal, 1999), it is tempting to speculate
2+that the observed enhancement in Ca removal rate is caused by R-Ras-V38-mediated activation
2+of Bcl-2. In this way, R-Ras-V38 expression increases the mitochondrial Ca sequestration 
capacity resulting in a more efficient protection against high Ca2+ levels associated with
apoptosis. Currently, experiments are in progress to test this hypothesis. The underlying
2+principle of Bcl-2 activation and how it increases the capacity of Ca storage is largely unkown. 
It has been demonstrated that Bcl-2 phosphorylation at serine 70 is required for the full and 
potent surpression of apoptosis (May etal., 1994; Ito et al., 1998). This Bcl-2 phosphorylation is 
in part mediated by mitochondrial-localized PKCa (Ruvolo et al, 1998). Since, Raf-1 has been 
reported to associate with Bcl-2 to increase cell survival only when expressed and localized to 
the mitochondria (Wang et al, 1996), it is tempting to speculate that by nature R-Ras 
translocates Bcl-2 to the mitochondrial membrane where, subsequently, PKCa activates Bcl-2 
by phosphorylation. How Bcl-2 increases the Ca2+ storage capacity of the mitochondria is 
unknown. The solving of the three-dimensional structure of the closely related Bcl-X protein 
strongly suggests that Bcl-X-like proteins form ion channels (Ali etal., 1997). At present, it is 
not clear how this affect mitochondrial Ca2+ storage capacity.
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In recent years, multiple phospholipase D (PLD) activities have been characterized in mammalian 
cells. At present, however, the contours of the pathways that regulate these activities are only 
beginning to emerge. Regulated PLD activity is present in almost all cell types and stimulatory 
effects have been demonstrated for a wide variety of hormones, neurotransmitters, growth factors 
and cytokines. As far as the pancreatic acinar cell is concerned, however, evidence for the presence 
of a regulated PLD activity is conflicting. Such knowledge is important because signal-activated 
PLD has been implicated, among other things, in regulated exocytosis. In this study, freshly isolated 
rat pancreatic acini were used to identify PLD transcripts by RT-PCR, to assess the presence and 
subcellular localization of PLD protein by Western blotting, and to evaluate the presence of a 
secretagogue-regulated PLD activity by means of the PLD-catalyzed transphosphatidylation 
reaction. Using specific primers which allowed to discriminate between PLD1a, PLD1b, and PLD2, 
transcripts of PLD1b and PLD2, but not PLD1a, were shown to be present in acinar cells. 
Moreover, using a specific anti-human PLD1 antibody the expression of substantial amounts of 
PLD1 protein was demonstrated. Intriguingly, however, the distribution pattern of acinar PLD1 as 
observed following subcellular fractionation was clearly atypical in that immunoreactivity was 
predominantly present in the acinar cytosol. In contrast, a typical membranous localization of 
PLD1 was observed in Chinese hamster ovary (CHO) cells. Pretreatment of intact acini with a 
phorbol ester (PMA), known to activate PLD1 in a protein kinase C (PKC)-dependent manner, did 
not change the subcellular distribution of PLD1. Similarly, pretreatment of a broken cell 
preparation of acini with GTPyS, known to activate PLD via small GTPases, and PMA did not 
influence this distribution. CCK-(26-33)-peptide amide (CCK8) did not increase the amount of 
radiolabelled phosphatidylethanol (PtdEth) in intact acini prelabelled with either 
ortho[32P]phosphate or [3H]myristic acid and stimulated in the presence of ethanol 
(transphosphatidylation reaction). Similarly, an increase in cytosolic Ca2+ evoked by the specific 
inhibitor of the endoplasmatic reticulum Ca2+-ATPase, thapsigargin, did not stimulate acinar PLD 
activity, whereas a slight stimulation was observed following high-level PKC activation with PMA. 
In contrast, all three stimuli were previously shown to readily increase PLD activity in CHO cells 
expressing the rat pancreatic acinar cell CCK-A receptor. Finally, the combination of PMA and 
GTPyS did not increase PLD activity following homologous reconstitution of acinar cytosol and 
membranes, whereas the same manoeuvre resulted in marked stimulation of PLD activity in the 
case of CHO cells. Heterologous reconstitution experiments revealed that PLD activity in CHO 
membranes was readily stimulated in the presence of acinar cytosol, indicating that the acinar 
cytosol contains the necessary factors for PMA/GTPyS-induced stimulation of membrane PLD 
activity. In contrast, the cytosol of CHO cells was unable to confer PMA/GTPyS-stimulation of 
PLD activity on acinar membranes, which is in agreement with the predominantly cytosolic 
localization of acinar PLD. In conclusion, the present findings show that rat pancreatic acinar 
cells express a cytosolic PLD1 isoform that is not regulated by the physiologically important 
secretagogue CCK.
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INTRODUCTION
Cholecystokinin (CCK) and acetylcholine are the most prominent physiological stimulators of 
digestive enzyme secretion from pancreatic acinar cells (Williams and Yule, 1993). The 
biochemical principle underlying their mechanism of action has been intensively studied and it is 
widely recognized now that both an increase in cytosolic calcium concentration and protein 
kinase C (PKC) activity are required for the full secretory response (De Pont and Fleuren-Jakobs, 
1984; Merritt and Rubin, 1985; Pandol and Schoeffield 1986; Willems et al., 1995). Additional 
evidence for a role of PKC was provided by the observation that down-regulation of PKC via 
prolonged phorbol ester treatment virtually halved CCK-induced amylase secretion (Sung et al, 
1988). PKC activity is increased via its physiological activator diacylglycerol (Nishizuka, 1992). 
This understanding has greatly stimulated investigations into the enzymology of stimulus- 
induced diacylglycerol production. As far as pancreatic acinar cells are concerned, it was 
demonstrated that CCK evokes a biphasic increase in mass diacylglycerol (Matozaki and 
Williams, 1989; Matozaki et al., 1990; Hermans et al., 1996). The first and transient increase in 
mass diacylglycerol was found to coincide with the rapid and transient increase in mass inositol
1,4,5-trisphosphate it was concluded that this diacylglycerol was formed by the action of 
phosphoinositide-specific phospholipase C (Berridge, 1993). The second and sustained increase 
in mass diacylglycerol was not paralleled by an increase in mass inositol 1,4,5-trisphosphate, 
indicating the involvement of a phospholipase other than phosphoinositide-specific 
phospholipase C. Molecular species analysis of the major phospholipids and diacylglycerol s 
provided evidence that both phosphatidylcholine (PtdCho) and inositolphospholipids are 
hydrolyzed during prolonged stimulation of rabbit pancreatic acini with CCK (Hermans et al., 
1996). PtdCho may be enzymatically broken down by either PtdCho-specific phospholipase C or 
PtdCho-specific phospholipase D (PtdCho-PLD), yielding diacylglycerol and phosphatidic acid 
(PtdOH), respectively (Exton, 1994). PtdOH for its part can serve as a substrate for phosphatidic 
acid phosphohydrolase to produce diacylglycerol.
Evidence for the involvement of PtdCho-PLD in CCK-induced diacylglycerol formation 
was provided by Morisset and co-workers who showed that the CCK analogue caerulein 
increased PLD activity in rat pancreatic acini (Rydzewska et al, 1993; Rivard et al, 1994; 
Rydzewska and Morisset, 1995). PLD activity was assayed by means of the 
transphosphatidylation reaction (Dawson, 1967). This method takes advantage of the unique 
property of PLD to catalyse the formation of phosphatidylethanol (PtdEth) rather than PtdOH in 
the presence of ethanol. Acini were prelabelled with [ H]myristic acid and the amount of 
[3H]PtdEth was quantified following stimulation of the acini in the presence of ethanol. 
However, in another series of experiments the presence of CCK-regulated PLD activity in acinar 
cells was seriously questioned (Matozaki and Williams, 1989; Matozaki et al, 1990; Matozaki et 
al, 1991). It was shown that CCK stimulated the formation of phosphoryl choline rather than 
choline in acinar cells prelabelled with [3H]choline. From this observation it was concluded that 
CCK primarily activates PtdCho-specific phospholipase C. At present, there is no good 
explanation for the discrepancy between these two studies. However, it should be noted that 
PtdEth is a stable end-product, whereas choline, liberated from PtdCho by the action of PtdCho- 
PLD, may be rapidly converted to phosphorylcholine. Another possibility might be that 
pancreatic acinar cells express a PLD that preferentially hydrolyses a phospholipid other than 
PtdCho. For instance, evidence has been provided for the existence of a PLD that catalyses the 
hydrolysis of phosphatidylethanolamine (Kiss and Anderson, 1989).
Recent work has implicated regulated PLD activity in a variety of cellular activities 
including exocytosis (Jones et al, 1999). Therefore, it is of eminent importance to unequivocally 
demonstrate the presence of secretagogue-regulated PLD activity in pancreatic acinar cells. In 
this study, freshly isolated rat pancreatic acini were used to identify PLD transcripts by RT-PCR,
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to assess the presence and subcellular localization of PLD protein by Western blotting, and to 
evaluate the presence of a secretagogue-regulated PLD activity by means of the PLD-catalyzed 
transphosphatidylation reaction.
MATERIALS AND METHODS
Materials
CCK8, PMA, leupeptin, soybean trypsin inhibitor, collagenase and 2,2,4-trimethylpentane were obtained from 
Sigma (St. Louis, MO, USA) and thapsigargin from LC Services (Woburn, MA, USA). Phenylmethylsulfonyl 
fluoride was purchased from SERVA (Heidelberg, Germany), hyaluronidase from Boehringer (Mannheim, 
Germany) and dithiothreitol from Research Organics (Cleveland, OH, USA). Ortho [32P]phosphate and [9,10(n)- 
3H]myristic acid (53 Ci/mmol) were obtained from The Radiochemical Centre (Amersham, UK), HPTLC silica gel 
60 plates, ethyl acetate and chloroform from Merck (Darmstadt, Germany) and phospholipid standards from Avanti 
Polar Lipids (Birmingham, AL, USA). Tissue-culture medium with additives was from Gibco (Paisley, Scotland, 
U.K.). All other chemicals were of reagent grade. Fatty acid-free BSA was obtained after dissolving BSA in water in 
the presence of active carbon, followed by extensive dialysis with 0.9% (w/v) NaCl.
Labelling o f rat pancreatic acini and CHO-CCKA cells
Rat pancreatic acini were isolated as described previously (Willems et al., 1984). For the labelling of acinar 
phospholipids, the acini were resuspended in a Krebs-Ringer bicarbonate medium (pH 7.4) containing 119 mM 
NaCl, 3.5 mM KCl, 25 mM NaHCO3, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.8 mM glucose, 0.2 mg/ml soybean 
trypsin inhibitor, an amino acid mixture according to Eagle and either 50 ^Ci/ml ortho[32P]phosphate, 10^M 
KH2PO4 and 1% (w/v) bovine serum albumin or 10 ^Ci/ml [3H]myristic acid, 1.2mM KH2PO4 and 1% (w/v) 
fatty acid-free bovine serum albumin and incubated for 1 h in a water-saturated atmosphere containing 5% CO2  
at 37°C. After 1 h, the acini were washed and the labelling was continued for another hour. Labelling of CHO- 
CCKa cells with [3H]myristic acid was performed as described previously (Bosch et al., 1998, 1999). Briefly, 
CHO-CCKa cells were grown to confluence in the presence of [3H]myristic acid (2 ^Ci/ml) in a humidified 
atmosphere of 5% CO2 for 24 h at 37°C.
Phospholipase D measurements in intact rat pancreatic acini
At the end of the labelling period, the acini were washed and resuspended in Krebs-Ringer bicarbonate medium 
without added label. For PLD measurements, aliquots were taken and stimulated with either CCK8 (10 nM), PMA (1 
^M), or thapsigargin (1 ^M), alone or in combination, in the presence of 1% (v/v) ethanol for 15 min at 37°C. At the 
end of the stimulation period, the reaction was quenched by the addition of an excess of ice-cold Krebs-Ringer 
bicarbonate medium and after centrifugation the acini were resuspended in 2 ml of ice-cold methanol/ 10 mM 
glycine (5:2, by vol.). Lipids were extracted according to the method described by Bligh and Dyer (1959). Briefly, 1 
ml of chloroform was added and the mixture was mixed vigorously. Phase separation was obtained by addition of 1 
ml of chloroform and 1 ml of water followed by centrifugation. The lower organic phase was collected and blown to 
dryness with N2.
Separation of labelled phospholipids
The dried extracts were dissolved in 20 ^l of chloroform/methanol (9:1, v/v) and the lipids were separated by thin- 
layer chromatography. [32P]-labelled phospholipids were separated using silica-gel 60 HPTLC plates. The plates 
were developed with chloroform/methanol/acetone/acetic acid/water (100:50:100:4:10, by vol.). [3H]myristic acid- 
labelled lipids were separated using potassium oxalate-treated silica-gel 60 HPTLC plates. The plates were 
developed with the upper phase of a mixture of ethyl acetate/2,2,4-trimethylpentane/acetic acid/water (13:2:3:10, by 
vol.). Radioactive spots corresponding to authentic lipid standards were visualised by I2-staining and scraped off. 
Radioactivity was measured by liquid- scintillation spectrometry.
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Phospholipase D measurements in membranes ofrat pancreatic acini
Membrane PLD activity was assayed according to the method described by Ohguchi et al. (1996). Prior to 
homogenisation, [3H]myristic acid-labelled acini were washed with Krebs-Ringer bicarbonate medium and 
centrifuged at 50 g for 5 min. Subsequently, cells were washed with an ice-cold homogenization solution containing 
100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl 
fluoride, 20 ^M leupeptin and 25 mM HEPES, adjusted with Tris to pH 7.4. Similarly, [3H]myristic acid-labelled 
CHO-CCKA cells were washed twice with ice-cold homogenization solution and collected by scraping. The cells 
were homogenized at 4°C using a Potter-Elvehjem homogenizer (glass-teflon) by 10 strokes at 500 rev./min, 5 
strokes at 1000 rev./min and 5 strokes at 1200 rev./min and the resulting homogenate was centrifuged at 100,000 g  
for 1 h. The cytosol fraction was collected and the membrane fraction was resuspended in homogenization buffer. 
For PLD measurements, aliquots of the acinar and CHO cell membrane fraction were taken and either 
homogenization buffer, acinar cytosol, or CHO cell cytosol was added. Mg-ATP (0.5 mM), CaCl2 (0.5 mM) and 1% 
(v/v) ethanol were added with or without PMA (1 ^M ) and GTPyS (10 ^M) and the reaction mixtures were 
incubated for 30 min at 37°C. The reactions were quenched with 1 ml ice-cold methanol/10 mM glycine (5:2, by 
vol.) and the lipids were extracted and separated as described above.
RNA extraction and reverse transcription (RT)-PCR
Total RNA was isolated from rat brain and pancreatic acini and from CHO-CCKA cells using TRIzol™ (Gibco, 
Paisley, Scotland, U.K.) and reverse-transcribed with M-MLV reverse transcriptase using random hexamer-mixed 
oligonucleotides. Specific primers for the amplification of PLD1 transcripts were designed on the basis of published 
sequences from rat liver (Katayama etal., 1998) and CHO cells (GenBank™ accession number: U94995). Primers 
were chosen such that they allowed to discriminate between PLD1a and PLD1b. The sense and antisense primers 
were 5’-GCCTATGGAAGGTGGGACGAC-3’ and 5’-GGAGTACCTGTCAATGAAATCAGC-3’, respectively. 
Primers to specifically amplify PLD2 transcripts were designed on the basis of the published sequence of rat brain 
PLD2 (Kodaki and Yamashita, 1997). In this case, the sense and antisense primer were 5’- 
GAACAGGGGCAGTGTTTCCGA-3’ and 5’-CGCTGTTTCTTGCCACAGCTG-3’, respectively. Amplification of 
PLD1 and PLD2 was carried out with 35 PCR cycles (94°C, 1 min; 55°C, 1 min; 72°C, 1 min), followed by a final 
elongation for 10 min at 72°C. DNA products, visualized by means of ethidium bromide staining, were scanned with 
an Imaging Densitometer (Biorad, München, Germany).
Western blotting
Western blotting was performed essentially as described previously (Smeets et al, 1996). Briefly, total cell 
lysates from CHO-CCKA cells and rat pancreatic acini and the membrane and cytosol fractions prepared from 
both cell types were subjected to SDS-polyacrylamide gel electrophoresis. Proteins were transferred overnight to 
polyvinylidene difluoride membranes (Immobillon P, Millipore, Bedford, MA, USA). Membranes were blocked 
for 1 h at RT with PBS (pH 7.4) containing 1% (w/v) milkpowder and 0.1% (v/v) Tween-20 (PBST-MLK). 
Subsequently, the blots were incubated overnight at 4°C with the rabbit anti-hPLD1 antibody, described by 
Müller-Wieprecht et al. (1998), diluted 1:1000 in PBST- MLK. The antibody was kindly provided by Prof. dr. 
C.C. Geilen (University Medical Center Benjamin Franklin, The Free University of Berlin, Germany). 
Immunoreactive protein was detected by incubating the blots for 1 h at RT with goat anti-rabbit IgG antibody 
diluted conjugated to alkaline phosphatase 1:1000 in PBST-MLK. Membranes were washed with PBS (pH 7.4) 
containing 0.1% (v/v) Tween-20 before staining with 0.1 M diethanolamine, 0.34 mg/ml Nitroblue tetrazolium, 
0.18 mg/ml 5-bromo-4-chloro-3-indolylphosphate and 50 mM MgCl2.
Analysis of the data
The data presented are expressed as the mean ± S.E.M of the number of experiments indicated. Overall statistical 
significance was determined by analysis of variance (ANOVA). In the case of significance, individual groups were 
compared according to Fisher. P  values of less than 0.05 were considered significant.
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Figure 1. Identification of PLD transcripts in rat 
brain, rat pancreatic acini and CHO-CCKA cells by 
means of RT-PCR. Total RNA was prepared from 
rat brain, freshly isolated rat pancreatic acini and 
CHO-CCKa cells and reverse-transcribed. Specific 
primers for PLD1, which allowed to discriminate 
between PLD1a and PLD1b, and PLD2 were used to 
amplify cDNA fragments. In rat brain, the PLD1- 
specific primers yielded a larger product of 550 bp 
and a smaller product of 450 bp, representing PLD1a 
and PLD1b, respectively (upper panel; left lane), and 
one product with the PLD2-specific primers (lower 
panel; left lane). Rat pancreatic acini expressed the 
PLD1b and PLD2 fragments (middle lanes), whereas 
CHO cells expressed the PLD 1b fragment (right 
lane). Of note, the primary sequence of CHO PLD2 
is presently unknown. Therefore, the PLD2 primers 
used here were designed only on the basis of the 
primary sequence of rat brain PLD2. This implicates 
that our PLD2 primers may have failed to detect 
CHO PLD2.
Figure 2. Demonstration o f PLD 1 protein in rat 
pancreatic acini and CHO-CCKA cells. Total cell 
lysates from rat acini and CHO-CCKA cells were 
subjected to SDS-PAGE and subsequently 
transferred to polyvinylidene difluoride membranes 
by Western blotting. The membranes were probed 
with a specific anti-human PLD1 antibody. The 
figure shows an immunoreactive band with an 
apparent mass of 110 kD for both pancreatic acini 
and CHO cells.
RESULTS
Identification and expression of PLD mRNA and protein in rat pancreatic acinar cells and 
CHO-CCKa cells
To investigate the PLD isoform composition of rat pancreatic acinar cells and CHO-CCKA 
cells we performed RT-PCR using specific primers for PLD1, which allowed to discriminate 
between PLD1a and PLD1b, and PLD2. Figure 1 shows the presence of all three PLD isoforms 
in total RNA from rat brain. Pancreatic acini clearly expressed PLD1b and PLD2, whereas CHO 
cells expressed PLD1b. Primers to amplify rat PLD2 did not generate a PCR product with cDNA 
from CHO cells. This indicates that PLD2 is either absent or different from rat PLD2 in these 
cells. Both acini and CHO cells lacked PLD1a. Western blot analysis of total cell lysate was 
performed to examine the expression of PLD1b at the protein level. Using an antibody directed 
against the C- and N-terminal sequences of human PLD1 we observed a positive band of 
expected size (~110 kD) in rat pancreatic acini and CHO cells (Fig. 2). These data show that 
both rat pancreatic acinar cells and CHO cells express PLD1b at the mRNA and at the protein 
level.
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Figure 3. Subcellular localization of PLD1 in rat pancreatic acini and CHO-CCKa cells. Rat pancreatic acinar 
cells and CHO-CCKA cells were homogenised and centrifuged for 1 h at 100,000 g  to obtain a cytosolic and 
membrane fraction. Both fractions were used for immunoblotting. (A) The cytosol and membrane fractions of 
unstimulated CHO cells and unstimulated or PMA-treated acinar cells. (B) The cytosol fraction of pancreatic 
acini was recombined with the membrane fraction of either pancreatic acini (homologous recombination) or 
CHO cells (heterologous recombination), stimulated with PMA (1 ^M) and GTPyS (10 ^M) for 30 min, and 
centrifuged for 1 h at 100,000 g  to re-obtain the cytosolic and membrane fraction.
Subcellular distribution of PLD1 in rat pancreatic acinar cells and CHO-CCKa cells 
The subcellular distribution of PLD1 immunoreactivity was investigated by subjecting both 
the membrane and cytosol fraction of rat pancreatic acini and CHO-CCKA cells to Western 
blot analysis. Figure 3 A shows that in rat acini PLD 1b was mainly present in the cytosol 
fraction, whereas, in CHO cells this PLD1 isoform predominated in the membrane fraction. 
Incubation of intact pancreatic acini with PMA (1 ^M) for 15 min did not change the 
subcellular distribution of PLD1. Similarly, treatment of the recombined acinar membrane 
and cytosol fraction with PMA and GTPyS for 30 min did not influence the predominantly 
cytosolic localization of PLD1 (Fig. 3B). The same observation was reached following 
heterologous reconstitution of the CHO membrane fraction with the acinar cytosol fraction.
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Figure 4. CCKs~, PMA- and thapsigargin induced formation of f 2P]PtdEth, ¡32P]PtdOH and ¡32P]PtdIns in rat 
pancreatic acini. Freshly isolated rat pancreatic acini were prelabelled with either ortho[32P]phosphate (A-C) or 
[3H]myristic acid (D) for 2 h and stimulated with CCK (10 nM), PMA (1 ^M), thapsigargin (1 ^M), or the 
indicated combinations of these stimuli in the presence of 1% (v/v) ethanol for 15 min. At the end of the stimulation 
period, the reaction was quenched and the lipids were extracted and separated by HPTLC. Radioactive spots were 
scraped off and radioactivity was measured by liquid-scintillation spectrometry. In each experiment, the amount of 
[32P]PtdEth (a), [32P]PtdOH (b), [32P]PtdIns (c), or [3H]PtdOH (d) present in unstimulated cells is set at 100%, to 
which all other values are related. The values presented are the mean ± S.E.M. of 3 experiments. Significantly 
different from unstimulated cells. Significantly different from CCKg-stimulated cells. &Significantly different from 
thapsigargin-stimulated cells.
*
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Figure 5. PMA/GTPyS-induced 
^HjPtdEth formation in 
membranes o f rat pancreatic 
acini and CHO CCKA cells. Rat
pancreatic acinar cells and CHO- 
CCKa cells, prelabelled with 
[3H]myristic acid, were 
homogenized and centrifuged for 
1 h at 100,000 g. The 
supernatant or cytosol fraction 
was collected and the pellet or 
membrane fraction was 
resuspended in homogenization 
buffer. PKC- and small GTPase- 
dependent PLD activity was 
measured by addition of PMA (1 
^M) and GTPyS (10 ^M) to the 
reaction mixture. The reaction mixture contained in addition, Mg-ATP (0.5 mM), CaCl2 (0.5 mM) and 1% (v/v) 
ethanol. PLD activity measurements were performed with either the acinar cell or CHO cell membrane fraction 
alone or following homologous or heterologous reconstitution with the cytosol fractions of these two cell types. 
After 30 min, the reaction was quenched and the lipids were analysed as described in the caption of figure 3. In 
each experiment, the amount of [3H]PtdEth in the unstimulated condition is set at 100% to which all other values 
are related. The values presented are the mean ± S.E.M. of 3 experiments. Significantly different from 
corresponding stimulated conditions.
CCKs-, PMA- and thapsigargin-induced formation of f 2P]PtdEth, f 2P]PtdOH and 
f 2P]PtdIns in rat pancreatic acini
To examine rat pancreatic acinar cells for the presence of CCK8-stimulatable PLD activity,
32 3freshly isolated acini were labelled with ortho[ P]phosphate or [ H]myristic acid for 2 h and 
subsequently stimulated with CCK8 in the presence of 1% (v/v) ethanol for 15 min. Under these 
conditions, PLD catalyzes the formation of a unique product, phosphatidylethanol (PtdEth), 
which can be separated from the other phospholipids using thin-layer chromatography (Dawson, 
1967). CCK8 (10 nM) did not significantly affect the amount of radiolabelled PtdEth (Figs. 4A 
and D), while readily increasing the amounts of [32P]PtdOH (Fig. 4B) and [32P]PtdIns (Fig. 4C). 
These findings demonstrate that CCK8 is unable to induce any detectable PLD activity in rat 
acini.
PKC and cytosolic free Ca2+ have been identified as important activators of PLD (Jones
et al., 1999; Exton, 1999). In intact cells, their involvement in PLD activation can be
2+demonstrated using phorbol esters to activate PKC and Ca ionophores or the specific inhibitor
of the endoplasmic reticulum Ca2+-ATPase, thapsigargin (Lytton et al., 1991). Thapsigargin
2+ 2+ depletes intracellular Ca stores leading to an increase in store-regulated Ca entry (Putney and
Bird, 1993). PMA (1 ^M) markedly increased the amount of radiolabelled PtdEth in rat acini
(Figs. 4A and 4D). The phorbol ester did not affect the amounts of [32P]PtdOH (Fig. 4B) and
32[ P]PtdIns (Fig. 4C). These data indicate that pancreatic acini do contain a PKC-stimulatable 
PLD activity. In addition, they show that PMA does not affect the turnover of PtdOH and PtdIns 
in these cells. In contrast to PMA, thapsigargin (1 ^M) did not increase PLD activity (Figs. 4A
32and 4D), while readily increasing the amount of [ P]PtdOH (Fig. 4B). The inhibitor did not
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significantly affect the acinar [ P]PtdIns content (Fig. 4C). These findings indicate that the mere 
increase of cytosolic free Ca2+ does not lead to any detectable stimulation of acinar PLD activity. 
Figure 4 (A and D) shows that also the combination of CCK8 and thapsigargin did not
32affect acinar PLD activity, while the amount of [32P]PtdOH was significantly higher than that 
obtained with each of the two stimuli alone (Fig. 4B). Thapsigargin did not significantly increase
32the amount of [ P]PtdIns formed in response to CCK8 (Fig. 4C). Neither CCK8 nor thapsigargin
32had an effect on the PMA-induced increase in [ P]PtdEth (Figs. 4A and 4D). On the other hand, 
PMA prevented CCK8 from significantly increasing [32P]PtdOH (Fig. 4B) without affecting,
32however, the CCK8-induced increase in [ P]PtdIns (Fig. 4C). PMA did not change the increase
32in [ P]PtdOH evoked by thapsigargin (Fig. 4B). Finally, also the combination of PMA and 
thapsigargin had no effect on the amount of [32P]PtdIns (Fig. 4C).
PMA/GTPyS-induced fH]PtdEth formation in membranes ofratpancreatic acini and CHO- 
CCKa cells
It is widely observed that whole-cell homogenates contain a significant PMA and GTPyS- 
stimulatable PLD activity. In addition, subcellular fractionation studies have revealed that 
most cell systems require both the cytosol and membrane fraction for this activity (Olson et 
al., 1991; Ohguchi et al., 1996; Nakashima and Nozawa, 1999). Here we examined rat 
pancreatic acini for the presence of PMA/GTPyS-stimulatable PLD activity using a membrane 
and cytosol fraction obtained from [3H]myristic acid-labelled acini after homogenisation and 
subsequent centrifugation for 1 h at 100,000 g. Simultaneous addition of PMA (1 ^M) and 
GTPyS (10 ^M) did not change the amount of [ H]PtdEth in the acinar membrane fraction 
(Fig. 5). Similarly, this combination of drugs did not significantly activate PLD following 
homologous reconstitution of the acinar membrane and cytosol fraction. We previously 
showed that PMA markedly stimulates PLD activity in a homogenate of Chinese hamster 
ovary (CHO) cells (Bosch et al., 1999). Preliminary experiments revealed that also GTPyS 
markedly stimulates PLD activity in a CHO cell homogenate and that the effects of PMA and 
GTPyS are more than additive (data not shown). The combination of PMA and GTPyS did not 
significantly change the amount of [3H]PtdEth in a membrane fraction of CHO cells. However, a 
marked PMA/GTPyS-stimulatable PLD activity was obtained following homologous 
reconstitution of the membrane and cytosol fraction of these cells. To further explore PLD 
activity in the membranes and cytosol fraction from acinar cells we performed heterologous 
reconstitutions. The cytosol fraction of CHO cells did not confer any PMA/GTPyS- 
stimulatability of PLD on the acinar membrane fraction, suggesting that acinar membranes might 
be deprived of PLD. On the other hand, addition of the acinar cytosol fraction to CHO 
membranes resulted in a similar PMA/GTPyS-stimulatability of PLD as observed following 
homologous reconstitution.
DISCUSSION
The data presented in this study are consistent with the idea that membrane association of 
PLD is a prerequisite for its receptor-mediated activation. This conclusion is based on the 
following observations: (a) rat pancreatic acinar cells and CHO-CCKa cells express the same 
PLD isoform; (b) in the acinar cells, however, this isoform, PLD1b, is predominantly present 
in the cytosol, whereas in CHO cells its localization is mainly membranous; (c) CCK does not 
increase PLD activity in pancreatic acinar cells, whereas it readily stimulates this activity in 
CHO-CCKa cells; (d) the combination of PMA and GTPyS does not increase PLD activity in
32
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a broken cell preparation of pancreatic acinar cells, whereas it markedly stimulates this 
activity in a similar preparation of CHO cells.
Thus far, two mammalian isoforms of PLD, PLD1 and PLD2, have been cloned from 
a wide variety of species (Exton, 1999). In addition, two alternatively spliced forms of PLD1, 
PLD 1a and PLD 1b, and three alternatively spliced forms of PLD2, PLD2a, PLD2b and 
PLD2c, have recently been identified (Hammond etal. , 1997; Lopez etal. , 1998). At present, 
information on the expression levels, cellular localization and function of PLD1 and PLD2 
proteins is limited. Using a specific antibody raised against N- and C-terminal sequences of 
human PLD1 (Muller-Wieprecht e ta l . , 1998) we now show that both rat pancreatic acinar 
cells and CHO cells contain substantial amounts of this PLD isoform. RT-PCR on total RNA 
suggests that in both cases it concerns the 1b splice variant of PLD1. In addition, rat 
pancreatic acinar cells gave a clear signal with specific primers for rat PLD2. At present, 
however, we do not know to what extent this latter isoform is expressed at the protein level. 
Northern blot analysis revealed high levels of PLD1 mRNA in human pancreas (Saqib etal., 
1997; Lopez et al., 1998; Steed et al., 1998). Although these studies did not discriminate 
between exocrine and endocrine pancreas, the present finding that the exocrine pancreas 
expresses substantial amounts of PLD1 protein indicates that in this tissue mRNA levels 
correspond well to protein levels. The PLD 1b transcript was found to predominate in all 
tissues examined including the pancreas (Steed et al., 1998). Again, this study did not 
discriminate between exocrine and endocrine tissue. Here we show that the rat exocrine 
pancreas predominantly expresses PLD1b. The absence of a detectable PLD1a signal suggests 
that this splice variant is either not expressed or expressed at very low levels in this tissue. 
Moderate PLD2 transcript levels were detected in human pancreas (Saqib etal., 1997; Lopez 
et al., 1998; Steed et al., 1998), whereas the rat pancreas was found to express low PLD2 
mRNA levels (Kodaki and Yamashita, 1997). We now demonstrate that at least part of the 
PLD2 transcript is expressed by the exocrine pancreas. Transcripts of the splice variants 
PLD2a and PLD2b, but not PLD2c, have been detected in human pancreas (Steed et al., 
1998). In the present study, however, we did not discriminate between these three forms of 
PLD2. Similarly to pancreatic acinar cells, CHO cells expressed substantial amounts of the 
PLD1 protein. Most probably it concerns the PLD1b splice variant as was indicated by RT- 
PCR. This is in agreement with the cloning of the full length PLD1b transcript from CHO 
cells (GenBank™, accession number: U94995). No PLD1a or PLD2 mRNA expression was 
detected in this cell line.
In vitro studies have grouped mammalian PLD1 and PLD2 in a class of 
phosphoinositide-dependent PLDs (Frohman etal., 1999). In contrast to fatty acid- or oleate- 
activated PLD, which behaves as an integral membrane protein (Danin etal., 1993), these 
phosphoinositide-dependent PLDs have been suggested to be either present in the cytosol or 
membrane-associated or both, depending on the physiological state of the cell (Frohman et 
al., 1999). The phosphoinositide-dependent PLDs show different regulatory properties, e.g. 
PLD1 activity is readily increased by certain PKCs and members of the ARF and Rho 
families of small G proteins, whereas the activity of PLD2, similarly to that of the fatty acid- 
or oleate-dependent enzyme, is not influenced by these regulators (Lee et al., 1998; Exton, 
1999; Frohman et al., 1999). In agreement with this, a PLD1 isoform, probably PLD1b, was 
identified in cells, CHO cells, in a broken cell preparation of which PLD activity was readily 
stimulated by the combination of PMA and GTPyS. Surprisingly, however, this latter 
manoeuvre did not increase the activity of PLD in a broken cell preparation of rat pancreatic 
acinar cells despite the fact that immunological and molecular biological evidence suggested 
the same PLD isoform, PLD1b, to be expressed in this cell type. This unexpected finding can 
be explained in three ways. First, this result may indicate that rat pancreatic acinar cells
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express a particular PLD1b isoform that is insensitive to PKC and/or small G proteins. 
However, this is not supported by the high degree of homology (nearly 95%) observed 
between the PLD1b transcripts cloned thus far, namely human PLD1b (GenBank™ accession 
number: A1338914), rat brain PLD1b (GenBank™ accession number: AB003171) and CHO 
PLD1b (GenBank™ accession number: U94995). Second, the acinar cytosol may contain a 
factor that inhibits the activation of PLD by PMA and/or GTPyS. Evidence for the existence 
of such an inhibitory factor has been provided previously (Brown etal. , 1995; Kim etal. , 
1996). However, this explanation seems unlikely because the acinar cytosol readily induced 
PMA/GTPyS-stimulated PLD activity in membranes of CHO cells. Third, acinar cells may 
lack a factor that is required for PKC- and/or small GTPase-induced activation of PLD1. 
Because of the predominantly cytosolic localization of rat pancreatic acinar PLD1 it is 
tempting to speculate that such a putative factor may act by recruiting this PLD isoform to the 
membrane. Stimulus-induced translocation of GFP-PLD1b to the plasma membrane was 
observed in rat basophilic leukemia cells (Brown etal., 1998). However, the predominantly 
cytosolic localization of acinar PLD1 was not influenced by the addition of PMA and GTPyS 
to the combined membrane and cytosol fractions, indicating that neither PKC activation nor 
the activation of small G proteins can induce membrane association of acinar PLD1. 
Similarly, PMA activation of PKC in intact acinar cells failed to change the subcellular 
distribution of PLD1.
Various cell types have been reported to contain a soluble, probably cytosolic, PLD 
activity (Brown etal., 1993; Siddiqi etal., 1995; Vinggaard etal., 1997). In any case, this 
activity was shown to be stimulatable by ARF. This latter finding has been interpreted as 
evidence that cytosolic PLD is related to PLD1. In agreement with this conclusion, the present 
study provides immunological evidence for the presence of PLD1 isoforms in the cytosolic 
fraction of rat pancreatic acinar cells. However, in contrast to previous observations the 
cytosolic PLD activity of rat pancreatic acinar cells proved to be insensitive to the 
combination of PMA and GTPyS. It is unlikely that this lack of stimulatability is due to the 
absence of a small G protein, possibly ARF, in the acinar cytosol because this cytosol was 
equally active to that of CHO cells in conferring PMA/GTPyS-stimulation of PLD activity on 
CHO cell membranes. Therefore, as discussed above, it is tempting to speculate that acinar 
membranes lack a factor that recruits cytosolic PLD1 to the membrane in order to become 
catalytically active.
Evidence has been provided for the existence of a membranous PLD isoform that is 
regulated by RhoA (Siddiqi et al., 1995). However, it is not likely that this small G protein 
plays a role in the membrane association of this PLD isoform because GTPyS-stimulated PLD 
activity was found by these investigators to be readily restored following reconstitution of 
Rho-GDI extracted membranes with recombinant RhoA. Moreover, the present study shows 
that addition of GTPyS did not induce the translocation of acinar cytosolic PLD1 to acinar 
membranes. The presence of RhoA and ARF in rat pancreatic acinar cells has been reported, 
indicating that these mediators of GTPyS-stimulated membrane PLD activity are present in 
these cells (Wagner et al., 1994; Nozu et al., 1999). This is in agreement with the present 
finding that the acinar cytosol readily confers PMA/GTPyS-stimulation of PLD activity on 
CHO cell membranes.
32The present study shows that CCK significantly increases the amounts of [ P]PtdOH
32 32and [ P]PtdIns without stimulating the formation of [ P]PtdEth in intact rat pancreatic acinar 
cells. This finding illustrates that in these cells the CCK-induced increase in PtdOH occurs 
primarily via phospholipase C (PLC) and not via PLD. We previously showed that a 
considerable part of the diacylglycerol that is produced during prolonged stimulation of rabbit 
pancreatic acini is derived from PtdCho (Hermans et al., 1996). The present findings indicate
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that this pathway involves PtdCho-specific PLC rather than PtdCho-specific PLD.
Intriguingly, a recent study showed that 1-butanol significantly increased the propagation
2+speed of CCK-induced cytosolic Ca waves in intact acinar cells. A similar increase was 
observed with inhibitors of PKC activity and suggests the presence of an active PLD that
produces PtdOH which is subsequently converted to diacylglycerol which activates PKC to
2+inhibit Ca wave propagation (González etal. , 1999). However, it is not clear whether this 
process involves the activation of PLD by CCK or the presence of a constitutively active 
PLD. The finding that CCK is unable to increase PLD activity in intact acinar cells is in 
contradiction to earlier reports (Rydzewska eta l . , 1993; Rivard eta l . , 1994; Rydzewska and 
Morisset, 1995). At present, however, we do not have a proper explanation for this 
discrepancy. Similarly to CCK, the other physiologically important pancreatic secretagogue 
acetylcholine failed to stimulate acinar PLD activity (Rubin etal . , 1992). Thus far, intact cell 
studies have shown that regulated PLD activity is present in almost all cell types excluding 
peripheral leukocytes and some lymphocyte cell lines (Kinsky etal., 1989; Bradshaw etal.,
1996). In contrast to CCK, PMA readily stimulated PLD activity in intact acinar cells. This 
observation is consistent with our immunoblotting data demonstrating the presence of 
substantial amounts of PLD1 protein in these cells. PMA did not increase the amount of
32[ P]PtdOH demonstrating the effectiveness of the transphosphatidylation reaction. At 
present, we have no explanation for the inability of PMA to stimulate PLD activity in a 
preparation of broken acinar cells, whereas it readily increases this activity in a broken cell 
preparation of CHO cells. However, it is tempting to speculate that PLD is relatively loosely 
attached to membranes of intact acinar cells as compared to membranes of intact CHO cells 
and that in acinar cells, but not CHO cells, this attachment is lost during cell fractionation. 
Membrane association of PLD may be a prerequisite for PMA-induced activation. A 
relatively weak membrane association may also mean that high-level PKC activation, as 
obtained with PMA, is required for PLD activation. Such a model is compatible with our
findings that low-level PKC activation by either CCK or the thapsigargin-induced increase in
2+cytosolic Ca is sufficient to activate PLD in CHO cells (Bosch et al., 1999), but not in 
acinar cells (this study).
We previously showed that the presence of PKC is a prerequisite for CCK-, 
thapsigargin-, and PMA-induced PLD activation in CHO-CCKA cells (Bosch etal., 1999). In 
the same study we demonstrated that the extent to which CCK activates this PKC-dependent
PLD depends largely, if not entirely, on the magnitude and duration of the hormone-induced
2+increase in cytosolic Ca . Furthermore we showed that the stimulatory effects of PMA and 
thapsigargin were additive. This latter finding may indicate that an increase in cytosolic Ca2+
does not act through PKC alone. It has been demonstrated that certain PLD isoforms can be
2+activated by Ca ions (Exton, 1994, 1999). However, the concentrations needed are well 
above the physiological range. This suggests the involvement of a Ca2+-dependent protein that 
regulates PLD activity.
Therefore, an alternative explanation for the present finding that CCK and
thapsigargin did not increase PLD activity in rat pancreatic acinar cells might be that these
2+cells lack a putative Ca -dependent regulatory protein. Thus, low-level PKC activation alone, 
as obtained with CCK, is insufficient to activate PLD and requires the additional action of a 
Ca2+-dependent protein. As to the nature of such a putative Ca2+-dependent protein, evidence 
has been provided that calmodulin can regulate PLD (Kumuda et al., 1995; Suzuki et al., 
1995; Takahashi et al., 1996). In addition, recent evidence suggests that calmodulin acts 
through calmodulin-dependent protein kinase II to exert its stimulatory effect (Sarri et al.,
1998). However, pancreatic acinar cells have been demonstrated to contain both calmodulin 
and calmodulin-dependent kinases (Bartelt etal., 1986). The present finding that stimulation 
of pancreatic acinar cells with thapsigargin increased the amount of [32P]PtdOH without
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32 32affecting the amounts of [ P]PtdEth and [ P]PtdIns suggests that an increase in cytosolic 
Ca2+ either activates diacylglycerol kinase or phospholipase C. The stimulatory effects of
32CCK and thapsigargin on the production of [ P]PtdOH were additive. Together with the
32finding that thapsigargin did not affect the amount of [ P]PtdIns this may favor the idea that 
an increase in cytosolic Ca2+ leads to activation of diacylglycerol kinase.
In conclusion, the present findings show that rat pancreatic acinar cells express a 
PLD1 isoform, probably PLD1b, that is predominantly present in the cytosol and that is not
regulated by the secretagogue CCK or other hormones or neurotransmitters that act through
2+an increase in cytosolic Ca or the activation of small GTPases such as ARF or RhoA. The 
physiological role of this PLD1 isoform remains to established.
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Phospholipase D (PLD) is distributed widely in mammalian tissues where it is believed to play 
an important role in the regulation of cell functions and cell fate by a variety of extracellular 
signals. In this study, we used primary cultures of rabbit connecting tubule (CNT) and cortical 
collected duct (CCD) cells, grown to confluence on a permeable support, to investigate the 
possible involvement of PLD in the mechanism of action of hormones that regulate Ca2+ 
reabsorption. RT-PCR revealed the presence of transcripts of PLD1b and PLD2, but not PLD1a, 
in these cultures. Moreover, the expression of substantial amounts of PLD1 protein was 
demonstrated by Western blotting. To measure PLD activity, cells were labelled with [3H]myristic 
acid after which the PLD-catalysed formation of radiolabelled phosphatidylethanol ([3H]PtdEth) 
was measured in the presence of 1% (v/v) ethanol. Deamino-Cys, D-Arg -vasopressin (dDAVP) 
and N6-cyclopentyladenosine (CPA), two potent stimulators of Ca2+ transport across these 
monolayers, stimulated PLD activity as was indicated by a marked increase in [3H]PtdEth. 
Similarly, adenosine 5’-triphosphate (ATP), a potent inhibitor of dDAVP- and CPA-stimulated 
Ca2+ transport, increased the formation of [3H]PtdEth. PLD activity was furthermore increased 
by 8Br-cAMP and following acute (30 min) stimulation of protein kinase C (PKC) with a 
phorbol ester (PMA). Chronic PMA treatment (120 h) to downregulate phorbol ester-sensitive 
PKC isoforms did not affect PLD activation by dDAVP, CPA and 8Br-cAMP, while markedly 
decreasing the effect of ATP and abolishing the effect of PMA. The PKC inhibitor chelerythrine 
significantly reduced PLD activation by dDAVP, CPA and 8Br-cAMP, without changing the 
effect of ATP. The inhibitor only partially reduced the effect of PMA. This study shows that 
Ca2+ transporting cells of CNT and CCD contain a regulated PLD activity. The physiological 
relevance of this activity, which is not involved in Ca + reabsorption, remains to be established.
2 +
INTRODUCTION
In mammals, the distal part of the nephron is the major regulatory site for Ca2+ excretion in
2+the urine (Bindels, 1993; Friedman and Gesek, 1995). Hormone-regulated active Ca
reabsorption proceeds against a transepithelial electrochemical gradient and involves several
components each of which forms a potential target of hormone action. In the first place, a 
2+ 2+Ca2+ influx pathway, probably the recently cloned epithelial Ca2+ channel (ECaC) (Hoenderop
2+et al., 1999a), present in the luminal membrane of the cell allows Ca to passively flow into
the cytosolic compartment down to a steep electrochemical gradient. Next, a vitamin D- 
2+ 2+ dependent Ca binding protein (calbindin-D28K) binds Ca with high affinity and shuttles it
to the basolateral membrane. Finally, a plasma membrane Ca2+-ATPase and Na+-Ca2+
exchanger transport Ca2+ out of the cytosol against a steep electrochemical gradient.
2+Presently, it is unknown which component of the Ca reabsorptive mechanism is subject to 
hormone-activated second messenger systems.
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2+Previous work showed that Ca reabsorption in primary cultures of cells from rabbit 
connecting tubule (CNT) and cortical collecting duct (CCD) is stimulated by various 
hormones, including parathyroid hormone (Van Baal et al., 1996a; Hoenderop et al., 1999b), 
vasopressin (Van Baal et al., 1996a, b; Hoenderop et al., 1999b), adenosine (Hoenderop et al., 
1998, 1999b), prostaglandin E2 (Van Baal etal., 1996a; Hoenderop etal., 1999b) and atrial
natriuretic peptide (Hoenderop et al., 1999c) and that ATP, which in itself does not affect
2+basal Ca reabsorption, significantly inhibits the effect of the stimulatory hormones (Koster 
etal., 1996; Van Baal etal., 1999). It was demonstrated that the action of the stimulatory 
hormones was independent of cAMP, insensitive to chronic phorbol ester treatment and 
markedly inhibited by the PKC inhibitor chelerythrine, suggesting the involvement of a 
phorbol ester-insensitive, chelerythrine-inhibitable PKC isoform (Hoenderop et al., 1999b).
By contrast, chronic phorbol ester treatment was shown to abolish the inhibitory effects of
2+both the phorbol ester and ATP on hormone-stimulated Ca reabsorption (Bindels et al., 
1993; Koster etal., 1996; Hoenderop etal., 1999c). These findings were taken as evidence
that ATP acts primarily via a downregulatable PKC isoform to inhibit hormone-stimulated
2+Ca reabsorption at the level of the pathway involving the non-downregulatable PKC isoform
(Van Baal et al., 1999). The possibility of a non-cAMP-mediated mechanism involved in
2+hormone-stimulated Ca reabsorption was first considered by Poujeoul etal. (1995) studying
2+calcitonin-induced Ca mobilization in rabbit convoluted distal tubule cultures. A major role 
of PKC in parathyroid hormone (PTH)-stimulated Ca2+ reabsorption was also deduced from 
studies with immortalized mouse distal convoluted tubule cells and primary cultures of mixed 
mouse CNT and cortical thick ascending limb cells (Friedman et al., 1996).
The finding that differential activation of phorbol ester-sensitive and -insensitive PKC
isoforms is the underlying principle in the action of inhibitory and stimulatory hormones on
2+Ca reabsorption raises the question on the mechanism of activation of these isoforms. The 
physiological activator of PKC is diacylglycerol and the hormone-induced formation of this 
lipid involves the action of hormone-sensitive phospholipases such as phosphatidylinositol- 
specific phospholipase C (PtdIns-PLC) and phosphatidylcholine-specific phospholipase D 
(PtdCho-PLD) (Exton, 1994; Natarajan et al., 1996a). The latter phospholipase hydrolyses 
PtdCho to yield phosphatidic acid and it has been proposed that phosphatidic acid is rapidly 
converted into diacylglycerol to activate PKC (Nishizuka, 1992). Since the diacylglycerols 
derived from PtdIns and PtdCho differ in fatty acid composition it is very well possible that 
they may activate different PKC isoforms (Hodgkin etal., 1998). In a recent study, evidence 
was provided that PTH acts through a pathway other than that involving PtdIns-PLC to 
promote the formation of PKC activating diacylglycerols (Friedman etal., 1999). PTH was 
shown to activate PtdCho-PLD and it was suggested that PTH acts through this pathway to 
increase diacylglycerol. Hormone-induced increases in PLD activity were also reported in 
rabbit CCD cells (Liu etal., 1999).
It has been demonstrated that agonists which stimulate the hydrolysis of PtdCho also 
cause the formation of phosphatidylalcohols as a result of the PLD-catalysed 
transphosphatidylation reaction (Dawson, 1967). The present study uses this PLD-specific
transphosphatidylation reaction to test the possibility that PLD is selectively activated by
2+either the inhibitory or the stimulatory hormones of Ca transport.
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MATERIALS AND METHODS
Materials
Collagenase A and hyaluronidase were obtained from Boehringer (Mannheim, Germany) and deamino-Cys, D-Arg8- 
vasopressin (dDAVP) from Bachem Feinchemikalien (Bubendorf, Switzerland). N ’-cyclopentyladenosine (CPA), 
adenosine 5’-triphosphate (ATP), 8-bromoadenosine 3',5'-cyclic monophosphate (8Br-cAMP), indomethacin, 1 2 -0  
tetradecanoyl phorbol 13-acetate (PMA) and 2,2,4-trimethylpentane were purchased from Sigma (St. Louis, MO, 
USA). Chelerythrine and pertussis toxin were obtained from Research Biochemicals International (Köln, Germany) 
and [9,10(n)-3H]-myristic acid (53 Ci/mmol) from The Radiochemical Centre (Amersham, UK). HPTLC silica-gel 
60 plates, ethyl acetate and chloroform were purchased from Merck (Darmstadt, Germany), phospholipid standards 
from Avanti Polar Lipids (Birmingham, AL, USA), and 2’,5’-dideoxyadenosine (DDA) from Biomol (Plymouth 
Meeting, PA, USA). All other chemicals were of reagent grade.
Primary cultures o f rabbit kidney cortical collecting system
Rabbit kidney connecting tubule (CNT) and cortical collecting duct (CCD) cells were immunodissected from kidney 
cortex of young New Zealand white rabbits (~0.5 kg) with antibody R2G9 and set in primary culture on permeable 
supports (0.33 cm2; Costar, Cambridge, MA, USA) as described in detail previously (Bindels etal., 1991). The 
culture medium was a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium (DME/F12; 
Gibco, Paisley, UK) supplemented with 5% (v/v) decomplemented fetal calf serum, 50 ^g/ml gentamicin, 10 ^l/ml 
nonessential amino acids (Gibco), 5 ^g/ml insulin, 5 ^g/ml transferrin, 50 nM hydrocortisone, 70 ng/ml prostag­
landin Ej, 50 nM Na2SeO3, and 5 pM triiodothyronine, equilibrated with 5% CO2-95% air at 37°C. PLD 
measurements were performed 8 days after seeding the cels.
RNA extraction and reverse transcription (RT)-PCR
Total RNA was isolated from rat brain and primary cultures of CNT and CCD cells using TRIzol™ (Gibco, Paisley, 
Scotland, U.K.) and reverse-transcribed with M-mlv reverse transcriptase using random hexamer-mixed 
oligonucleotides. Specific primers for the amplification of PLD1 transcripts were designed on the basis of published 
sequences from rat liver (Katayama et al., 1998). Primers were chosen such that they allowed to discriminate 
between PLD1a and PLD1b. The sense and antisense primers were 5’-GCCTATGGAAGGTGGGACGAC-3’ and 
5’-GGAGTACCTGTCAATGAAATCAGC-3’, respectively. Primers to specifically amplify PLD2 transcripts were 
designed on the basis of the published sequence of rat brain PLD2 (Kodaki and Yamashita, 1997). In this case, the 
sense and antisense primer were 5’-GAACAGGGGCAGTGTTTCCGA-3’ and 5’- 
CGCTGTTTCTTGCCACAGCTG-3’, respectively. The PCR of PLD1 and PLD2 transcripts was based on 35 cycles 
of 1 min at 94 °C; 1 min at 55 °C and 1 min at 72 °C, with an elongation time of 10 min at 72 °C following the last 
cycle. DNA products, visualized by means of ethidium bromide staining, were scanned with an Imaging 
Densitometer (Biorad, München, Germany).
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Western blotting
Total cell lysates (100|j,g) from primary cultures of rabbit CNT and CCD cells were subjected to SDS- 
polyacrylamide gel electrophoresis. Proteins were transferred overnight to polyvinylidene difluoride membranes 
(Immobillon P, Millipore, Bedford, MA, USA). Membranes were blocked for 1 h at RT with PBS (pH 7.4) 
containing 1% (w/v) milkpowder and 0.1% (v/v) Tween-20 (PBST-MLK). Subsequently, the blots were 
incubated overnight at 4 °C with the rabbit anti-hPLD1 antibody described by Müller-Wieprecht et al. (1998) 
diluted 1:1000 in PBST-MLK. The antibody was kindly provided by Prof. dr. C.C. Geilen (University Medical 
Center Benjamin Franklin, The Free University of Berlin, Germany). Immunoreactive protein was detected by 
incubating the blots for 1 h at RT with goat anti-rabbit IgG antibody conjugated to alkaline phosphatase diluted 
1:1000 in PBST-MLK. Membranes were washed with PBS (pH 7.4) containing 0.1% (v/v) Tween-20 and 
stained with 0.1 M diethanolamine, 0.34 mg/ml Nitroblue tetrazolium, 0.18 mg/ml 5-bromo-4-chloro-3- 
indolylphosphate and 50 mM MgCl2. The membranes were scanned by an Imaging Densitometer (Biorad, 
Münich, Germany).
PLD measurements
PLD measurements were performed essentially as described previously (Bosch et al., 1998, 1999). Briefly, 
monolayers, labelled with [3H]myristic acid (3 ^Ci/ml) for 24 h, were washed and incubated in DME/F12 
containing 5 |jM indomethacin for another 3 h. Subsequently, the monolayers were washed and preincubated in a 
physiological salt solution (PSS) containing 140 mM NaCl, 2 mM KCl, 1 mM K2HPO4, 1 mM KH2PO4, 1 mM 
MgCl2, 1 mM CaCl2, 5 mM glucose, 5 mM L-alanine, 5 |jM indomethacin and 10 mM HEPES (adjusted to pH 7.40 
with Tris) for 15 min. Next, the monolayers were washed and incubated in PSS containing 1% (v/v) ethanol for 
another 30 min. At 30 min, the filter was excised and rapidly transferred into a lipid tube (Sarstedt, Essen, Germany) 
containing 1 ml of methanol, 500 |jl of chloroform and 400 |j.l of water (4°C). The extract was mixed vigorously and 
phase separation was achieved by addition of 400 |j.l of chloroform and 400 |jl of water followed by centrifugation. 
The lower organic phase was collected and blown to dryness with N2. The dried extracts were dissolved in 20 |jl of 
chloroform/ methanol (9:1, v/v) and the lipids were separated by TLC using potassium oxalate-treated silica-gel 60 
HPTLC plates. The plates were developed with the upper phase of a mixture of ethyl acetate/ 2,2,4-trimethylpentane/ 
acetic acid/ water (13:2:3:10, by vol.). Radioactive spots corresponding to authentic lipid standards were visualized 
by I2 -staining and scraped off. Radioactivity was measured by liquid-scintillation spectrometry.
Analysis of the data
The data presented are expressed as the mean ± SEM of the number of experiments indicated. Overall statistical 
significance was determined by analysis of variance. In the case of significance (P < 0.05), individual groups were 
compared according to Fisher. P  values of less than 0.05 were considered significant.
RESULTS
To investigate the PLD isoform composition of primary cultures of rabbit CNT and CCD cells 
we performed RT-PCR using specific primers for PLD1, which allowed to discriminate 
between the two splice variants of PLD1, PLD1a and PLD1b, and PLD2. Figure 1a shows the 
three PLD transcripts in total RNA from rat brain for comparison. Cultured rabbit CNT and CCD 
cells clearly expressed PLD1b and PLD2. In contrast, the cells did not express transcripts of 
PLD1a. Western blot analysis of total cell lysate was performed to examine the expression of 
PLD1b at the protein level. Using an antibody directed against the C- and N-terminal sequences 
of human PLD1 we observed a positive band of expected size of ~110 kD (Fig. 1b). These data 
show that primary cultures of rabbit CNT and CCD express significant amounts of PLD1b at 
both the mRNA and the protein level.
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Figure 1. Identification ofPLD transcripts and PLD1 protein in primary cultures of rabbit CNT and CCD cells. 
A) Total RNA was prepared from rat brain and primary cultures of rabbit CNT and CCD cells and reverse- 
transcribed. Specific primers for PLD1, which allowed to discriminate between the PLD1 slice variants, PLDla and 
PLDlb, and PLD2 were used to amplify cDNA fragments. In rat brain, the PLDl-specific primers yielded a larger 
product of 550 bp and a smaller product of 450 bp, representing PLDla and PLDlb, respectively (upper panel; left 
lane), and one product with the PLD2-specific primers (lower panel; left lane). Primary cultures of rabbit CNT and 
CCD cells expressed the PLDlb and PLD2 fragments (right lanes). B) Total cell lysates from primary cultures of 
rabbit CNT and CCD cells were subjected to SDS-PAGE and subsequently transferred to polyvinylidene difluoride 
membranes by Western blotting. The membranes were probed with a specific anti-human PLDl antibody. The 
figure shows an immunoreactive band with an apparent mass of l l0  kD.
In order to assess the effects of various hormones and second messenger systems
2+ 3involved in the regulation of Ca reabsorption on PLD activity, [ H]myristic acid-labelled 
monolayers of rabbit CNT and CCD cells were stimulated in the presence of l% (v/v) ethanol 
for 30 min after which the amount of [ H]PtdEth was determined. Incubations were 
performed in the presence of indomethacin (5 ^M) added 3 h prior to stimulation to inhibit the 
production and release of autostimulatory prostanoids (Van Baal et al., l996a). Under these 
conditions, basal [ H]PtdEth formation amounted to 0.44 ± 0.03 % (n=l0) of total 
[ H]myristic acid-labelled lipid. To study the role of PKC in hormone-induced PLD 
activation, monolayers were pretreated with PMA (0.l ^M) for l20 h. This treatment is 
widely used to selectively downregulate phorbol ester-sensitive PKC isoforms. Chronic PMA 
treatment slightly increased basal [ H]PtdEth formation to 0.58 ± 0.02 % (n=9) of total 
labelled lipid. The data presented hereafter are corrected for basal [ H]PtdEth formation.
Both the phorbol ester PMA (0.l ^M; both sides; 30 min) and the membrane 
permeable cAMP analogue 8Br-cAMP (0.l mM; both sides; 30 min) markedly increased the 
formation of [3H]PtdEth (Fig. 2). The amount of [3H]PtdEth formed during this acute 
treatment with PMA was 2.9-fold higher than that obtained with 8Br-cAMP. Since both drugs 
were added at high concentrations, this indicates that the PKC pathway is much more 
effective than the PKA pathway in increasing PLD activity. The combination of PMA and 
8Br-cAMP did not further increase the amount of [ H]PtdEth, suggesting the absence of a 
synergistic interaction between the two pathways. Chronic PMA treatment (l20 h) virtually 
abolished the stimulatory effect of acute PMA treatment, while leaving that of 8Br-cAMP 
intact.
A
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Figure 2. Chronic phorbol ester treatment does not 
affect 8Br-cAMP activation o f PLD but abolishes the 
increase in PLD activity following acute phorbol ester 
activation o f PKC. Primary cultures of rabbit CNT and 
CCD cells, grown on permeable filters and labelled with 
[3H]myristic acid for 24 h, were incubated with the 
indicated stimulants in the presence of l% (v/v) ethanol 
for 30 min after which the amount of [3H]PtdEth was 
determined. Additions were: the phorbol ester PMA (0.l 
|xM; both sides), and the membrane-permeable cAMP 
analogue, 8Br-cAMP (0.l mM; both sides). To 
downregulate phorbol ester-sensitive PKC isoforms, 
monolayers were incubated in the presence of PMA (0.l 
|xM; both sides) for l20 h (closed bars). For each filter, 
the amount of [3H]PtdEth is expressed as percentage of 
total labelled lipid that was extracted. The data presented 
for PMA and 8Br-cAMP alone show the mean ± SEM of 
at least 3 filters. The data presented for the combination 
of PMA and 8Br-cAMP are representative of two 
experiments. &Significantly lower than the value 
obtained with PMA (P<0.05). Significantly lower than 
the value without chronic phorbol ester treatment 
(P<0.05).
ATP (0.l mM; both sides) stimulated the formation of [3H]PtdEth to the same extent as 8Br- 
cAMP (Fig. 3a). The increase obtained with the combination of ATP and 8Br-cAMP was 
approximately l.8-fold higher than that obtained with each of the two stimuli alone. The 
stimulatory effect of ATP was more than halved following chronic PMA treatment and in the 
combination experiment only the stimulation by 8Br-cAMP was left. The V2  receptor agonist 
dDAVP (l0 nM; basolateral side) evoked a similar increase in the amount of [ H]PtdEth as 
ATP and 8Br-cAMP (Fig. 3b). In combination with ATP, the amount of [3H]PtdEth was 
further increased by a factor 2 as compared to the effect of each stimulus alone. Chronic PMA 
treatment did not affect the stimulatory action of dDAVP, while in the combination it 
decreased the amount of [3H]PtdEth practically to the value obtained with dDAVP alone. 
Previous work showed that dDAVP evokes a marked increase in cAMP that is virtually 
abolished by the potent adenylyl cyclase inhibitor 2’,5’-dideoxyadenosine (DDA) (Hoenderop 
etal., l999b). To test whether this increase in cAMP is responsible for dDAVP-induced PLD 
activation, monolayers were stimulated with dDAVP in the presence of DDA (l00 ^M, both 
sides) added l5 min prior to stimulation. DDA did not significantly affect the dDAVP- 
induced increase in [3H]PtdEth (0.74 ± 0. l l  %, n=3 and 0.72 ± 0.03 %, n=4 in control and 
DDA-treated monolayers, respectively). The adenosine Al receptor agonist CPA (l0  ^M; 
apical side) increased the amount of [3H]PtdEth to the same extent as 8Br-cAMP, ATP or 
dDAVP (Fig. 3c). When added in combination with ATP a l.8-fold increase in [3H]PtdEth 
formation was observed as compared to the value obtained with ATP alone. Chronic PMA 
treatment did not affect the stimulatory action of CPA and reduced the effect of the 
combination to the value obtained with CPA alone. CPA-induced PLD activation was not 
affected in monolayers pretreated with pertussis toxin (l70 ng/ml) for 24 h, indicating that 
CPA does not act via Gi (data not shown).
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Table l. Stimulatory hormones for Ca2+ reabsorption and 8Br-cAMP do not increase PLD activity in an 
additive manner.
No treatment Chronic PMA treatment
Stimulant [3H]PtdEth (% of total)
8Br-cAMP 0.46 ± 0.07 0.42 ± 0.05
dDAVP 0.57 ± 0.07 0.64 ± 0.10
CPA 0.39 ± 0.09 0.35 ± 0.06
8Br-cAMP + dDAVP 0.76 ± 0.07 0.77 ± 0.04
8Br-cAMP + CPA 0.68 ± 0.11 0.51 ± 0.09
dDAVP + CPA 0.56 ± 0.09 0.46 ± 0.07
Chronic phorbol ester treatment and PLD activity measurements were performed as described in the caption of 
Fig.l. Additions were: 8Br-cAMP (0.l mM; both sides), dDAVP (l0 nM; basolateral side) and CPA (l0 |xM; 
apical side). For each filter, the amount of [3H]PtdEth is expressed as percentage of total labelled lipid that was 
extracted. Of note, the values for 8Br-cAMP, dDAVP and CPA alone are also shown in Figs. l and 2. The data 
presented show the mean ± SEM of at least 3 filters. In none of the cases the value obtained with the 
combination was significantly higher than that obtained with the most active stimulant alone.
Table l shows that the effects of dDAVP and 8Br-cAMP were not additive, whereas a
l.5-fold increase in [ H]PtdEth formation was observed with the combination of CPA and 
8Br-cAMP as compared to the effect of 8Br-cAMP alone. Finally, no additive effect was 
observed with the combination of CPA and dDAVP. In none of these cases the values 
obtained with vehicle-treated monolayers differed from those obtained following chronic 
PMA treatment.
To investigate the role of PKC in more detail monolayers were stimulated in the 
presence of the selective PKC inhibitor chelerythrine (l0 ^M, both sides) added l5 min prior 
to stimulation. In the presence of chelerythrine, basal [ H]PtdEth formation amounted to 0.40 
± 0.06 % (n=5) of total [3H]myristic acid-labelled lipid. PMA-induced [3H]PtdEth formation 
was reduced by 60% in monolayers treated with chelerythrine (Fig. 4a). Similarly, this 
inhibitor virtually abolished the stimulatory action of 8Br-cAMP. ATP-induced [ H]PtdEth 
formation was not affected by chelerythrine, while the stimulatory actions of dDAVP and 
CPA were decreased by 90% and 60%, respectively (Fig. 4b).
DISCUSSION
2+This study demonstrates that Ca2+ transporting cells of rabbit CNT and CCD contain a
regulated PLD activity which is, however, not involved in regulated Ca2+ reabsorption. This
2+conclusion is based on the finding that both stimulatory and inhibitory hormones for Ca2+ 
transport promote the transphosphatidylation reaction in primary cultures of rabbit CNT and 
CCD cells. This observation also disfavours the idea that selective activation of PtdCho- 
specific PLD by either stimulatory or inhibitory hormones underlies their differential 
activation of phorbol ester-insensitive and -sensitive PKC isoforms.
Thus far, two mammalian isoforms of PLD, PLDl and PLD2, have been cloned from 
a wide variety of species (Exton, l999). In addition, two alternatively spliced forms of PLDl 
(PLDla and PLDlb), and three alternatively spliced forms of PLD2 (PLD2a, PLD2b and
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8Br-cAMP dDAVP CPA
Figure 3. Chronic phorbol ester treatment does not affect 8Br-cAMP, dDAVP, or CPA activation o f PLD but 
markedly reduces the effect of ATP. Chronic phorbol ester treatment (closed bars) and PLD activity 
measurements were performed as described in the caption of Fig.l. Additions were: a) ATP (0.l mM; both sides) 
and/or 8Br-cAMP (0.l mM; both sides), b) ATP (0.l mM; both sides) and/or dDAVP (l0  nM; basolateral side), 
and c) ATP (0.l mM; both sides) and/or CPA (l0 |xM; apical side). Of note, the values for 8Br-cAMP are also 
shown in Fig.l. For each filter, the amount of [3H]PtdEth is expressed as percentage of total labelled lipid that 
was extracted. The data presented show the mean ± SEM of at least 3 filters. $ Significantly higher than the value 
obtained with either stimulant alone (P<0.05). * Significantly lower than the value without chronic phorbol ester 
treatment (P<0.05).
PLD2c) have recently been identified (Hammond etal., l997; Lopez etal., l998). At present, 
information on the expression levels, cellular localization and function of PLDl and PLD2 
proteins is limited. Using an antibody raised against N- and C-terminal sequences of human 
PLDl (Muller-Wieprecht et al., l998) we now show that rabbit cortical collecting system 
cells contain substantial amounts of this PLD isoform. RT-PCR on total RNA suggests that it 
concerns the lb splice variant of PLDl. In addition, the cells gave a clear signal with specific 
primers for PLD2. At present, however, we do not know to what extent this latter isoform is 
expressed at the protein level. Thus far, Northern blot analysis has revealed the presence of 
PLDl as well as PLD2 transcripts in human and rat kidney (listed by (Meier etal., l999).
Chronic phorbol ester treatment (l20 h) did not affect PLD activation by the 
stimulatory hormones CPA and dDAVP, while it markedly reduced PLD activation by the
inhibitory hormone ATP. These findings suggest that both the stimulatory and inhibitory
2+pathway for Ca reabsorption lead to PLD activation (for a schematized model, see Fig. 5). 
The effectiveness of chronic phorbol ester treatment was demonstrated by abolishment of 
PMA-induced PLD activity. Chronic phorbol ester treatment has been used in many cell 
systems to demonstrate the involvement of phorbol ester-sensitive PKC isoforms in hormone- 
stimulated PLD activity (Balboa et al., l994; Gupta et al., l995; Bosch et al, l999). In other 
cell models, however, such treatment did not affect hormone-stimulated PLD activity 
(Sandmann et al., 1991; Schmidt et al., l994; Balboa et al., l998). In this context, rabbit 
cortical collecting system cells represent a unique system in that chronic phorbol ester 
treatment inhibits PLD activation by one group of hormones (represented by ATP), while it 
does not affect PLD activation by another group of hormones (represented by dDAVP and 
CPA).
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Figure 4. Chelerythrine does not affect the ATP-induced increase in PLD activity but markedly reduces the 
effects o f 8Br-cAMP, dDAVP, CPA andPMA. PLD activity measurements were performed as described in the 
caption of Fig.l. Monolayers were stimulated in the presence of chelerythrine (10 |xM, both sides) added 15 min 
prior to stimulation (closed bars). Additions were: a) PMA (0.1 |xM; both sides) and 8Br-cAMP (0.1 mM; both 
sides), and b) ATP (0.1 mM; both sides), dDAVP (10 nM; basolateral side), and CPA (10 |xM; apical side). For 
each filter, the amount of [3H]PtdEth is expressed as percentage of total labelled lipid that was extracted. The 
data presented show the mean ± SEM of at least 3 filters. & Significantly lower than the value obtained with 
PMA (P<0.05). * Significantly lower than the value without chronic phorbol ester treatment (P<0.05).
2+The present finding that hormones that stimulate Ca reabsorption increase PLD 
activity is in line with the observation that PTH(1-84) stimulated the transphosphatidylation 
reaction in immortalized mouse distal convoluted tubule cells (Friedman et al., 1999). 
However, our finding that the inhibitory nucleotide ATP, which in itself does not change 
basal Ca2+ reabsorption (Van Baal etal., 1999), markedly increases PLD activity disfavours
the idea put forward by these authors that PLD may represent the non-PtdIns-PLC pathway
2+generating the diacylglycerols for PKC-dependent Ca reabsorption. In contrast to chronic 
phorbol ester treatment, chelerythrine markedly inhibited PLD activation by the stimulatory
hormones CPA and dDAVP. This finding is in agreement with the previous observation that
2+chelerythrine effectively inhibits the stimulatory effect of these hormones on Ca
reabsorption (Hoenderop et al., 1999b), and stresses the idea that the same phorbol ester-
2+insensitive, chelerythrine-inhibitable PKC pathway that leads to increased Ca2+ reabsorption 
leads also to PLD activation (see also, Fig. 5). Chelerythrine did not affect PLD activation by 
the inhibitory hormone ATP. Chelerythrine neither abolished the increase in PLD activity
evoked by PMA. These findings may suggest that the phorbol ester-sensitive PKC pathway
2+used by ATP to activate PLD and inhibit hormone-stimulated Ca reabsorption is less 
sensitive to chelerythrine than the phorbol ester-insensitve PKC pathway used by the 
stimulatory hormones.
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In addition to PMA, 8Br-cAMP 
markedly increased PLD activity in these 
primary cultures. This suggests the 
presence of a cAMP-dependent pathway 
leading to PLD activation. Recently, the 
existence of a such a pathway has been 
reported in FRTL-5 thyroid cells 
(Ginsberg et al., 1997). Chronic phorbol 
ester treatment did not affect 8Br-cAMP 
stimulation of PLD activity, indicating that 
8Br-cAMP, similar to dDAVP and CPA 
but in contrast to ATP and PMA, does not 
require the presence of phorbol ester­
sensitive PKC isoforms for activation of 
PLD. Similar to dDAVP and CPA 
stimulation of PLD activity, 8Br-cAMP 
stimulation of PLD activity was virtually 
abolished by chelerythrine. Moreover, the 
stimulations by CPA, dDAVP and 8Br- 
cAMP were not additive. These findings 
suggest that 8Br-cAMP uses the same 
phorbol ester-insensitive, chelerythrine- 
inhibitable PKC pathway as dDAVP and 
CPA to stimulate PLD activity. 
Importantly, the dDAVP-induced increase
CPA dDAVP 
\ /
chelerythrine
v
Phorbol ester- 
insensitive PKCs
Ca2+ 
reabsorption
7 \
PLD
Phorbol ester­
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ATP PMA
Figure 5. Schem atic m odel o f the hormonal 
regulation o f PLD activity in rabbit CNT and  
CCD cells. For explanation see  text.
in PLD activity was not reduced by the potent adenylyl cyclase inhibitor 2’,5’- 
dideoxyadenosine (DDA), indicating that dDAVP does not act via the cAMP-dependent 
pathway. Similarly, the involvement of the cAMP-dependent pathway in the mechanism of 
action of CPA is excluded by the fact that CPA does not increase cAMP in these monolayers 
(Hoenderop et al., 1998). When the inhibitory nucleotide ATP was added in combination with 
either 8Br-cAMP, dDAVP or CPA, the increase in PLD activity was higher than that 
observed with each of the stimulants alone. These observations are in agreement with the idea 
that ATP and the stimulatory hormones activate PLD via two distinct pathways. Conversely, 
none of the combinations of the stimulatory hormones gave an additive effect. This latter 
observation suggests that the pathway used by the stimulatory hormones is already maximally 
activated by each of the hormones. The observation that addition of 8Br-cAMP did not lead to 
a further increase of PMA-stimulated PLD activity then suggests that the phorbol ester­
sensitive PKC pathway, in contrast to the phorbol ester-insensitive PKC pathway, can fully 
activate PLD.
2+It is unknown at which of the steps involved in transepithelial Ca2+ transport, i.e.
apical Ca2+ influx, cytosolic diffusion of Ca2+ bound to calbindin or basolateral Ca2+
extrusion, the regulatory hormones act. However, voltage-clamp studies with Xenopus laevis
2+oocytes heterologously expressing the recently cloned epithelial Ca2+ influx channel (ECaC)
provide evidence for a strong inhibition of Ca2+ influx by intracellular Ca2+, suggesting that
2+ECaC is a major site for regulation of Ca reabsorption (Hoenderop et al., 1999d). Moreover, 
elucidation of the primary structure of ECaC revealed the presence of seven potential PKC
phosphorylation sites (Hoenderop etal., 1999a), and future studies will decide whether or not
2+these sites are involved in the hormonal regulation of Ca reabsorption.
In conclusion, the present observation that both hormones that stimulate and inhibit 
Ca2+ reabsorption readily increase PLD activity suggests that PLD activation does not play a
128
role in the mechanism by which these hormones exert their regulatory action. At present, the 
physiological relevance of PLD activation in CNT and CCD cells is unclear and awaits 
further investigation.
Chapter 8
129

Chapter 9
Increased PLD activity and altered expression of 
PKCa and e and the GTPase-deficient Rho 
protein memB in human melanoma cells 
with high metastasizing capacity
Manuscript in preparation

Chapter 9
Increased PLD activity and altered expression of PKCa and @ and the 
GTPase-deficient Rho protein memB in human melanoma cells 
with high metastasizing capacity
Remko R. Bosch1, Mohammad R. Ahmadian2, Michiel Langeslag1, Mayte Y. Jonsson3, 
Sjenet E. van Emst-de Vries1, Leon C.L.T. van Kempen4,
Guido W.M Swart4 and Peter H.G.M. Willems1
department of Biochemistry, Medical faculty, University of Nijmegen, Nijmegen, The Netherlands 
2Max-Planck-Institut fur Molekulaire Physiologie, Dortmund, Germany 
3Division of Biosciences, University of Hertfordshire, Hatfield, Hertfordshire, UK 
4Department of Biochemistry, faculty of Science, University of Nijmegen, Nijmegen, The Netherlands
The growth rate of human melanoma cells appeared to be highly dependent on their metastatic 
potential (3.8- and 11.9-fold increase in cell number of non-metastatic 530 cells and metastatic BLM 
cells in 48 h, respectively). Many studies have implicated phospholipase D (PLD) in cell growth. To 
assess possible differences in PLD activity, 530 and BLM cells were cultured in the presence of 
butanol. Under this condition, PLD catalyses the formation of phosphatidylbutanol rather than its 
biologically active product phosphatidic acid. In the presence of 0.2% (v/v) 1-butanol, cell growth 
was inhibited by 82% and 30% in 530 and BLM cells, respectively, indicating that PLD activity is 
increased in the metastatic BLM cells. In agreement with this, the increase in PLD activity 
following activation of protein kinase C (PKC) by PMA was markedly higher in the BLM cells. 
Because the amount of PLD protein was not different between 530 and BLM cells, this suggests the 
upregulation of activating and/or downregulation of inhibiting PLD regulators in metastatic cells. 
PKCa and members of the Rho family of small GTPases are generally believed to function as 
endogenous activators of PLD, whereas recent reports suggest that PKCe might inhibit this 
enzyme. We previously reported the isolation of the metastatic melanoma clone B (memB). Here we 
show that memB is identical to Rho8, also referred to as Rnd3, and RhoE, albeit that the latter 
protein lacks the 15 NH2-terminal amino acids. The amino acid sequence of memB shows strong 
similarity with that of the Rho GTPases and the switch I region, which is a crucial interaction 
site for PLD, is conserved. However, memB lacks intrinsic GTPase activity. Both memB and 
PKCa are upregulated in metastatic cells, whereas PKCe is downregulated in these cells. PLD 
activation in response to GTPyS, a non-discriminatory activator of GTPases, was considerably 
lower in a cell-free system of metastatic cells. Downregulation of memB by transfecting BLM cells 
with the adenovirus-5 E1A gene did not alter the response to GTP7S excluding the possibility that 
memB interacts with PLD to prevent binding and activation by GTPyS-activated Rho proteins. In 
agreement with an activatory role of PKCa, the PMA-induced increase in PLD activity was 
significantly higher in a cell-free system of metastatic cells. However, no increase in PMA-induced 
PLD activation was observed in a cell-free system of non-metastatic 530 cells overexpressing PKCa. 
O f note, PKCe is still highly expressed in these cells. Taken together, although PLD activity is 
increased in metastatic cells a direct link with changes in expression levels of endogenous PLD 
regulators is not yet established.
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INTRODUCTION
Many extracellular signals activate phospholipase D (PLD) and it is widely believed that this 
activation plays an important role in the regulation of a variety of processes including vesicular 
trafficking, stress fiber formation and cell proliferation and differentiation (Cross et al, 1996; Bi 
et al, 1997; Singer et al, 1997; Gomes-Cambronero and Keire, 1998; Exton, 1999; Nakashima 
and Nozawa, 1999). PLD catalyses the hydrolysis of phosphatidylcholine to phosphatidic acid 
which may then be converted to diacylglycerol by the action of phosphatidate phosphohydrolase 
(Exton, 1999; Liscovitch et al, 2000). Diacylglycerol is the endogenous activator of protein 
kinase C (PKC) and evidence has been provided that activation of this enzyme leads to the 
induction of transcription factors (Mollinedo et al, 1994; Cesnjaj et al, 1995; Nakashima and 
Nozawa, 1999). On the other hand, PLD has also been proposed to act through phosphatidic 
acid in, for instance, the activation of Raf-1 (Daniel et al, 1999).
In the presence of a primary alcohol, PLD catalyses the formation of 
phosphatidylalcohol, an inert phospholipid, instead of phosphatidic acid. This unique reaction 
has been used to demonstrate the involvement of PLD in the hormone-induced expression of the 
transcription factors c-fos and c-jun (Cesnjaj ef al., 1995). In agreement with this, the production 
of c-fos and AP-1 was found to be decreased in senescent fibroblasts displaying a severely 
diminished PLD activity and markedly reduced diacylglycerol levels (Venable and Obeid,
1999). On the other hand, addition of PLD to organ-cultured skin was found to induce 
melanogenesis of melanocytes, a differentiation process believed to be involved in epidermal 
hyperpigmentation (Maeda et al, 1996). In agreement with this latter finding, mRNA levels of 
PLDla and lb were shown to increase during differentiation of HL60, PC12 and C6 glial cells 
(Nakashima and Nozawa, 1999). Conversely, when apoptosis was induced in C6 glial and RBL- 
2H3 cells, the mRNA levels of hPLDla and lb were found to decrease. This led these authors to 
propose that high levels of PLD activity cause cells to proliferate or differentiate, whereas 
apoptotic signals downregulate PLD activity to shut off survival pathways.
Several authors have suggested that elevated levels of PLD activity contribute to tumor 
progression and metastasis (Song and Foster, 1993; Luo et al, 1997; Yoshida et al, 1998; 
Uchida et al, 1999). In this context, PLD has been implicated in the induction of several 
proteases (Aguirre-Ghiso et al., 1997, 1999; Williger et al., 1999). For instance, Reich et al. 
(1995) have shown that laminin, a major constituent of the extracellular matrix, acts through 
PLD to trigger MMP-2 production in metastatic cells but not in non-metastatic cells. The 
reported overexpression of gelatinase A (MMP-2) and tissue- and urokinase-type plasminogen 
activators in the highly metastatic human melanoma cell lines MV3 and BLM further adds to this 
hypothesis (Quax ef al., 1991; Hofmann ef al., 1999).
PLD has been identified as a major target of small GTPases of the Rho family (Bowman 
et al, 1993) and it has been demonstrated that the switch I region of RhoA is of crucial 
importance for this interaction (Bae et al, 1998). In addition, evidence is accumulating that 
PKCa is another major regulator of PLD activity (Frohman et al, 1999; Zhang et al, 1999). Rho 
GTPases form an important family of the monomeric guanine nucleotide-binding regulatory 
proteins and are ubiquitously expressed from yeast to man (van Aelst and D’souza-Schorey,
1997). In mammals, this family comprises at least 10 distinct members which are implicated in a 
wide variety of cellular activities such as cytoskeletal reorganization, membrane trafficking, 
transcriptional regulation, cell growth and development (Hall, 1998). Experimental evidence is 
now accumulating suggesting that members of the Rho family are involved in invasion and 
metastasis of tumor cells (Michiels and Collard, 1999). For instance, recent work by Nobes et al. 
(1998) showed that microinjection of Swiss 3T3 cells with the Rho-like proteins Rndl and Rnd3 
resulted in a phenotype resembling that reported previously for highly metastatic human
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melanoma cells (van Groningen et al., 1996). Rndl and Rnd3 appeared to antagonize the effects 
of RhoA and Rac and to promote the disassembly of actin stress fibers and focal adhesion 
complexes, a typical feature of transformed cells. It was therefore suggested that Rnd proteins 
contribute to the transformed phenotype of tumor cells.
Rnd3, also referred to as Rho8, Rndl and Rnd2 appear to form a new subgroup within 
the Rho family (Foster et al., 1996; Nobes et al, 1998). The amino acid sequences of the Rnd 
proteins show strong similarity with those of the other members of the Rho family. Of crucial 
importance, the switch I region, is completely conserved in this subgroup. On other hand, these 
Rnd proteins differ from the common GTPases in that they possess three amino acid residues 
that specifically confer oncogenicity to Ras. As a consequence, these proteins lack intrinsic 
GTPase activity.
Metastatic melanoma is one of the most invasive cancers and its incidence has rapidly 
increased in the last decades. In the past years we have isolated a number of metastatic 
melanoma (mem) clones by applying the differential RNA display method to human melanoma 
cell lines with different metastatic capacity (Swart and van Kempen, 1999). Obviously, 
characterization of these clones for their biochemical function is essential for a better 
understanding of the mechanism of tumor progression and metastasis at the molecular level. We 
previously reported the isolation of memB (van Groningen et al, 1996) and here we show that 
this metastatic melanoma clone is identical to Rnd3. The aim of this study was to assess whether 
metastatic and non-metastatic human melanoma cells differ in PLD activity and expression 
levels of putative regulators of PLD activity such as the PKC isoforms a  and e and the Rho-like 
protein memB.
MATERIALS AND METHODS
Materials
PMA, leupeptin and 2,2,4-trimethylpentane were obtained from Sigma (St. Louis, MO, USA). Phenylmethylsulfonyl 
fluoride was purchased from SERVA (Heidelberg, Germany) and GTPyS from Boehringer (Mannheim, Germany). 
Dithiothreitol was obtained from Research Organics (Cleveland, OH, USA) and [9,10(n)-3H]myristic acid (53 
Ci/mmol) from The Radiochemical Centre (Amersham, UK). Tran35S-label (>1000 Ci/mmol) was purchased from 
ICN (Costa Mesa, CA, USA) and HPTLC silica gel 60 plates, ethylacetate and chloroform from Merck (Darmstadt, 
Germany). Phospholipid standards were obtained from Avanti Polar Lipids (Birmingham, AL, USA) and isotype- 
specific PKC antibodies and tissue culture medium with additives from Gibco (Paisley, Scotland). I-block Reagent 
was purchased from Tropix (Bedford, MA, USA). All other chemicals were of reagent grade.
Cell lines
Human melanoma cell lines MV3, BLM, 1F6-L and 530 were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% (v/v) fetal calf serum, glutamine (2 mM), penicillin G (100 units/ml), streptomycin (100 
|J.g/ml) and pyruvate (1 mM). Analysis of the metastatic behavior of these cell lines in nude mice showed that BLM 
and MV3 are highly metastatic, whereas, in contrast, 530 and 1F6-L are non-metastatic (van Muijen et al., 1991a,b; 
Westphal et al, 1997). For overexpression of PKCa in 530 melanoma cells, cells were tranfected with full-length 
cDNA of bovine PKCa subcloned in the mammalian expression vector pcDNA3. This vector was kindly provided 
by dr. W.J. van Blitterswijk (Netherlands Cancer Institute, Amsterdam, The Netherlands). For transfection, 0.5 |j.g of 
vector, mixed with 300 |jl of fugene-6 (Roche, Mannheim, Germany), was applied to 530 cells grown to 40% 
confluence on 35 mm dishes. After 48 h, the plates were washed to remove dead cells and G418 (1 mg/ml) was 
added. G418-resistant colonies were selected at 14 days after transfection and kept in culture in the presence of 0.5 
mg/ml G418. The cells were tested on PKCa overexpression by Western blotting. The generation of a BLM cell line 
expressing the adenovirus-5 E1A gene has been described elsewhere (van Groningen et al., 1996).
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Generation o f memB-specific monoclonal antibodies
We previously reported the isolation of a clone, designated metastatic melanoma clone B or memB, from a cDNA 
library derived from the cell line MV3 (van Groningen et al, 1996). To obtain recombinant memB, Escherichia Coli 
BL21 (DE3) was transformed with pGEX-memB. The pellet of a 10 l culture was lysed by sonication in a buffer 
containing 5 mM MgCl2, 100 mM NaCl, 3 mM dithioerythreitol and 50 mM Tris, adjusted with HCl to pH 7.5. After 
centrifugation, the supernatant was loaded on a GSH-sepharose column. The column was washed thoroughly and 
thrombin was added to cleave memB from GST. The protein was eluted from the column and applied to a superdex 
75 gel filtration column (Pharmacia, Milwaukee, WI, USA). Purified memB was concentrated, frozen in liquid 
nitrogen and stored at -80°C until further use. Mass-spectrometry revealed that the recombinant memB protein had a 
molecular mass of 25 kDa rather than the expected 27 kDa. Further characterization revealed that the recombinant 
protein was not farnesylated, suggesting the absence of the C-terminal tail. Balb/c mice were immunized with 
recombinant memB protein and splenic cells were isolated to fuse with NSO myeloma cells. Hybridomas were 
cloned twice and tested by ELISA. The culture supernatant of positive hybridomas was filtered, adjusted to pH 7.0 
with HCl, and applied to a G-column (GammaBind-plus Sepharose, Pharmacia). After extensive washing with 
binding buffer (150 mM NaCl, 10 mM EDTA, 10 mM Na2HPO4, adjusted to pH 7.0 with NaOH), the monoclonal 
antibodies were eluted with 500 mM acetic acid (adjusted to pH 3.0 with NaOH). Fractions of 1 ml were collected 
and adjusted to pH 4.0 with 1 M Tris/HCl (pH 9.0). Protein positive fractions were pooled, dialysed against PBS, and 
concentrated to 4 mg/ml (final concentration) using Viaspin (Millipore, Bedford, MA, USA). The purified 
monoclonal antibodies were frozen in liquid nitrogen and stored at -20°C.
Western blotting
Total cell lysates from human melanoma cells were subjected to SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred overnight to polyvinylidene difluoride membranes (Immobillon P, Millipore, Bedford, 
MA, USA). Membranes were blocked for 1 h at RT with PBS (pH 7.4) containing 1% (w/v) milkpowder and 
0.1% (v/v) Tween-20 (PBST-MLK). For the detection of PLD1, membranes were incubated overnight at 4°C 
with the rabbit anti-hPLDl antibody described by Muller-Wieprecht et al. (1998) diluted 1:1000 in PBST-MLK. 
The antibody was kindly provided by Prof. dr. C.C. Geilen (University Medical Center Benjamin Franklin, The 
Free University of Berlin, Germany). Membranes were incubated for 1 h at RT with alkaline phosphatase 
conjugated goat anti-rabbit IgG antibody diluted 1:1000 in PBST-MLK, washed with PBS (pH 7.4) containing 
0.1% (v/v) Tween-20, and stained with 0.1 M diethanolamine, 0.34 mg/ml Nitroblue tetrazolium, 0.18 mg/ml 5- 
bromo-4-chloro-3-indolylphosphate and 50 mM MgCl2. Determination of PKC-isotypes was performed as 
described previously (Smeets et al, 1996, 1998b).
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Immunoprecipitation
To determine endogenous memB at the protein level, BLM, MV3, 1F6-L and 530 cells were grown to 70% 
confluence in a T75 flask. Cells were washed with PBS and incubated overnight with Tran35S-label diluted 
1:1000 in culture medium without methionine and cysteine (final concentrations of [35S] methionine and 
[35S]cysteine of 7 and 1.5 ^Ci/ml, respectively). Labelled cells were washed three times with ice-cold PBS, 
resuspended in 1 ml lysis buffer containing 150 mM NaCl, 1% (v/v) Triton X-100, 1 mM phenylmethylsulfonyl 
fluoride, 1 |J.g/ml aprotinine and 50 mM Tris/HCl (pH 8.0), and incubated for 1 h at 4°C. The cell lysate was 
cleared by centrifugation at 3000 g  for 10 min and the resulting supernatant was subjected to a second 
centrifugation step at 10,000g for 30 min. After addition of glycerol at a final concentration of 15 % (v/v) the 
supernatant was frozen in liquid nitrogen and stored at -80°C until further use. For immunoprecipitation, aliquots 
of cell lysate were taken and incubated under constant agitation with a mixture of 6 different memB-specific 
monoclonal antibodies in either the absence or presence of recombinant memB for 2 h at 4°C. At the end of this 
incubation, GammaBind-plus Sepharose beads (Pharmacia) were added and the mixture was incubated for 
another 3 h at 4°C. Beads were washed four times with a buffer containing 150 mM NaCl, 10 |xM EDTA and 10 
|xM Na2HPO4, adjusted to pH 7.0 with NaOH, and once with PBS. Bound proteins were eluted by boiling in 
SDS-sample buffer and subjected to SDS-polyacrylamide gel electrophoresis. Radiolabelled proteins were 
visualized by autoradiography.
RT-PCR, Northern blotting, DNA probes and hybridization
For RT-PCR, total RNA was isolated from human melanoma cells using RNAzol (Tel-test, Friendswood, TX, 
USA) and reverse-transcribed with M-mlv reverse transcriptase (Gibco) using random hexamer-mixed 
oligonucleotides. Specific primers for the amplification of PLD1 transcripts were designed on the basis of 
published sequences from rat liver (Katayama et al., 1998). Primers were chosen such that they allowed to 
discriminate between PLD1a and PLD1b. Sense and antisense primers were 5’- 
GCCTATGGAAGGTGGGACGAC-3 ’ and 5 ’ -GGAGTACCTGTCAATGAAATCAGC-3 ’, respectively. 
Amplification of PLD1 transcripts was based on 35 cycles of 1 min at 94 °C; 1 min at 55 °C and 1 min at 72 °C, 
with an elongation time of 10 min at 72 °C following the last cycle. DNA products, visualized by means of 
ethidium bromide staining, were scanned with an Imaging Densitometer (Biorad, München, Germany). For 
Northern blotting, total RNA from human melanoma cells was isolated using RNAzol. Total RNA from 
xenografts was isolated using the lithium-urea procedure as decribed by Auffray and Rougeon (1980). RNA 
oligo-deoxythymidine selections were performed using oligo-deoxythymidine columns (type II, Coll. Research, 
Bedford, MA, USA). Total RNA was glyoxylated according to the method described by McMaster and 
Carmichael (1977), size fractionated on 1% (w/v) agarose gels, and blotted onto Hybond N-plus (Amersham, 
Aylesbury, UK). To confirm that equal amounts were loaded in each lane, the blots were afterwards hybridized 
with an 18S ribosomal RNA probe. DNA probes were radiolabelled using the random prime labelling method 
described by Feinberg and Vogelstein (1983). Hybridization was performed according to standard protocols 
(Sambrook et al., 1989).
DNA sequencing and computer analysis
DNA fragments were sequenced using a Sequenase sequencing kit (USB, Cleveland, OH, USA). Large 
fragments were sequenced by constructing a set of deletion clones using the Erase-a-base kit (Promega, 
Madison, WI, USA). Identification of known sequences was performed using the Genbank and EMBO databases 
(Devereux et al, 1984; Pearson and Lipman, 1988). DNA sequence analysis was performed using the 
CAMMSA programs which are part of the Wisconsin Package V 7.0 (Devereux et al, 1984).
Butanol treatment o f530 and BLM cells
Human melanoma cells were seeded in T25 flasks at 10% and 20% confluency for BLM and 530 cells, respectively. 
After 24 h of culturing, medium containing either 1-butanol or 2-butanol was added and the cells were grown for 
another 48 h. The medium was replaced twice a day. After 48 h of butanol treatment, cell numbers were determined 
with an heamacytometer.
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Phospholipase D measurements in intact melanoma cells
For PLD measurements, human melanoma cells were cultured in 12-well plates (2.2x105 cells/well) and labelled 
with [3H]myristic acid (2 ^Ci/ml) for 24 h. At the end of the labelling period, the cells were washed and incubated in 
DMEM without FCS for 3 h. Subsequently, the cells were washed and stimulated with 1 |xM PMA in DMEM 
containing 1% (v/v) ethanol. After 30 min, the medium was aspirated and the reaction was quenched by the addition 
of 1 ml ice-cold methanol. The cells were scraped off and the mixture was transferred into a lipid tube (Sarstedt, 
Essen, Germany). Lipids were extracted according to the method described by Bligh and Dyer (1959). Briefly, 500 
|j.l of chloroform and 400 |j.l of water were added and the mixture was mixed vigorously. Phase separation was 
obtained by addition of 400 |j.l of chloroform and 400 |j.l of water followed by centrifugation. The lower organic 
phase was collected and blown to dryness with N 2 .
Separation o f labelled phospholipids
The dried extracts were dissolved in 20 ^l of chloroform/methanol (9:1, v/v) and the lipids were separated by thin- 
layer chromatography using potassium oxalate-treated silica gel 60 HPTLC plates. The plates were developed with 
the upper phase of a mixture of ethylacetate/2,2,4-trimethylpentane/acetic acid/water (13:2:3:10, by vol.). Ra­
dioactive spots corresponding to authentic lipid standards were visualised by I2 -staining and scraped off. Radioacti­
vity was measured by liquid-scintillation spectrometry.
Phospholipase D measurements in homogenates of melanoma cells
PLD activity was measured in cell homogenates according to the method described by Ohguchi et al. (1996) as 
described previously (Bosch et al, 1998; 1999). Human melanoma cells were grown to 80-90% confluence in the 
presence of [3H]myristic acid (2 ^Ci/ml) for 24 h. Prior to homogenization, the cells were washed and incubated in 
DMEM without FCS for 3 h. At the end of this incubation period, cells were washed twice with ice-cold 
homogenization solution containing 100 mM KCl, 3 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 5 mM dithiothreitol, 
0.5 mM phenylmethylsulfonyl fluoride, 20 ^M leupeptin and 25 mM HEPES, adjusted with Tris to pH 7.4 and 
collected by scraping. The cells were homogenized at 4°C using a Potter-Elvehjem homogenizer (glass-teflon) by 10 
strokes at 500 rev./min, 5 strokes at 1000 rev./min and 5 strokes at 1200 rev./min. For PLD measurements, aliquots 
of the supernatant were incubated in the presence of Mg-ATP (0.5 mM), CaCl2  (0.5 mM) and 1% (v/v) ethanol and 
in the absence or presence of PMA (1 |jM) or GTPyS (10 |xM) for 30 min at 37°C. The reaction was quenched with 1 
ml ice-cold methanol and the lipids were extracted and separated as described above.
Analysis of the data
The results presented are the mean ± S.E.M of the number of experiments indicated. Overall statistical significance 
was determined by analysis of variance (ANOVA). In the case of significance (P < 0.05), individual groups were 
compared according to Fischer. P  values of less than 0.05 were considered signficant.
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Figure 1. Differential inhibition 
of cell growth in non-metastatic 
and metastatic human 
melanoma cells by 1 -butanol.
BLM and 530 cells were seeded 
at a density of 10% and 20%, 
respectively. After 24 h of 
culturing, the indicated 
concentrations of 1-butanol were 
added and the cells were 
cultured for another 48 h. At the 
end of the butanol treatment, the 
increase in the number of cells 
was determined. The increase in 
the amount of cells in the 
absence of 1-butanol is set at 
100% to which the other values 
are related . The number of cells 
increased 3.8-fold (S.E.M.=0.96; n=3) and 11.9-fold (S.E.M.=2.4; n=3) in the case of 530 and BLM cells in the 
absence of 1-butanol, respectively. The data presented are the mean ± S.E.M. of 3-7 experiments. *Significantly 
different from the value obtained in the absence of 1-butanol (P<0.05).
RESULTS
Butanol differentially inhibits cell growth in metastatic and non-metastatic melanoma cells
PLD catalyses the hydrolysis of phosphatidylcholine (PtdCho) into choline and phosphatidic 
acid (Exton, 1999; Liscovitch et al, 2000). However, in the presence of a small primary 
alcohol PLD catalyses the formation of phosphatidylalcohol rather than phosphatidic acid. 
Here we used this property of PLD to study the role of PLD-induced PtdOH formation in cell 
growth. Highly metastatic BLM cells and non-metastatic 530 cells were cultured in the 
presence of increasing concentrations of 1-butanol. After 48 h, the increase in the number of 
cells was determined and expressed as percentage of the increase in cell number in the absence 
of 1-butanol. As indicated in the legend of figure 1, in the absence of 1-butanol the number of 
cells increased 3.8-fold (S.E.M.=0.96; n=3) and 11.9-fold (S.E.M.=2.4; n=3) in the case of 530 
and BLM cells, respectively. 1-Butanol reduced this increase dose-dependently with the 
understanding, however, that 530 cells were considerably more sensitive to this alcohol than 
BLM cells. With 530 cells virtually complete inhibition of cell growth was observed at 0.2% 
(v/v) 1-butanol. BLM cell growth was only minimally affected at this 1-butanol concentration. 
Complete inhibition of BLM cell growth was observed at 0.4% (v/v) 1-butanol. At this latter 
concentration, however, the number of 530 cells even decreased below starting values indicating 
a cytotoxic effect of this alcohol. Secondary alcohols are relatively inefficient nucleophilic 
acceptors (only 10% of the efficiency of primary alcohols) (Bi et al, 1997). In agreement with 
this, 2-butanol reduced the increase in cell number significantly less potently than 1-butanol 
(data not shown).
% 1-butanol (v/v)
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Figure 2. Identification of PLD transcripts and 
protein in non-metastatic and metastatic human 
melanoma cells. A. Total RNA was prepared from 
530 cells and BLM cells and reverse-transcribed.
Specific primers for PLD1, which allowed to 
discriminate between PLD1a and PLD1b were used to 
amplify the cDNA fragments. The upper panel shows 
that the PLD 1-specific primers yielded a larger 
product of 550 bp and a smaller product of 450 bp, 
representing PLD1a and PLD1b, respectively. B. Total 
cell lysates of 530 and BLM cells was subjected to 
SDS-PAGE and subsequently transferred to 
polyvinylidine difluoride membranes by Western 
blotting. The membranes were probed with a specific 
anti-human PLD1 antibody. The lower panel shows an 
immunoreactive band with an apparent mass of 110 kD
PLD1 protein is equally expressed in metastatic and non-metastatic melanoma cells
The expression of the PLD1 isoforms PLD1a and PLD1b was determined by RT-PCR. Figure 
2A shows that both transcripts are present in 530 and BLM cells and that the ratio of the two 
transcripts was virtually the same in both cell lines. Western blot analysis revealed that both cell 
lines expressed the same amount of PLD1 protein (Fig. 2B). This latter finding suggests that the 
different sensitivities of 530 and BLM cells to growth inhibition by butanol is not due to 
differences in PLD1 expression.
PLD activity is differentially stimulated in metastatic and non-metastatic melanoma cells
Intact cells- To measure PLD activity, [3H]myristic acid labelled cells were incubated in the 
presence of 1% (v/v) ethanol for 30 min after which the lipids were extracted and the amount of
3 3[ H]PtdEth was determined. For normalization, the amount of radioactivity in [ H]PtdEth is 
expressed as percentage of the total amount of lipid-incorporated radioactivity. Figure 3 shows 
that basal PLD activity was low in both 530 and BLM cells but markedly increased following 
stimulation of PKC with the phorbol ester PMA. Importantly, the PMA-induced increase ino # # # #
[ H]PtdEth was significantly higher in BLM cells as compared to 530 cells.
Cell free system- Both PMA and GTPyS, a non-discriminatory activator of GTPases, can 
increase the activity of PLD in a cell free system (Exton, 1999; Liscovitch et al., 2000). It is 
generally accepted, that the phorbol ester acts through PKCa whereas RhoA and/or ARF mediate 
the stimulatory action of GTPyS. Here we examined the characteristics of PLD activition in a 
cell free system of two metastatic (MV3 and BLM) and two non-metastatic (530 and 1F6-L) 
melanoma cell lines. To this end, homogenates of cells labelled with [ H]myristic acid were 
stimulated with either PMA (1 ^M) or GTPyS (10 ^M) in the presence of 1% (v/v) ethanol for 
30 min after which the amount of [3H]PtdEth was determined. Figure 4 shows that similar
o  • •  •  •
amounts of [ H]PtdEth were generated in all four cell lines in the absence of any stimulus. Basal 
values for [ H]PtdEth production in homogenates of metastatic MV3 and BLM cells and non­
metastatic 530 and 1F6-L cells were 0.09% (S.E.M.=0.01; n=3), 0.13% (S.E.M.=0.02; n=8), 
0.11% (S.E.M.=0.05; n=9) and 0.10% (S.E.M.=0.02; n=8), respectively. PMA significantly 
increased the formation of [ H]PtdEth in all four cell lines. However, the PMA effect was 
considerably higher in the metastatic cells (6.0- and 4.3-fold in MV3 and BLM homogenates, 
respectively) as compared to the non-metastatic cells (2.5- and 2.3-fold in 530 and 1F6-L
M (kb)
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Figure 3. Increased PMA-induced PLD activation in metastatic human melanoma cells. BLM and 530 cells 
were cultured in the presence of [3H]myristic acid for 24 h. At the end of the labelling period, cells were 
stimulated with 1 |jM PMA in the presence of 1% (v/v) ethanol for 30 min. At the end of the stimulation period, 
the lipids were extracted, separated by thin layer chromatography and counted for radioactivity. PLD activity is 
expressed as the percentage of total lipid-incorporated label that is present in PtdEth. The data presented are the 
mean ± S.E.M. of 3 experiments. *Significantly different from PMA-stimulated 530 cells (P<0.05).
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Figure 4. Opposite effects o f PMA and GTPyS on PLD activity in a cell-free system of non-metastatic and 
metastatic human melanoma cells. Cells were labelled with [3H]myristic acid for 24 h and homogenized. For 
PLD measurements, aliquots were removed and incubated in the presence of 1% (v/v) ethanol and the absence 
(black bars) or presence of either PMA (0.1 |xM; grey bars) or GTPyS (10 |xM; white bars) for 30 min. At the end 
of the incubation period, the lipids were extracted, separated by thin layer chromatography and counted for 
radioactivity. PLD activity is expressed as the percentage of total lipid-incorporated label that is present in 
PtdEth. The data presented are the mean ± S.E.M. of 3-6 experiments. * Significantly different from the 
corresponding unstimulated homogenates (P<0.05). Significantly different from the corresponding PMA-treated 
homogenates (P<0.05).
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Figure 5. Differential expression of memB 
RNA in non-metastatic and metastatic 
human melanoma cells and their xenografts.
Northern blot analysis of total RNA extracted 
from a panel of human melanoma cell lines 
(A) and their xenografts (B). Lane 1, 530 
cells; lane 2, 1F6-L cells; lane 3, BLM cells 
and lane 4, MV3 cells. Blots were hybridized 
with probes for the 2.7 kb memB cDNA insert 
of pWT1. The molecular weight marker was 
XDNA digested with Hindll. For comparison, 
blots were hybridized with a probe for 18S 
ribosomal RNA.
homogenates, respectively). Similarly, GTPyS significantly increased the amount of [3H]PtdEth 
in all four cell lines. In the case of GTPyS, however, the increase was significantly higher in the 
non-metastatic cells (3.7- and 5.4-fold in 530 and 1F6-L homogenates, respectively) as compared 
to the metastatic cells (2.3- and 2.2-fold in MV3 and BLM cells, respectively).
Primary structure of human memB
Originally, the memB clone was isolated from a cDNA library derived from the human 
melanoma MV3 cell line (van Groningen et al., 1996). Here we report that the memB cDNA 
consists of 2745 nucleotides with a longest open reading frame, encoding a polypeptide of 245 
amino acids, starting at position 223 (not shown). The coding region o f memB proved to be 
identical to human mRNA for Rho8/Rnd3 (accession number X95282; Nobes et al, 1998). 
Moreover, comparison of the mRNA sequences shows that the earlier described RhoE protein 
(Foster et al, 1996; Guasch et al., 1998) starts at the second AUG codon (nucleotide position 
268) of the memB messenger and lacks the 15 NH2-terminal amino acids. It is noteworthy that 
the Kozak context of this second AUG is considerably better than that of the first AUG.
BLAST searches in the public EST databases demonstrated a high degree o f conservation of 
human memB (RhoE/Rho8/Rnd3): 100% identity with respect to that over the complete 
sequence of 245 amino acids and 93% identity (97% similarity) with respect to zebrafish over a 
peptide length of 152 amino acids starting from the second AUG. The corresponding degrees of 
conservation at the nucleotide level are 94% and 83%, respectively.
MemB is differentially expressed in metastatic and non-metastatic human melanoma cells
Northern blot analysis showed that the memB transcript is readily expressed in the highly 
metastatic human melanoma MV3 and BLM cell lines (Fig. 5A) and their xenografts (Fig. 5B).
In contrast, only trace amounts o f this transcript were found in non-metastatic human melanoma 
530 and 1F6-L cells and their xenografts (data not shown). In addition, no transcripts of the 
memB-related genes Rndl and Rnd2 were detected by RT-PCR in the melanoma cell lines used 
in this study (data not shown).
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Figure 6. Differential expression of memB protein in non-metastatic and metastatic human melanoma cells.
Cells, grown to 70% confluency, were washed with PBS and incubated overnight with Tran35S-label in culture 
medium without methionine and cysteine. Subsequently, memB was immunoprecipitated with a mixture of 6 
monoclonal antibodies bound to GammaBind-plus Sepharose beads. A small but specific band was detected at 
30 kDa in BLM and MV3 cells, but not in 530 and 1F6-L cells. The specificity of this band was demonstrated by 
its disappearance in the presence of excess recombinant memB (+) and absence of anti-memB antibody (bg). 
Data are representative of 3 independent experiments.
The differential expression of memB was confirmed by immunoprecipitation of the 
protein from lysates of 35S-labelled melanoma cells using a mixture of 6 anti-human memB 
monoclonal antibodies. Figure 6 shows the presence of a specific protein band between 25 
and 30 kDa in lysates from BLM (lane BLM) and MV3 (lane MV3), but not 530 (lane 530) 
and 1F6 (lane 1F6) cells. The specificity of the reaction is demonstrated by its disappearance 
in both the presence of excess recombinant memB (lanes +) or absence of anti-memB antibody 
(lanes bg).
PMA- and GTPyS-induced PLD activation are not changed in a metastatic cell line in which 
memB is downregulated
We previously reported the generation of a BLM cell line in which the memB transcript was 
downregulated following transfection with the adenovirus-5 E1A gene (van Groningen etal., 
1996). Here we used this cell line to investigate whether elevated levels of memB could explain 
the lower GTPyS-induced PLD activity in metastatic cells. Figure 7 shows that this maneuver 
did not increase in the stimulatory effect of GTPyS. Similarly, overexpression of memB did 
not affect the PMA-induced increase in [3H]PtdEth.
PKCa and £ are differentially expressed in metastatic and non-metastatic melanoma cells
It is well established that PKCa interacts with PLD to increase PLD activity (Exton, 1999; 
Frohman et al, 1999). Because the stimulatory effect of PMA was significantly higher in 
metastatic cells as compared to non-metastatic cells we used Western blotting to determine 
possible differences in PKCa expression between these two phenotypes. Figure 8A shows that 
the expression level of PKCa was markedly higher in BLM and MV3 cells, whereas, in contrast, 
that of PKCe was considerably higher 1F6-L and 530 cells.
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Figure 7. Downregulation o f memB is 
without effect on PMA-and GTPyS- 
induced PLD activation in a cell-free 
system of human melanoma cells. BLM- 
E1A cells, in which memB is 
downregulated by transfection with the 
adenovirus-5 E1A gene (van Groningen et 
al, 1996), were labelled with [3H]myristic 
acid for 24 h and homogenized. For PLD 
measurements, aliquots were removed and 
incubated in the presence of 1% (v/v) 
ethanol and the absence (black bars) or 
presence of either PMA (0.1 |xM; grey 
bars) or GTPyS (10 |xM; white bars) for 30 
min. At the end of the incubation period, 
the lipids were extracted, separated by thin 
layer chromatography and counted for 
radioactivity. PLD activity is expressed as the percentage of total lipid-incorporated label that is present in 
PtdEth. The data presented are the mean ± S.E.M. of 3 experiments. * Significantly different from the 
corresponding unstimulated homogenates (P<0.05). Significantly different from the corresponding PMA-treated 
homogenates (P<0.05).
PMA- and GTPyS-induced PLD activation are not changed in a non-metastatic cell line 
overexpressing PKCa
To investigate whether elevated levels of PKCa could explain the higher PMA-induced PLD 
activity in metastatic cells, a non-metastatic 530 cell line was generated that overexpressed 
bovine PKCa (Fig. 8B). Figure 9 shows that this maneuver did not significantly affect the PMA- 
induced increase in [ H]PtdEth. Similarly, overexpression of PKCa did not change the 
stimulatory action of GTPyS.
DISCUSSION
Originally, memB was isolated from a cDNA library derived from the human melanoma cell line 
MV3 (van Groningen et al, 1996). The isolation was performed by applying the differential 
mRNA display method to cell lines with different metastatic capacity and here we show that both 
the memB transcript and protein are indeed preferentially expressed in highly metastasizing 
melanoma cell lines and xenografts derived from these cell lines. In addition, we report that 
memB is identical to Rho8 (Nobes etal., 1998), also referred to as Rnd3, and RhoE (Foster et al., 
1996; Guasch et al., 1998) albeit that the latter protein lacks the 15 NH2-terminal amino acids of 
memB. The predicted amino acid sequence of memB shows strong similarity with that of 
members of the Rho family of small GTPases and the effector binding or switch I domain is 
completely conserved. On the other hand, memB differs from the common small GTPases in that 
it contains three amino acid residues that specifically confer oncogenicity to Ras. As a 
consequence memB lacks intrinsic GTPase activity and will be present in the GTP-bound form. 
These properties of memB make a reasonable case for its ability to interact with effector and/or
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Figure 8. Opposite expression 
levels of PKCa and PKCe in 
non-metastatic and metastatic 
human melanoma cells. Total 
cell lysates of non-metastatic 
530 and 1F6-L cells and 
metastatic BLM and MV3 
cells were subjected to SDS- 
PAGE. Proteins were 
transferred to polyvinylidine 
difluoride membranes by 
Western blotting and probed 
with either rabbit anti-PKCa 
or rabbit anti-PKCe. A. The 
relative expression of PKCa 
(upper panel) and PKCe 
(lower panel). B. A 530 cell 
line overexpressing PKCa. 
Mock-transfected cells (m) are 
added for comparison.
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Figure 9. Overexpression of 
PKCa is without effect on 
PMA- and GTPyS-induced 
PLD activation in a cell-free 
system o f non-metastatic 
human melanoma cells. 530- 
PKCa cells, overexpressing 
PKCa, were labelled with 
[3H]myristic acid for 24 h and 
homogenized. For PLD 
measurements, aliquots were 
removed and incubated in the 
presence of 1% (v/v) ethanol 
and the absence (black bars) or 
presence of either PMA (0.1 
|xM; grey bars) or GTPyS (10 
|xM; white bars) for 30 min. At
the end of the incubation period, the lipids were extracted, separated by thin layer chromatography and counted for 
radioactivity. PLD activity is expressed as the percentage of total lipid-incorporated label that is present in PtdEth. 
The data presented are the mean ± S.E.M. of 3 experiments. *Significantly different from the corresponding 
unstimulated homogenates (P<0.05). Significantly different from the corresponding PMA-treated homogenates 
(P<0.05).
530-PKCa
regulatory proteins of the Rho GTPases thus interfering with the normal function of these 
GTPases.
Tumor progression and metastasis are accompanied by a multitude of changes in gene 
expression. In most cases, however, the link between the differential gene activities and the 
newly acquired properties of the progressing tumor cell is unclear. PLD has been identified as
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one of the effector proteins of the Rho family of small GTPases (Bowman et al, 1993; 
Hammond etal., 1997; Exton, 1999; Yamazaki etal., 1999) and evidence has been provided that 
this interaction critically depends on the switch I region of these GTPases (Bae et al, 1998). 
Here we show that the rapidly growing metastatic cells are considerably more sensitive to growth 
inhibition by butanol than the slowly growing non-metastatic cells. Because butanol prevents the 
PLD-catalysed formation of phosphatidic acid it is postulated that the activity of this enzyme is 
markedly increased in melanoma cells displaying a high metastasizing potential. A similar 
inhibition of FCS-induced cell proliferation by 1-butanol, and to a lesser extent 2-butanol, was 
recently described for astroglial cells (Kotter and Klein, 1999). In a previous study, Reich etal. 
(1995) showed that 1-butanol inhibited the laminin-induced production of MMP-2 in metastatic 
cells but not in non-metastatic cells. This finding implicates PLD in the enhanced invasiveness of 
metastatic tumor cells.
Importantly, metastatic and non-metastatic human melanoma cells were shown to 
express similar amounts of PLD protein. This suggests that metastasis is associated with the 
increased action of one or more of the activatory PLD regulators. At first glance, memB is a good 
candidate to fulfil such a role. MemB might directly activate PLD or bind to Rho-GAP to inhibit 
the inactivation of Rho thus enhancing Rho-mediated PLD activation. In addition, memB might 
enhance the stimulatory effect of Rho proteins by binding to Rho-GDI thus facilitating the 
exchange of GDP for GTP. However, the present study shows that the activity of PLD in a cell- 
free system was not different between metastatic and non-metastatic cells. This demonstrates that 
memB does not interact with PLD in a stimulatory fashion. Moreover, the GTPyS-induced 
increase in PLD activity was even lower in a cell-free system obtained from metastatic cells. 
Obviously, this finding excludes an interaction between memB and Rho-GDI or Rho-GAP. 
Finally, the present observation that the GTPyS-induced increase in PLD activity remained 
unaltered in metastatic cells following down-regulation of memB (BLM-E1A cells; van 
Groningen et al, 1996) demonstrates that increased memB levels are not responsible for the 
decreased response to GTPyS. Similarly, the present finding that the GTPyS-induced increase in 
PLD activity was not changed in a cell-free system of non-metastatic cells overexpressing PKCa 
(530-PKCa cells) shows that a high expression of PKCa does not cause a decreased response to 
GTPyS.
The above conclusion that PLD activity is higher in metastatic cells as compared to non­
metastatic cells does not seem to be supported by the PLD activity measurements performed in 
intact cells. In these measurements, no difference in PLD activity was observed between 
metastatic and non-metastatic cells. However, it should be noted that these measurements, in 
contrast to those aimed to assess the effect of butanol on cell growth, were performed in medium 
without FCS. Together with the observation, that the PKC-induced increase in PLD activity was 
3-fold higher in metastatic cells as compared to non-metastatic cells, this suggests that metastatic 
cells show an increase in PLD activity only in the presence of a proper external stimulus. In other 
words, the postulated higher level of PLD activity in metastatic cells cannot be explained by the 
increased expression of an activatory PLD regulator alone. The idea that the difference in PLD 
activity between metastatic and non-metastatic cells is observed only in the presence of a proper 
stimulus is supported by the data obtained in studies using a broken cell preparation. As in intact 
cells, PKC-induced PLD activity was 2.5-fold higher in a broken cell preparation of metastatic 
cells. Taken together these findings suggest that metastatic cells grow faster in a medium 
containing stimuli that activate PLD through the action of PKC.
It is generally agreed that PKCa is the major PKC isoform involved in PKC-mediated 
PLD activation (Frohman et al, 1999). Here we show that the metastatic cells express 
considerably more PKCa than the non-metastatic cells. Recent evidence suggests that binding of 
diacylglycerol or phorbol ester is required for PKCa to activate PLD. This is consistent with the
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present observation that the difference in PLD activity between metastatic and non-metastatic 
cells is only observed in the presence of a proper stimulus. On the other hand, the non-metastatic 
cells contain considerably more PKCe than the metastatic cells. Recently, we (RR Bosch, AMP 
Patel, SE van Emst-de Vries, M Beetz, PCJ van der Hoeven, WJ van Blitterswijk, JJHHM De 
Pont and PHGM Willems, unpublished observations) and others (Kiss etal., 1999) have shown 
that overexpression of PKCe results in a marked inhibition of PMA-induced PLD activation. In 
this context, the postulated lower level of PLD activity in the non-metastatic cells can be 
explained in that the high amounts of PKCe inhibit the stimulatory action of an external factor 
present in the medium.
The present study shows that overexpression of PKCa in a non-metastatic cell line (530- 
PKCa cells) did not result in an enhancement of the PKC-mediated increase in PLD activity in a 
broken cell preparation. Obviously, this finding does not support the idea that increased 
expression of PKCa leads to an increase in PKC-mediated PLD activation. It might be argued 
that this negative finding indicates that the enhanced PKC-mediated increase in PLD activity 
observed in metastatic cells is due to the presence of memB. However, this idea is not supported 
by the present finding that the PKC-mediated increase in PLD activity remained unaltered in 
metastatic cells in which memB was downregulated (BLM-E1A cells; van Groningen et al., 
1996). Finally, because PKCa overexpression is not likely to affect PKCe expression (RR 
Bosch, AMP Patel, SE van Emst-de Vries, M Beetz, PCJ van der Hoeven, WJ van Blitterswijk, 
JJHHM De Pont and PHGM Willems, unpublished observations), it is still possible that the 
relative amount of PKCe is too high for PKCa to exert its stimulatory effect. Therefore, a better 
approach would be to first downregulate PKCe in the non-metastatic cells by using the antisense 
technique and then overexpress PKCa.
Correct functioning of the complex cellular signal transduction networks is highly 
dependent on delicate equilibria between the many components involved. We have described 
remarkable differences between PLD responses in metastatic and non-metastatic human 
melanoma cells. Subtle changes in the expression levels of PKCa and e, but possibly not memB, 
may be responsible for aberrant PLD behavior, putatively shifting many equilibria and causing 
multiple changes in downstream effects, which may eventually lead to metastasis.
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Many extracellular stimuli promote the enzymatic cleavage of membrane phospholipids to 
generate intracellular signaling molecules. An important enzyme in transmembrane signaling is 
phosphatidylcholine-specific phospholipase D (PLD), which catalyses the breakdown of 
phosphatidylcholine to yield phosphatidic acid (PtdOH) and choline (reviewed in Exton, 1999 
and Frohman ef al., 1999). Initially, PtdOH, produced by the action of PLD, was thought to be 
converted to DAG, a process catalyzed by PtdOH-phosphohydrolase, to cause long-term 
activation of PKC (Nishizuka, 1992). However, modern insights implicate PtdCho-derived 
PtdOH as an important messenger in regulated exocytosis, membrane delivery and vesicle 
budding (reviewed in Jones et al, 1999), cytoskeleton reorganization (reviewed in Liscovitch et 
al, 1999) and cell proliferation (reviewed in Daniel et al, 1999). PLD activity is routinely 
measured by taking advantage o f its characteristic feature to prefer primary short-chain alcohols 
to water in the catalysis reaction (Dawson, 1967; described in detail in Waite, 1999). The product 
formed in this transphosphatidylation reaction, phosphatidylalcohol, is a unique phospholipid 
that can be separated by thin layer chromatography for quantification. Using this method it has 
been demonstrated that almost all mammalian cells contain a regulated PLD activity (listed in 
Exton, 1999).
Role of PLC in regulated PLD activity
In recent years, in vivo studies provided circumstantial evidence for a role of PKC in regulated 
PLD activity. Thus, in many, but not all systems, agonist-induced PLD activation was found to 
be enhanced by PKC overexpression or inhibited by PKC inhibitors, prolonged phorbol ester 
treatment to downregulate novel and conventional PKC isozymes, or transfection with antisense 
cDNA to deplete PKC (summarized in Exton, 1999). PKC activity is increased by extracellular 
ligands that interact with cell surface receptors coupling to PLC to promote the generation of 
DAG. To demonstrate the involvement o f PLC in receptor-mediated PLD activation 
investigators make frequent use o f the aminosteroid U73122, which is documented to 
specifically inhibit this enzyme (Wu et al., 1992; Sugiyama et al., 1994; Zheng et al., 1994; 
Freeman et al., 1995). Here we demonstrate that both U73122 and its inactive analogue 
U73343 inhibit CCK8-induced PLD activation equipotently in CHO cells expressing the 
CCKa receptor (chapter 4). In addition, we show that both aminosteroids act downstream of 
PLC to exert their inhibitory effect on receptor-mediated PLD activation. In a cell-free 
system, U73122, but not U73343, inhibited both PMA/Ca2+-stimulated PLD activation and 
PMA/phosphatidylserine-stimulated PKC activation. This suggests that U73122 may act at 
the level o f PKC to inhibit activation o f PLD. On the other hand, this study did not provide 
information on the exact site o f action o f U73343. In conclusion, our findings show that 
U73122 cannot be used to investigate the involvement o f PLC in receptor-regulated PLD 
activation.
Importance of PKC in regulated PLD activity
The PKC family consists o f 12 isoforms that can be divided into 3 classes. The classical or 
conventional PKC-isotypes (a, Pi, Pn and y) which are stimulated by both Ca2+ and DAG; the 
novel isoforms (8 , e, n, 0 and ^) which are stimulated by DAG but Ca2+-insensitive; and the 
atypical isozymes (Z, ^ and l) o f which stimulating factors are not identified yet (Nishizuka, 
1995; Jaken, 1996; Hofmann, 1997). To date, PKCa is the best-characterized regulator of 
PLD activity in vivo. The PKC downregulation experiments described in chapter 2 confirmed 
such a role o f PKCa in CCK8-induced PLD activation in CHO cells expressing the CCKA 
receptor. The PKC inhibitor chelerythrine, known to act in a competitive fashion with respect
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to the phosphate acceptor (Herbert et al, 1990), completely inhibited CCK8-induced PLD 
activation. In contrast, staurosporine, which acts as competitive inhibitor at the ATP-binding 
site on PKC (Ruegg and Burgess, 1989), was unable to completely inhibit the stimulatory 
effect o f the hormone. These findings suggest that the greater part o f the receptor-mediated 
increase in PLD activity occurs in a phosphorylation-dependent manner. The smaller 
staurosporine-resistant part most probably reflects the ATP-independent PKC-mediated 
mechanism of PLD activation originally proposed by Conricode et al. (1992). This latter 
activity was only observed in case cytosolic calcium was elevated. This led us to propose that 
this ATP-independent pathway is activated by an increase in cytosolic calcium (chapter 2).
In most systems, inhibition o f PKC activity results in a partial or total inhibition of 
regulated PLD activity (Exton, 1994, 1999). In addition, PKC-independent pathways have 
been reported (Sandmann and Wurtman, 1991; Schmidt et al., 1994; Balboa and Insel, 1998; 
Singh et al., 1999). However, the latter idea is seriously questioned by the recent finding of 
Zhang et al. (1999) that a PKC-insensitive PLD mutant was not stimulated in vivo. O f note, 
this work was performed with a system in which PLD was previously reported to be activated 
in a PKC-independent manner. This is in agreement with our observation that the presence of 
PKC is required for the staurosporine-resistant PLD activity.
Some reports have suggested a role for PKCe in receptor-mediated PLD activity. For 
instance, in rat renal mesanglial cells angiotensin II-induced PLD activation was abolished 
after PKCe was downregulated (Pfeilschifter and Huwiler, 1993). However, here we show 
that overexpression o f PKCe inhibited PMA- and CCK8-induced PLD activity in CHO cells 
expressing the CCKA receptor (chapter 3). A similar observation was reached by Kiss et al. 
(1999). In contrast, overexpression o f PKCe failed to affect PMA-induced 
phosphatidylethanolamine breakdown in R6 rat fibroblasts and NIH 3T3 fibroblasts 
(Mukherjee et al., 1996). We showed that the inhibitory effect o f PKCe overexpression was 
not due to downregulation o f PLD, PKCa, RhoA or ARF6. From the observation that PMA- 
induced PLD activation was abolished following heterologous reconstitution (i.e. combination 
of cytosol o f PKCe overexpressing cells and membranes o f mock transfected cells), we 
tentatively concluded a direct interaction between PKCe and PLD. Thus far, attempts to co- 
immunoprecipitate these two proteins were not successful. In this context, it should be noted 
that co-immunoprecipitation o f PKCa and PLD has been proven to be problematic as well 
(Min and Exton, 1998). Only, in case o f NIH 3T3 cells this maneuver appeared to be 
successful (Lee et al., 1997). The inhibitory effect o f PKCe can be explained in two ways. 
One possibility is that PKCe binds to PLD thus hindering the binding o f PKCa. A second 
possibility is that PKCe phosphorylates PLD to decrease its activity and/or stimulatability by 
PKCa. However, the latter explanation seems to be excluded by the finding that PLD 
activation was reduced following overexpression o f either the regulatory domain fragment or 
the cysteine-rich zinc finger domain, but not the catalytic domain, o f PKCe in NIH 3T3 cells 
(Kiss etal., 1999).
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Role of cytosolic Ca2+ in regulated PLD activity
CCK8-induced PLD activation was shown to depend largely on the presence o f external Ca2+ 
(chapter 2). This suggests that receptor-mediated PKC activation in itself only marginally 
contributes to agonist-induced PLD activation. In agreement with this conclusion, low-level
PKC activation by a sub-optimal PMA concentration did not change basal PLD activity while
2+potentiating the stimulatory effect o f thapsigargin. The absence o f external Ca prevented
2+cytosolic Ca from being increased for prolonged periods o f time. It did not affect, however, 
the initial increase in cytosolic Ca2+ caused by the Ins(1,4,5)P3-induced release o f Ca2+ from
internal stores. This observation clearly demonstrates that a sustained increase in cytosolic
2+Ca is required for full activation o f PLD. Our study shows that CCK8, when added at a 
concentration o f 10 nM, increased PLD activity to a much higher extent than a saturating 
concentration o f 1 ^M PMA. In contrast, agonist and PMA displayed the same maximal effect 
in CHO-V1a (Garces et al., 1995) and CHO-PAF (Liu et al., 1994) cells. In view o f the
above discussion, this discrepancy might be explained by the higher amplitude o f the
2+sustained increase in cytosolic Ca in CHO-CCKA cells as compared to CHO-V1a cells. 
Taken together, our data are compatible with the idea that in CHO-CCKA cells receptor- 
mediated PLD activation is completely dependent on PKC but that the extent to which PLD
becomes activated depends largely, if  not entirely, on the magnitude and duration o f the
2+agonist-induced increase in cytosolic Ca .
Involvement ofRacl in regulated PLD activity
Small GTPases are distributed widely in eukaryotic cells and elucidation o f their regulation 
and roles in cell function is a challenge in modern cell biology. The involvement o f members 
of the ADP-ribosylating factor (ARF) and Rho families o f small GTPases in regulated PLD 
activity was demonstrated by the use o f Brefeldin A and botulinum C3 exozyme, inhibitors of 
ARF and Rho, respectively, or by transfection with interfering mutants (Rumenapp et al., 
1995; Malcolm et al., 1996a, b, Mitchell, 1998; Zhang et al., 1999). Using a homogenate of 
CHO cells we showed the presence o f a GTPyS-stimulatable PLD activity (chapter 5). This 
effect o f GTPyS is generally believed to reflect the action o f small GTPases. PLD activity was 
also increased by PMA and the effects o f both stimuli were synergistic. Importantly, 
downregulation o f PKC did not affect the response to GTPyS. This shows that small GTPases 
can activate PLD in a PKC-independent manner. Therefore, the finding that CCK8-stimulated
PLD activity is abolished in PKC-depleted CHO-CCKA cells led to the conclusion that small
2+GTPases, if  involved at all, act in a synergistic manner with PKC and Ca in receptor- 
mediated PLD activation.
Overexpression o f a dominant negative form of the Rho family member Rac1 (Rac1- 
N17) completely inhibited EGF-mediated PLD activity in Rat1 fibroblasts (Hess et al., 1997). 
In contrast, stimulation with PDGF was not affected by this Rac1 mutant. In chapter 5, we 
demonstrated that signaling through the CCKA receptor was also not affected upon 
overexpression o f dominant negative Rac1. However, overexpression o f constitutively active 
Rac1 (Rac1-V12) significantly reduced receptor-mediated PLD activation in CHO-CCKA 
cells. Recent work showed that Ca2+ mobilizing G-protein-coupled receptors (GPCRs) that 
increase PLD activity in an ARF- and RhoA-dependent manner form functional complexes 
with these small GTPases on ligand binding in human astrocytoma cells (Mitchell et al., 
1998). Moreover, mutational analysis revealed that the presence o f a NPXXY motif in the 
seventh transmembrane domain o f the GPCR is a prerequisite for agonist-induced complex 
formation and PLD activation. The rat CCKA receptor contains the NPXXY motif, suggesting 
that CCK8 increases PLD activity in an ARF- and RhoA-dependent manner. The finding that 
CCK8-induced PLD activation is reduced in CHO-CCKA cells overexpressing Rac1-V12
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together with the given that Racl is less efficacious than RhoA in activating PLD (Siddiqi et 
al, 1995) provides a rationale to propose that constitutively active Rac1-V12 competes with 
RhoA to form a functional complex with the CCKA receptor on CCK8 binding. The Rac1-V12 
complex is less efficacious than the RhoA complex in activating PLD thus explaining the 
reduced CCK8-induced increase in PLD activity. Overexpression of Rac1-V12 did not affect 
the increase in PLD activity in response to PMA and thapsigargin. This is consistent with the 
proposal that Rac1-V12 does not exert its effect downstream of the CCKA receptor. 
Intriguingly, inhibition of Rac1-V12 was removed following overexpression of Rac1-V12 in 
CHO cells expressing a CCKA receptor engineered to have mutations in the four potential 
sites for PKC phosphorylation. This receptor mutant is not phosphorylated in response to CCK8 
(Rao et al, 1997). According to the above model, this finding suggests that phosphorylation of 
key PKC sites on the receptor is required for Rac1-V12 to compete with RhoA to form a 
functional complex with the CCKA receptor (Fig. 1). From a regulatory point of view, it is 
tempting to speculate that factors other than CCK8 activate endogenous Rac1 to promote the 
formation of Rac1/CCKA receptor complexes during CCK8 stimulation thus attenuating CCK8- 
induced PLD activation (heterologous desensitization).
High affinity CCKA receptor Low affinity CCKA receptor
Figure 1. Possible involvement of Rac1 in h e  mechanism of PLD activation by CCK. 
For details see text.
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Possible involvement R-Ras/Ral signaling in regulated PLD acitivity
In addition to Rac1, RalA has been implicated in agonist-induced PLD activation (Jiang et al., 
1995; Schmidt et al., 1998). RalA does not stimulate PLD activity by itself but forms a 
complex with ARF and PLD in the presence of GTPDS (Luo et al., 1997, 1998; Kim et al., 
1998). R-Ras has been shown to interact with RalA-GEF (Wittinghofer and Nassar, 1996). To 
investigate the possibility that R-Ras acts through Ral to modulate ARF-mediated PLD 
activation, we studied the effect of interfering R-Ras mutants on CCK8-induced PLD 
activation in CHO-CCKA cells. It was found that neither constitutively active R-Ras-V38 nor 
dominant negative R-Ras-N43 affected the increase in PLD activity in response to CCK8 
(data not shown). This result is in agreement with the finding that the interaction of R-Ras 
with RalA-GEF does not increase the activity of RalA. However, despite of the lack of effect
of R-Ras on CCK8-induced PLD activation, marked effects of R-Ras-V38 overexpression on
2+CCK8-induced Ca mobilization were observed (chapter 6). The major finding was that 
CHO-CCKa cells overexpressing constitutively active R-Ras displayed a higher rate of Ca2+
removal from the cytosol following maximal CCK8 stimulation. The same observation was
2+reached when cytosolic Ca was increased with thapsigargin. This latter finding excludes the 
possibility that R-Ras-V38 acts by increasing Ca2+ uptake via the endoplasmic reticulum Ca2+
ATPase (SERCA). Thus far, we have two explanations for this finding. First, R-Ras-V38
2+overexpression increases Ca extrusion across the plasma membrane. Second, R-Ras-V38 
overexpression might increase mitochondrial Ca2+ uptake. With respect to the latter 
explanation, it has been shown that R-Ras can associate with the anti-apoptosis protein Bcl-2 
(Fernandez-Sarabia and Bischoff, 1993) and that Bcl-2 is capable of increasing mitochondrial
Ca2+ sequestration (Zhu et al., 1999). At present, however, we do not know whether the latter
2+effect of R-Ras underlies its effect on cytosolic Ca removal.
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Initially, the presence and subcellular localization o f PLD activity was demonstrated using the 
transphosphatidylation reaction. PLD activity was detected in a wide variety o f different 
tissues and cell types, with the exception o f peripheral leukocytes and some lymphocyte cell 
lines (Meier etal., 1999). In addition, subcellular centrifugation studies showed the presence 
of PLD activity in plasma membrane, cytosol and different organelles such as Golgi, nucleus 
and endoplasmic reticulum (Wang et al., 1991; Ktistakis et al., 1995; Whatmore etal., 1996; 
Banno etal., 1997). The work presented in this thesis shows the presence o f agonist-induced 
PLD activity in CHO cells (chapters 2-5) and primary cultures o f rabbit cortical collecting 
system (chapter 8). In addition, we showed the presence o f PMA-induced PLD activity in 
human melanoma cells (chapter 9) and freshly isolated rat pancreatic acinar cells (chapter 
7). In the latter cell type, PLD activity was not activated by CCK8, whereas this hormone 
readily increased the activity o f this enzyme in CHO-CCKA cells.
The recent cloning o f various PLD isoforms allowed to use RT-PCR and Northern blot 
analysis to detect the expression o f PLD. At present, two isoforms have been cloned 
designated PLD1 (Hammond etal., 1995) and PLD2 (Colley eta l., 1997). PLD1 is subject to 
alternative splicing yielding PLD1a and PLD1b, which lacks 38 amino acids (Hammond et 
al., 1997). In the majority o f tissues and cell lines, PLD1b has been shown to predominate 
(Meier etal., 1999). Accordingly, we observed mRNA transcripts o f PLD1b in CHO cells 
(chapter 7), rat pancreatic acinar cells (chapter 7), rabbit cortical collecting system cells 
(chapter 8), human melanoma cells (chapter 9) and, as a reference, rat brain. PLD1a was 
detected only in rat brain and the human melanoma cell lines. Using primers to amplify PLD2 
fragments, we detected its presence in rat brain and acinar cells and in rabbit cortical 
collecting system cells but not in CHO cells. In contrast to PLD1, PLD2 contains a very high 
basal activity that is not further increased by PKCa, RhoA or ARF. Because in this thesis we 
focused on regulated PLD activity and the possible roles o f PKC, Ca2+ and the small GTPases 
therein, it is highly likely that we dealt with PLD1 rather than PLD2.
Until very recently no workable anti-PLD antibodies were available. This hampered 
the demonstration o f the presence o f PLD protein. In this thesis we used a newly developed 
anti-PLD-antibody directed against the C- and N-terminal sequences of human PLD1 
(Muller-Wieprecht et al, 1998). Western blot analysis revealed the presence o f PLD1 in 
CHO-cells (chapter 3), rat pancreatic acinar cells (chapter 7), rabbit cortical collecting 
system cells (chapter 8) and human melanoma cells (chapter 9). Moreover, using this 
antibody we were able to demonstrate that PLD1 was predominantly present in the membrane 
fraction o f CHO cells, whereas in pancreatic acinar cells it was mainly present in the cytosol 
(chapter 7). Stimulus-induced translocation o f GFP-PLD1b to the plasma membrane was 
observed in rat basophilic leukemia cells (Brown etal., 1998). However, PMA did not evoke 
such a translocation o f PLD1 in intact acinar cells . Moreover, the combination o f GTPyS and 
PMA, which did not increase PLD activity in an acinar cell homogenate, did also not induce 
PLD translocation in this system. These findings have been interpreted as evidence that the 
inability o f CCK8 to increase PLD activity in these cells is due to its inability to recruite 
PLD1 from the cytosol to the membrane.
EXPRESSION AND LOCALIZATION OF PHOSPHOLIPASE D
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As discussed above, it is believed that PLD generates PtdOH that is converted into DAG to 
activate PKC, which, on its turn, promotes the expression o f transcriptional genes leading to 
cell proliferation. Alternatively, it has been suggested that PtdOH itself can act as second 
messenger. However, in vivo evidence for the regulation o f cellular activities by PtdOH is 
minimal (Cockcroft, 1996a; Singer et al., 1997). PLD has been implicated in membrane 
trafficking and cytoskeletal remodeling and some authors have suggested that these effects of 
the enzyme may be related to the ability o f PtdOH to increase the activity o f PIP 5-kinase, an 
enzyme needed for PIP2 synthesis (Moritz et al, 1992). PIP2, on its turn, is essential in 
membrane trafficking (Cockcroft, 1998). In addition, it is a physiological regulator o f  
cytoskeletal dynamics (Takenawa et al, 1999), although its precise role remains elusive. An 
attractive hypothesis is that PIP2 serves as a molecular glue that allows the formation of 
protein complexes as it interacts with proteins containing pleckstrin homology (PH) domains 
or phosphotyrosine binding (PTB) domains thus localizing these proteins to the membrane. 
The central role for phosphoinositides in membrane trafficking and stress fiber formation 
would explain the wide spectrum of PLD regulators.
Involvement of PLD in CCKg-induced DAG production in pancreatic acinar cells
The production o f DAG upon stimulation with hormones is biphasic by nature (Nishizuka,
1992). A small transient increase is followed by a larger sustained increase. The first and 
transient increase in mass DAG was found to coincide with the rapid and transient increase in 
mass Ins(1,4,5)P3 suggesting that this DAG was formed by the action o f PLC (Berridge,
1993). Because, the second and sustained increase in mass DAG was not paralleled by an 
increase in mass Ins(1,4,5)P3, the involvement o f another enzyme was concluded. Molecular 
species analysis o f the major phospholipids and DAGs provided evidence that both PtdCho 
and inositolphospholipids are hydrolyzed during prolonged stimulation o f rabbit panceratic 
acini with CCK8 (Hermans et al., 1996). The conversion of PtdCho into DAG can be 
mediated by either a PtdCho-specific PLC or, as already mentioned above, by PtdCho- 
specific PLD. Evidence that CCK8 can activate pancreatic acinar PLD was provided by 
Morisset and co-workers (Rydzewska et al., 1993; Rivard et al., 1994; Rydzewska and 
Morisset, 1995). However, in another series o f experiments the presence o f CCK-regulated 
PLD activity was seriously questioned (Matozaki et al., 1990, 1991). Because, PLD has been 
implicated in regulated exocytosis (Jones et al., 1999), we found it important to unequivocally 
demonstrate the presence of secretagogue-regulated PLD activity in these cells. Using 
ortho[32P]phosphate we showed that CCK8 significantly increased the amounts o f [32P]PtdOH
32 32and [32P]phosphatidylinositol without affecting, however, the formation o f [32P]PtdEth in
intact rat pancreatic acinar cells (chapter 7). This demonstrates that CCK8 works and
activates the phosphatidylinositol-specific PLC and not PtdCho-specific PLD. Therefore, the
observation that PtdCho hydrolysis contributes to the sustained DAG formation cannot be
ascribed to PtdCho-specific PLD but rather suggests the involvement o f PtdCho-specific PLC.
Role of PLD in cell proliferation and/or metastasis
It speaks for itself to believe that the main physiological function o f PLD is maintenance o f  
the structural integrity o f cellular membranes. Although such a role o f PLD as housekeeping 
enzyme is commonly accepted, evidence that PLD plays a role in a multitude o f other cellular 
activities is vast, but largely indirect. Many papers suggest the involvement o f PLD in a wide 
variety o f cellular activities including cell signaling, vesicle formation and trafficking,
CURRENT VIEW ON THE PHYSIOLOGICAL ROLE OF PHOSPHOLIPASE D
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secretion, inflammation, tissue damage, respiratory burst, DNA synthesis, cell proliferation 
and differentiation and actin assembly (Gomez-Cambronero et al., 1998). An intriguing 
finding is that PKC, RhoA and ARF, which play a crucial role in cell signaling and/or 
vesicular transport, stimulate PLD. However, it remains a challenge to elucidate the precise 
role o f PLD in the above-mentioned cellular events. At present, there are no reports showing 
the effect o f PLD inhibitors, PLD downregulation or PLD mutants on a particular cellular 
activity, with the exception of yeast PLD (Spo14p). Mutation o f Spo14p revealed that in this 
system PLD is essential for the induction o f meiosis (Rose etal., 1995; Sciorra etal., 1999). 
Similar studies in mammalian cells will eventually reveal the physiological significance o f  
PLD.
At present, the majority o f evidence favoring a role o f PLD in the processes listed 
above comes from experiments employing small primary alcohols (Cross et al., 1996; Singer 
et al., 1997; Nakashima and Nozawa, 1999). The underlying principle is that in the presence 
of these alcohols instead o f PtdOH a phosphatidylalcohol is formed, which is inert. Chapter 7 
shows that 1-butanol dose-dependently inhibits growth o f human melanoma cells. This is in 
agreement with other reports suggesting a relationship between PLD activity and cell 
proliferation (Mollinedo et al., 1994; Cesnjaj et al., 1995; Nakashima and Nozawa, 1999; 
Kotter and Klein, 1999). In these studies it was observed that 1-butanol lowered the hormone- 
induced expression o f transcriptional factors such as c-fos and c-jun. Moreover, in some of 
these studies similar effects were reached with inhibitors o f the enzyme PtdOH- 
phosphohydrolase, which converts PtdOH into diacylglycerol. These latter results clearly 
indicate a role o f PKC. Evidence for the involvement o f this kinase in PLD-mediated growth 
comes from the finding that senescent fibroblasts with a severely diminished PLD activity 
displayed both a low diacylglycerol content and markedly reduced transcription o f c-fos 
(Venable and Obeid, 1999). Taken together, these findings suggest that diacylglycerol 
produced via the PLD/PtdOH-phosphohydrolase pathway acts through PKC to promote the 
expression o f transcriptional genes.
The important finding o f chapter 7 is that metastatic human melanoma cells proved to 
be considerably less sensitive to inhibition o f growth by 1-butanol than cells with a low  
metastatic potential. Furthermore, it was observed that activation o f PKC by the phorbol ester 
PMA increased the activity o f PLD to a much higher extent in metastatic cells than non­
metastatic cells. In the first experiment cells were grown in the presence o f FCS whereas in 
the latter experiment FCS was omitted from the medium. Therefore, these findings are 
compatible with the idea that stimulated metastatic cells display a higher PLD activity than 
stimulated non-metastatic cells. Because metastatic and non-metastatic cells were found to 
express similar amounts of PLD1 these observations suggest the increased action o f some 
intracellular PLD modulator in stimulated metastatic cells. This idea was supported by the 
finding that PMA-induced PLD activity was significantly higher in a cell-free system of these 
latter cells as compared to non-metastatic cells. In agreement with this latter finding PKCa 
was shown to be upregulated in metastatic cells whereas PKCe, believed to inhibit PLD 
activity (chapter 3), was found to be upregulated in non-metastatic cells. Taken together, 
these findings suggest that when cultured in the presence o f growth stimulating hormones 
metastatic cells grow faster than non-metastatic cells because they express more PKCa and 
less PKCe and therefore display a higher PLD activity and consequent PKC-mediated 
induction o f transcriptional factors. Thus far, initial experiments to test this idea did not give a 
clear answer. For instance, 'restoration' o f the PKCa level by means o f an overexpression 
technique did not increase PMA-induced PLD activation in a cell-free system of non­
metastatic cells. However, it should be taken into account that PKCe expression was still high 
in these cells. The effect o f PKCa overexpression on cell growth and sensitivity o f cell
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growth to inhibition by 1-butanol has not been tested yet. Therefore, it is still possible that 
PKCa overexpression does affect cell growth and that the difference in PMA-induced PLD 
activation between metastatic and non-metastatic cells is not related to this but to some other 
cellular activity.
In addition to PKCa, metastatic cells displayed increased expression levels o f the 
Rho-like small GTP-binding protein memB (also referred to as Rho8 or Rnd3). MemB differs 
from RhoE in that the latter protein lacks the 15 NH2-terminal amino acids. Importantly, 
memB has no intrinsic GTPase activity and is therefore permanently present in the GTP- 
bound or active state (Foster et al., 1996; Nobes et al., 1998). Rho proteins, in particular 
RhoA, have been shown to activate PLD in vitro and have therefore been implicated in 
regulated PLD activity (Exton, 1999). MemB shares the complete amino acid sequence o f the 
effector domain o f RhoA and recent studies have provided evidence that this domain is 
involved in the binding o f PLD (Bae et al., 1998). Based on these findings, it is postulated 
that increased expression o f MemB interferes with normal RhoA functioning. The present 
finding that PLD activity was not increased in a cell-free system of metastatic cells as 
compared to non-metastatic cells excludes the possibility that memB-GTP interacts with PLD 
to increase its activity. Intriguingly, GTPyS-induced PLD activation was reduced in a cell-free 
system of metastatic cells. This might suggest that memB-GTP interacts with either PLD, to 
prevent association o f and activation by RhoA-GTP, or RhoA-GDI and/or RhoA-GEF, to 
inhibit GDP/GTP-exchange on RhoA. In accordance with this idea, other researchers 
suggested that RhoE (memB) inhibits RhoA-regulated responses in a competitive manner 
(Guasch et al., 1998). However, preliminary experiments with recombinant memB did not 
give a clear result. Moreover, GTPyS-induced PLD activation was not 'restored' in metastatic 
cells in which memB was downregulated following transfection with the adenovirus-5 E1A  
gene. Here it is important to note that this latter maneuver resulted in the downregulation of 
multiple melanoma-associated progression markers (van Groningen etal., 1996). This might 
suggest that the difference in GTPyS-induced PLD activation is not directly related to 
differences in metastatic potential. A role o f PLD in tumor progression was suggested by the 
finding that transformation o f NIH3T3 cells with the oncogenes v-Src or v-Ras increased 
PLD activity (Song and Foster, 1993; Luo etal., 1997). PLD activity was also increased in 
gastric carcinoma and colon cancer tissue as compared to adjacent non-cancerous tissue 
(Yoshida etal., 1998; Uchida etal., 1999). Based on these findings these authors implicated 
increased levels o f PLD activity in tumor progression. As far as cells with a different 
metastatic potential are concerned, we show here that a difference in PLD activity is observed 
only in the stimulated situation.
Taken together, the observations reported in chapter 7 are compatible with a model in which 
increased expression o f proteins can contribute to metastatic features by altering the 
consequences o f signaling events induced by hormones and growth factors.
Role of PLD in regulated Ca2+ reabsorption in the rabbit kidney
In addition to a possible role o f PLD in proliferation and metastasis o f human melanoma cells
2+we investigated the involvement o f the enzyme in the regulation o f active Ca transport in the 
cortical collecting system of rabbit kidney (chapter 6). It was suggested that PLD activity 
was required to generate diacylglycerols for PKC-dependent Ca2+ reabsorption (Friedman et
al., 1999). This suggestion was based on the observation that parathyroid hormone readily
2+increased Ca transport and diacylglycerol formation in mouse kidney cells under conditions 
that PLCP was inhibited. The best-characterized function o f agonist-induced diacylglycerol 
formation is to activate PKC. Because the diacylglycerols generated through the action of
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may activate different PKC isoforms (Hodgkin et al., 1998). In earlier studies we
2+demonstrated that hormone-stimulated Ca reabsorption involves a phorbol ester-insensitive
2+PKC isoform, whereas hormone-inhibited Ca reabsorption involves a phorbol ester-sensitive 
PKC isoform (Koster e ta l., 1996; Hoenderop etal., 1999b). Therefore, we investigated the 
possibility that PLD may be selectively activated by either the stimulatory or the inhibitory 
hormones thus providing a mechanism for the differential activation of phorbol ester-
insensitive and -sensitive PKC isoforms by these hormones. However, we observed that both
2+stimulatory and inhibitory hormones for Ca reabsorption increase PLD activity thus 
disfavoring the idea that activation of the enzyme plays a role in the mechanism of differential 
PKC isoform activation. At present, the physiological relevance of PLD activation in the 
cortical collecting system is unclear and awaits further investigation.
In conclusion, this thesis dealt with the regulation and possible role of PLD in different
2+systems. We demonstrated the importance of Ca , PKC and small GTPases during hormone­
regulated PLD activity in Chinese hamster ovary cells. Additionally, we analyzed the 
involvement of PLD in different physiological systems.
PLC and PLD have been reported to differ in fatty acid composition, it is very likely that they
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Het onderzoek beschreven in dit proefschrift had tot doel de vraag te beantwoorden 
hoe hormonen, in het bijzonder cholecystokinine (CCK), in verschillende celtypen het enzym 
fosfolipase D (PLD) activeren. PLD katalyseert de hydrolyse van fosfatidylcholine in 
fosfatidezuur en choline. Binding van CCK aan zijn specifieke G-eiwit-gekoppelde receptor 
stimuleert de productie van diacyl glycerol (DAG), de fysiologische activator van proteïne 
kinase C (PKC). Onderzoek toonde aan dat het geproduceerde DAG na stimulatie van 
acineuze cellen uit de pancreas met CCK voor een belangrijk deel afkomstig is van 
fosfatidylcholine, het substraat van PLD. Daarom heeft dit onderzoek zich gericht op de 
karakterisering van het enzym PLD. Dit heeft op drie niveaus plaatsgevonden. Ten eerste is 
een Chinese Hamster Ovary (CHO) cel gebruikt, waarin de CCKA-receptor stabiel tot 
expressie was gebracht. Ten tweede, is de regulatie van PLD in meer fysiologische systemen 
onderzocht. Hiertoe is gebruik gemaakt van vers-geïsoleerde acineuze cellen van de pancreas 
en een primaire celkweek van cellen afkomstig uit de verbindingsbuis en het corticale 
gedeelte van de verzamelbuis van de konijnennier. Tenslotte is de betrokkenheid van PLD 
onderzocht bij een pathofysiologisch proces. Hiervoor werd gebruik gemaakt van een panel 
van tumorcellijnen die sterk varieerden in hun metastaserende capaciteit. De relatie tussen de 
PLD-activiteit en de mate van tumorprogressie is hierbij vastgesteld.
Het belangrijkste hulpmiddel dat gebruikt is om de PLD-activiteit te bestuderen is de 
eigenschap van PLD om in aanwezigheid van primaire alcoholen, een 
transfosfatidyleringsreactie te katalyseren. PLD katalyseert onder fysiologische condities de 
hydrolyse van fosfatidylcholine in fosfatidezuur en choline. Echter, in aanwezigheid van 
primaire alcoholen, wordt in plaats van fosfatidezuur, een fosfatidylalcohol gevormd. De 
vorming van fosfatidylalcoholen is uniek voor PLD en diende als maat voor de activiteit van 
dit enzym.
In hoofdstuk 2 staat beschreven op welke wijze intracellulaire calciumionen en PKC 
betrokken zijn bij de door CCK gestimuleerde activatie van PLD. In CHO-cellen waarin de 
CCKA-receptor tot expressie was gebracht, werd aangetoond, dat de PKCa-isoform een 
essentiële rol speelt bij de stimulatie van PLD door het hormoon. Langdurige behandeling met 
forbolesters leidt tot de proteolytische afbraak van PKC-isotypes die gevoelig zijn voor 
diacyl glycerol. Na drie uur behandeling met een bepaalde forbolester (PMA) is PKCa 
volledig afgebroken en blijkt CCK niet langer in staat te zijn om PLD te activeren. Bij 
kortdurende behandeling (10 min) met PMA wordt PKC echter geactiveerd. Het bleek dat de 
forbolester het enzym PLD slechts gedeeltelijk kon activeren vergeleken met de met CCK 
verkregen respons. Dit impliceert dat ondanks de essentiële rol voor PKCa, CCK via een 
additionele route het stimulerend effect van PKCa op PLD potentïeert. Deze additionele route 
blijkt via intracellulaire calciumionen te verlopen. Onder condities waarbij extracellulair 
calciumionen afwezig zijn, is de intracellulaire calciumconcentratie na stimulatie met CCK 
slechts tijdelijk verhoogd. Het bleek nu dat onder deze omstandigheden de capaciteit van 
CCK om PLD te activeren met bijna 90% was afgenomen, wat er op duidt dat PLD actief is 
zolang de intracellulaire calciumconcentratie verhoogd is. Samengevat, CCK activeert PLD 
met tussenkomst van PKCa; echter de mate van activiteit van PLD wordt bepaald door de 
tijdsduur waarin de calciumconcentratie in de cel is verhoogd.
Zoals beschreven is in hoofdstuk 9 blijkt in niet-metastaserende, t.o.v. 
metastaserende, melanomen de expressie van PKCe te zijn verhoogd. Daarentegen blijkt in 
metastaserende vergeleken met niet-metastaserende melanomen de expressie van PKCa te 
zijn verhoogd. Parallel hieraan kon PMA de PLD activiteit in de metastaserende melanomen 
drie keer beter stimuleren dan in niet-metastaserende cellen. Daarom is in hoofdstuk 3 zowel 
PKCa als PKCs specifiek tot overexpressie gebracht in de CHO-cellijn. Vervolgens is
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bestudeerd of er een verandering werd waargenomen in de door het hormoon geïnduceerde 
activatie van PLD. Het bleek dat de verbindingen CCK, PMA en thapsigargine, dat de 
calciumconcentratie in het cytosol verhoogt, PLD minder konden activeren wanneer er een 
overmaat aan PKCs aanwezig was. Deze activiteitsverlaging was niet te wijten aan een 
verlaagde eiwitexpressie van PLD of PKCa. Uit de literatuur blijkt dat naast PKCa ook 
monomere G-eiwitten en in het bijzonder Rho- en ARF-gerelateerde eiwitten betrokken zijn 
bij stimulatie van PLD. Daarom werd onderzocht of de expressie van de kleine G-eiwitten 
RhoA en ARF6 veranderd was. Dit bleek niet het geval te zijn. Bovendien bleek GTPyS, een 
stimulator van alle G-eiwitten, in homogenaten van cellen met een verhoogde expressie van 
PKCs, PLD in dezelfde mate te activeren als in controlecellen. De door PMA geïnduceerde 
activiteit van PLD werd ook geremd als de membraanfractie van controlecellen vervangen 
was door die van cellen waarin PKCe tot overexpressie was gebracht. Hetzelfde geschiedde 
als aan membranen van controlecellen de cytosolfractie van cellen waarin PKCe tot overex­
pressie was gebracht. Mogelijk bezet PKCs de bindingsplaats van PKCa op PLD en remt op 
een dergelijke wijze de stimulatie van PLD door PKCa. Deze bevindingen kunnen mogelijk 
ook verklaren waarom een lagere forbolester geïnduceerde activatie van PLD wordt gemeten 
in melanomen met een lage metastaserende capaciteit.
Fosfolipase C (PLC) katalyseert de omzetting van fosfatidylinositol-4,5-bisfosfaat in 
zowel inositol-1,4,5-trisfosfaat, dat calciumionen vrijmaakt uit intracellulaire opslagplaatsen, 
als in DAG, de activator van PKC. Daar de door CCK geïnduceerde activatie van PLD in 
CHO cellen in sterke mate afhankelijk is van calcium en PKC werd de activiteit van PLC 
geremd met het aminosteroïde U73122, dat in de literatuur beschreven was als een specifieke 
remmer van het PLC. De inactive controle voor U73122 is U73343. Hoofdstuk 4 laat zien dat 
beide aminosteroïden even effectief de door CCK gestimuleerde activatie van PLD in CHO­
cellen remmen. Bovendien bleek dat stimulatie van PLD door zowel de forbolester als 
thapsigargine, die beide PLD stimuleren zonder tussenkomst van PLC, ook waren geremd. 
Dit leidde tot de conclusie dat de veel gebruikte aminosteroïden ongeschikt zijn om de 
betrokkenheid van PLC bij dit soort processen te bestuderen.
In hoofdstuk 5 is onderzocht of Rac1, afkomstig uit de familie van Rho- eiwitten, 
betrokken is bij de door CCK-geïnduceerde activatie van PLD. Daartoe is zowel een 
dominant-negatieve (N17) als een constitutief-actieve (V12) Rac1-mutant tot overexpressie 
gebracht in de CHO-cellijn. Het bleek dat de Rac1-N17-mutant niet in staat was om de door 
het hormoon geïnduceerde activatie van PLD te remmen. Dit suggereert dat Rac1 niet direct 
betrokken is bij de regulatie van PLD door het hormoon CCK. Echter, de door CCK 
gestimuleerde activatie van PLD werd wel geremd wanneer Rac1-V12 tot overexpressie werd 
gebracht. In de literatuur staat beschreven dat G-eiwit gekoppelde receptoren die een 
NPXXY-motief bezitten, in staat zijn om met RhoA en ARF te een complex te vormen dat 
vervolgens PLD kan activeren. Het gegeven dat de CCKA-receptor hetzelfde motief bevat 
suggereert dat ook de CCKA-receptor een complex met RhoA en ARF vormt. Het feit dat 
Rac1 een minder goede activator is dan RhoA bij de stimulatie van PLD leidt tot de hypothese 
dat Rac1-V12 in staat is met RhoA te competeren bij de complexvorming. Op deze wijze 
ontstaat er een minder efficiënt complex tussen CCKA, Rac1-V12 en ARF. Een additionele 
interessante bevinding was dat de verminderde PLD-activatie door CCK8 niet optrad wanneer 
constitutief-actief Rac1 tot expressie werd gebracht in een CHO-cellijn waarin een CCK- 
receptor aanwezig is, die niet door PKC kan worden gefosforyleerd. De CCKA-receptor komt 
zowel voor in een niet-gefosforyleerde als in een gefosforyleerde vorm. Activatie van de 
CCK-receptor induceert activatie van PKC dat vervolgens de receptor fosforyleert en daarmee 
deze minder gevoelig maakt voor het hormoon CCK. Op deze manier beschermt de cel 
zichzelf tegen overstimulatie. Wanneer een mutante receptor, die louter in de niet- 
gefosforyleerde toestand voorkomt, tot expressie werd gebracht bleek Rac1 niet in staat te zijn
164
Chapter 11
om te competeren met RhoA omdat er geen remming meer werd gemeten. Deze gegevens 
suggereren dat Rac1-V12 alleen kan competeren met RhoA in de complexvorming als de 
receptor in de gefosforyleerde vorm voorkomt.
Een ander klein G-eiwit dat mogelijk betrokken is bij de regulatie van PLD activiteit is 
R-Ras. Dit homologe eiwit van Ras kan een complex vormen met Ral-GEF, dat Ral activeert. 
Een aantal publicaties toonde aan dat Ral betrokken is bij de activatie van PLD. Echter 
overexpressie van R-Ras-mutanten in CHO cellen had geen effect op de activiteit van PLD 
wanneer dat gestimuleerd was door CCK (niet getoonde gegevens). Wel bleek constitutief- 
actief R-Ras in staat om de calciumkinetiek bij hoge cellulaire calciumconcentraties te 
beïnvloeden (hoofdstuk 6). Inductie van hoge calciumconcentraties door hoge 
hormoonconcentraties of met thapsigargine, werd in cellen waarin de R-Ras mutant tot 
overexpressie was gebracht sneller te niet gedaan dan in controlecellen. Op dit moment wordt 
onderzocht welk mechanisme hieraan ten grondslag ligt.
In hoofdstuk 7 is onderzocht of de CCKA-receptor aanwezig op het basolaterale 
membraan van de acineuze cel uit de pancreas in staat was om PLD te activeren zoals 
gevonden was in het expressiemodel, de CHO-cel. Echter onder vrijwel alle verschillende 
condities werd met CCK nooit een transfosfatidyleringsprodukt gevonden, hetgeen er op wijst 
dat PLD niet werd geactiveerd. Alleen met extreme hoge forbolesterconcentraties werd een 
minimale PLD-activatie waargenomen. Lokalisatiestudies toonden aan dat PLD in acineuze 
cellen, in tegenstelling tot in de CHO-cellijn, gelokaliseerd is in het cytosol en niet 
membraangebonden is. Stimulatie van regulatoren van PLD leidde niet tot translocatie van het 
eiwit naar de membraanfractie. Mogelijk verklaart het onvermogen van het PLD-eiwit om in 
acineuze cellen te transloceren, de waarneming dat er geen door het hormoon geïnduceerde 
activatie van PLD werd gemeten.
De nier speelt een belangrijke rol bij de regulatie van de calciumhomeostase. Een 
belangrijk regulatiemechanisme is het actieve transepitheliale transport van calciumionen dat 
plaats vindt in het distale deel van de nier. Er zijn hormonen die dit actieve transport 
stimuleren en hormonen die dit proces remmen. In hoofdstuk 8 is met deze verschillende 
hormonen onderzocht of PLD mogelijk selectief geactiveerd wordt. Het bleek dat zowel 
stimulerende als remmende hormonen van het calciumtransport PLD-activatie stimuleren. De 
fysiologische relevantie om PLD te activeren in dit celtype is vooralsnog onopgehelderd.
In de literatuur zijn verschillende aanwijzingen dat PLD-activiteit gedurende 
tumorprogressie toeneemt. In een panel van humane melanomen bleken PKCa en de RhoA- 
homoloog memB verhoogd tot expressie te komen in de metastaserende cellijnen ten opzichte 
van die in de niet-metastaserende cellijnen (hoofdstuk 9). Daarnaast bleek dat activatie van 
PLD door de forbolester in de metastaserende cellen sterk was toegenomen terwijl stimulatie 
door GTPyS was afgenomen. Er is onderzocht of de veranderende expressieniveaus van 
PKCa en memB van invloed waren op de karakteristieken van de activatie van PLD. Echter 
overexpressie van PKCa in een niet-metastaserende cellijn en verlaagde expressie van memB 
in een metastaserende cellijn bracht geen verandering teweeg in de stimulatie door de 
forbolester of GTPyS. Op het moment wordt onderzocht welk mechanisme ten grondslag ligt 
aan de opmerkelijke verschillen in PLD-activering in de niet- en wel- metastaserende humane 
melanomen.
Samengevat beschrijft dit proefschrift de karakteristieken van het enzym PLD op 
verschillende niveaus. Met behulp van het CHO expressiemodel is de regulatie van PLD 
onderzocht. Daarnaast is de rol van PLD bestudeerd in verschillende (patho)fysiologische 
systemen.
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